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Abstract 
Infections with Salmonella enterica usually present as a self-limiting diarrhoeal disease. 
Occasionally, antimicrobial intervention is required for invasive infection or patients with 
underlying disease or at the extremities of age. In adults the therapeutic agents of choice 
are the fluoroquinolones, especially ciprofloxacin, which is also used in addition to third 
generation cephalosporins in children. 
Fluoroquinolone resistance is rare and is mostly detected in strains associated with foreign 
travel. Nevertheless, reports from around the world describing treatment failures with these 
drugs in nalidixic acid-resistant isolates have been increasing. 
To determine the levels of fluoroquinolone resistance in Scotland from 1990-2000, this 
study examined a collection of 180 isolates of Salmonella enterica isolated from human, 
veterinary and environmental sources. These were characterised using the genotypic 
methods of Plasmid Profile Analysis and Pulsed Field Gel Electrophoresis and levels of 
resistance were determined for quinolone and fluoroquinolone antimicrobials by the agar 
dilution method. 
By exposing susceptible isolates to subinhibitory concentrations of fluoroquinolones, 
resistant mutants were selected. Amplification and sequencing of the topoisomerase genes 
gyrA and parC was performed on a number of these mutants in an attempt to characterize 
the mutations. 
The prevalence of the recently described plasmid-borne resistance qnr genes was 
determined for a selection of 53 strains of Salmonella enterica from years 1997-2007 
susceptible to nalidixic acid (40mg/L) but resistant to ciprofloxacin (0.125mg/L) in V 
 
addition to 17 strains of Salmonella enterica from years 1997-2007 resistant to 
ciprofloxacin (0.125mg/L) and cefotaxime (1mg/L).  
The determined resistance levels indicated that with the exception of the isolates deemed 
fully susceptible by breakpoint method, all other isolates examined were resistant to the 
quinolone nalidixic acid. Resistance to fluoroquinolones was rare during this time as has 
been previously reported. 
With the exception of a single mutation in the parC gene, mutations, if present were 
confined to gyrA. Although significant increases in minimum inhibitory concentrations 
(MICs) were observed between wild-type isolates and selected mutants, only single point 
mutations were characterised. This, and the absence of mutations in some mutants with 
raised MICs compared to their wild-type, may indicate additional mechanisms of 
resistance such as increased efflux or porin changes not investigated in this study. 
Thirty-four from a total of 70 strains investigated for the presence of qnr genes were 
shown to harbour qnrA, qnrB, or qnrS. Twelve serotypes were represented, 7 of which 
have not previously been shown to harbour these genes. Positive strains were from human, 
environmental and veterinary sources; 58% of the strains of human origin were from 
patients with a history of foreign travel.   
Plasmid-mediated  quinolone  resistance  has  recently  been  identified  in  isolates  of  S. 
enterica in a number of countries at low prevalence. This study of Scottish isolates has 
identified  a  higher  prevalence  of  qnr  than  expected  and  a  wider  dissemination  of  qnr 
resistance genes among different serotypes.   
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Chapter 1:  INTRODUCTION AND REVIEW OF THE LITERATURE 
 
1:1  History of the Genus Salmonella 
In 1885, an American veterinarian named Daniel Elmer Salmon and his colleague, 
bacteriologist Theobald Smith discovered what they believed to be the causative agent of 
hog cholera (Salmon & Smith, 1886). The micro-organism they described was ultimately 
identified as the cause of the secondary infections which were often associated with the 
disease, which was eventually shown to be of viral origin. The generic designation 
Salmonella was coined in 1900 as a tribute to the veterinarian, and the newly described 
bacillus was given the name Salmonella choleraesuis.  
Other bacilli displaying similar phenotypic characteristics were subsequently added to the 
genus. These included organisms which, prior to the creation of the Salmonella genus, had 
been given names describing the disease they caused or the host from which they were first 
isolated. As time progressed, these names became frequently inaccurate and so the practice 
of naming the organism after the geographic location in which it was first isolated was 
adopted. 
 
1:2  Characteristics of the genus Salmonella 
The genus Salmonella consists of non-sporing, Gram-negative, facultatively anaerobic 
straight rods that conform to the general definition of the family Enterobacteriaceae. With 
the exception of S. Pullorum and S. Gallinarum, which are always non-motile, these 
organisms are usually motile due to peritrichous flagella which exhibit diphasic variation  
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(Le Minor, 1984). They produce hydrogen sulphide from triple sugar iron agar and can use 
citrate as their sole carbon source. They produce gas from glucose, mannitol and usually 
sorbitol, an important exception being S. Typhi which never produces gas. They rarely 
ferment sucrose, lactose or adonitol and are urease- and indole-negative. 
These biochemical characteristics are used for the identification of Salmonella to 
subspecies level. Serologic identification of the bacterial surface ‘O’ and ‘H’ antigens is 
then used to distinguish serotypes as described in the Kauffmann-White scheme (Popoff & 
Le Minor, 1997). 
 
1:3  Nomenclature 
Initially, Salmonella nomenclature was based on a one serotype-one species concept 
introduced by P.B. White in 1929 and later modified by Kauffmann in 1966. Each 
serotype, based on its antigenic structure and biochemical characteristics, was considered a 
separate species. Following the development of new techniques such as DNA-DNA 
hybridisation (Crosa, et al, 1973), it was demonstrated that all serotypes were closely 
related at the species level with the exception of subspecies V, which appeared to have 
evolved sufficiently to be significantly different from all the other subspecies (Reeves, et 
al, 1989). 
The nomenclature most frequently used in today’s literature is based on the system devised 
by Le Minor and Popoff of the World Health Organisation Collaborating Centre for 
Reference and Research on Salmonella, at the Institut Pasteur, Paris. In 1987, their group 
made a proposal as a “Request for an Opinion” to the Judicial Commission of the 
International Committee on Systematic Bacteriology (Le Minor & Popoff, 1987) that the  
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genus Salmonella consist of a single species and that the name which, up until that time 
was S. choleraesuis, be changed to S. enterica since “choleraesuis” was the name of a 
serotype as well as the name of the species. “Enterica”, coined by Kauffmann and Edwards 
in 1952, had no serotype (Kauffmann & Edwards, 1952). The Commission denied their 
proposal (Judical Commission of the International Committee on Systematics of 
Prokaryotes, 2005). In 1999, J.P. Euzéby made an amended request that S. enterica be 
adopted as species name, while conserving the name Salmonella typhi as an exception 
(Euzéby, 1999). The request was successful. 
Euzéby proposed that the genus Salmonella consist of two species, S. enterica, the type 
species and S. bongori, which was formerly subspecies V (Reeves et al, 1989).  S. enterica 
is divided into six subspecies; (I, S. enterica subspecies enterica; II, S. enterica subspecies 
salamae; IIIa, S. enterica subspecies arizonae; IIIb, S. enterica subspecies diarizonae; IV, 
S. enterica subspecies houtenae; VI, S. enterica subspecies indica).  
In 2004, a new species was identified through physiological and phylogenetic analyses and 
was named Salmonella subterranae (Shelobolina et al, 2004). 
The serotypes belonging to S. enterica subspecies enterica are written in Roman (not 
italicised) and the first letter is capitalised, for example S. enterica subspecies enterica 
serotype Typhimurium. Serotypes belonging to other subspecies are designated by their 
antigenic formulae.  
There are currently 2,463 Salmonella serotypes, with the majority of these belonging to S. 
enterica subspecies enterica (Popoff et al, 2000). New serotypes are listed in annual 
updates of the Kauffmann-White scheme.  
4 
 
This thesis will use the nomenclature Salmonella enterica subspecies enterica serotype 
Typhimurium and the shortened version Salmonella Typhimurium or S. Typhimurium. 
1:4  Salmonella Pathogenicity 
Salmonella is a genus of zoonotic bacteria that is capable of causing disease in a wide 
range of species. In humans, infection is a result of ingestion of contaminated food or 
water. There are three types of infection associated with Salmonella: gastroenteritis, 
systemic disease and a carrier state.  
Gastroenteritis is usually associated with acute, but mild enteritis with a short incubation 
period of 6-72 hours after the ingestion of contaminated food or water. For disease to occur 
in healthy humans an infective dose as low as 10
3 organisms must be ingested (Blaser & 
Newman, 1982). They must reach the stomach where they are exposed to gastric acid and a 
pH of 1-2. Viable bacteria must then pass to the small intestine where they must compete 
with normal microbial gut flora, and adhere to the intestinal epithelia. Factors that reduce 
gastric acidity such as antacids or underlying disease, immature or compromised humoral 
and cellular immune responses all aid the passage of the bacteria to the small intestine. 
The non-systemic infection of the intestinal tract results in varying degrees of nausea and 
vomiting followed by abdominal pain and mild to severe diarrhoea. The disease is self-
limiting and normally subsides within seven days. Electrolyte and water loss may lead to 
more severe disease in young children and the elderly. 
Severe systemic diseases fall into three main categories: enteric; bacteraemic and focal. 
The bacteria cross the intestinal epithelium to the reticulo-endothelial system where they 
are phagocytosed by macrophages. The bacilli multiply within the cells of the liver, spleen,  
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lymph nodes, gallbladder, bone marrow, lungs and kidneys. After intracellular 
multiplication, the bacilli re-enter the bloodstream resulting in bacteraemia. 
Bacteraemia occurs in approximately 5% of intestinal non-typhoidal gastroenteritis cases. 
It is a serious and potentially fatal illness that is more likely to occur in immunologically 
compromised patients (Hohmann, 2001). 
 Focal lesions may occur, mainly in immunocompromised patients, at any anatomical site 
after Salmonella bacteraemia and include meningitis (Varaiya et al, 2001), septic arthritis 
(Sarguna, 2005), osteomyelitis (Khan, 2006) and pneumonia (Samonis et al, 2003).  
Clinical symptoms depend largely on the site affected, although most patients present with 
spiking fever in the absence of enteritis. 
Faecal shedding of non-typhoidal salmonellae has been demonstrated to be resolved 
approximately 12 days after a positive culture result (Sirinavin et al, 2003), much shorter 
than previously believed (Buchwald, & Blaser, 1984). In long-term Salmonella carriage, 
sufferers are usually asymptomatic and may continue to excrete organisms from the 
gallbladder, one of the sites of persistent infection. 
 Enteric fever caused by either S. Typhi or S. Paratyphi, is a severe and debilitating illness. 
An infectious dose of approximately 10
2 organisms must be ingested with sufficient 
numbers surviving long enough to reach the intestinal mucosa. The incubation period is 
between 7 and 14 days during which time the typhoid bacilli must penetrate the intestinal 
mucosa and translocate to the lymphoid follicles and the reticuloendothelial cells of the 
liver and spleen. After multiplication within the mononuclear phagocytic cells, they are 
released into the bloodstream (Parry et al, 2002). The patient is largely asymptomatic 
during the incubation stage however; once the bacilli enter the bloodstream symptoms  
6 
 
include remittent fever in the range of 38°C-40°C, malaise, myalgia and headache. In 
untreated cases, once typhoid fever has resolved, convalescent faecal excretion is seen in 
approximately10% of acute infections for up to 3 months, with 1-4% becoming long-term 
carriers (Parry et al, 2002). 
 A manifestation of the disease seen frequently in animals that is of great economic 
importance is the ability of some serotypes to induce abortion. S. Dublin, a host-adapted 
serotype, primarily infects cattle including calves, causing enteritis and/or systemic 
disease. Fever and anorexia due to severe diarrhoea eventually lead to death. Milder 
infections result in acute diarrhoea and abortion in pregnant cows; it also induces abortion 
in sheep, usually accompanied by death of the ewe (Uzzau et al, 2000). S. Dublin has the 
ability to cause systemic disease in humans, often resulting in bacteraemia and metastatic 
sites of infection, especially in immunocompromised individuals (Fang & Fierer, 1991).  
S. Choleraesuis is another host-adapted serotype that is mainly associated with disease in 
pigs. It causes severe systemic disease in weaned pigs between 2 and 4 months of age. 
Septicaemia, fever and chronic wasting generally lead to death, with abortion induced in 
pregnant sows (Uzzau et al, 2000). S. Choleraesuis is associated with bacteraemia and 
extraintestinal focal infections in immunocompromised humans (Chen et al, 2007).  
 
1:5  Epidemiology of Salmonella 
Salmonellae are essentially intestinal parasites of humans and animals including domestic 
pets, farm animals, birds, reptiles and rodents. They are found in the environment and have 
been isolated from rivers, sewage and soil where, under the correct conditions, they can 
survive for many years. They have been detected in animal feeds as well as food such as  
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fruit and vegetables. The vast majority of salmonellosis cases are a result of consumption 
of contaminated food (including milk) or water, or by direct faecal-oral spread.  
Members of Salmonella enterica are primarily associated with warm-blooded vertebrates, 
while members of the other five subspecies and S. bongori are usually isolated from the 
environment, cold-blooded animals and exceptionally, humans. 
Many serotypes such as Typhimurium and Enteritidis are ubiquitous, inhabiting a wide 
range of host species, while others known as host-adapted serotypes are restricted to 
infecting a single host species. For example, S. Typhi is almost exclusively associated with 
systemic disease in humans as is S. Gallinarum in fowl (Barrow, 1994). Some host-adapted 
serotypes are able to cause disease in more than one host species. S. Dublin normally 
associated with systemic disease in cattle has been shown to cause abortion in pregnant 
ewes (McCaughey et al, 1971).  
To avoid confusion in the literature, it has been proposed that ubiquitous serotypes be 
referred to as “un-restricted serotypes”, serotypes almost exclusively associated with a 
particular host species be referred to as “host-restricted serotypes” and lastly, serotypes 
usually associated with a particular host species but also able to cause disease in at least 
one other, be referred to as “host-adapted serotypes” (Uzzau et al, 2000). 
 
1.6  Review of Typing methods used in investigating Salmonella epidemiology 
There are many typing methods to help scientists investigate the origins and relatedness of 
isolates of Salmonella. During outbreak situations, these methods are valuable 
epidemiological tools that help in locating the source of the infection. Typing methods  
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should fulfil four main criteria; high discriminatory power (the ability to separate 
epidemiologically-unrelated organisms), reproducibility (the same conclusion should be 
reached upon repeat testing of an organism), typeability (all isolates should be assigned a 
“type” by the method applied) and transportability (the ability to replicate the method and 
achieve the same results in different laboratories). 
Bacterial typing methods fall into two categories; phenotypic and genotypic methods.  The 
former includes traditional methods such as serotyping, bacteriophage typing and 
antimicrobial sensitivity testing. These methods characterize the products of gene 
expression and therefore are capable of great variation depending on growth conditions, 
growth phase and spontaneous mutation. Genotypic methods such as plasmid profile 
analysis, plasmid restriction analysis and pulsed field gel electrophoresis investigate the 
genetic structure of the organism and are therefore less subject to natural variation. They 
can, however, be affected by loss or gain of plasmids, insertions and deletions of DNA into 
the chromosome or mutations that result in either the loss or the gain of a cutting site by 
restriction endonucleases. 
 
 
 
1:6:1  Phenotypic methods 
Serotyping 
Serotyping of Salmonella is used to identify the isolates at subspecies level. A series of 
antibodies is used to identify the O (somatic) and H (flagellar) antigens on the bacterial cell  
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surface. In those isolates that possess a capsule or a cell envelope, a third antigen Vi, is 
also identified. The Kauffman-White scheme is then used to identify the serovar based on 
the antigens present (Popoff & Le Minor, 1997). 
 
Bacteriophage typing 
This method is based on the principle that isolates of Salmonella are susceptible to 
infection by bacteriophages. Bacteriophages are viruses that specifically infect bacteria and 
either cause lysis of the cell or lysogeny in which they remain inside the cell. This provides 
a means of further differentiating certain serovars based on their susceptibilities to these 
bacteriophages. A phage agar plate is flooded with a bacterial culture and allowed to dry at 
room temperature. Using a multipoint inoculator a series of bacteriophage specific to the 
serovar is inoculated onto the agar plate. Upon exposure, some (or in some phage types, 
all) of the bacteriophage lyse the organism creating a lysis pattern that can be interpreted to 
give the phage type. Phage typing schemes have been developed for, among others; S. 
Enteritidis (Ward et al 1987); S. Typhimurium (Anderson et al 1977); S. Typhi (Craigie & 
Felix, 1947); S. Infantis (Kasitya et al 1978) and S. Virchow (Chambers et al 1989). 
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Figure 1:1  Typical phage reactions of a strain of S. Enteritidis PT1b. 
 
 
 
 
 
 
 
 
Antimicrobial sensitivity testing 
Antimicrobial sensitivity testing can provide valuable information for clinicians to use 
when prescribing antimicrobial therapy and may also be used in surveillance as a means of 
observing trends in sensitivity patterns among bacterial isolates. Resistance patterns are 
very changeable mainly due to the methods through which resistance arises such as 
mutation and plasmid-mediated resistance. 
There are various methods used in different laboratories to determine the R-type 
(resistance pattern) of isolates. For therapeutic advice, the objective is to produce a readily 
understood value that is both reproducible in the laboratory and relevant to the clinician 
(Frost, 1994). Minimum Inhibitory Concentration (MIC) determination using a culture 
grown on a non-selective medium to which an antimicrobial-impregnated strips is a fast 
and generally accurate method of obtaining such data. However, it can be very expensive if  
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large numbers of MICs need to be determined. Disks with known concentrations can be 
used in place of the antimicrobial strips. The zone if inhibition around the disk is measured 
and compared to published standards set by organisations such as the British Society for 
Antimicrobial Chemotherapy (BSAC) or the Clinical Laboratory and Standards Institute 
(CLSI-formally known as NCCLS).  Testing by the agar dilution method is useful for 
determining the MICs of a large number of isolates as multiple isolates can be tested on a 
single plate using a multipoint inoculator. This is regarded as labour intensive and MICs 
might be difficult to interpret when they require finer discrimination than the usual two-
fold serial dilutions provide. 
For epidemiological and surveillance purposes, the MIC of resistant isolates tends not to be 
so important. It is sufficient to determine whether isolates are sensitive or resistant. For 
such information, a breakpoint method is very useful. In this method a known 
concentration of antimicrobial is incorporated into agar such as Isosensitest agar or 
Diagnostic Sensitivity agar and bacterial cultures are spotted onto the agar plates using a 
multipoint inoculator. In this way numerous sensitivities/resistances can be determined 
against multiple antimicrobials with the minimum of effort and time. 
 
1:6:2  Genotypic methods 
Plasmid Profile Analysis 
In most bacteria plasmids are extrachromosomal covalently-closed supercoiled circular 
pieces of DNA that are capable of autonomous replication. Many encode products and/or 
functions that are beneficial to the bacterial host; resistance to antimicrobials or virulence 
factors are important examples. During cell division, copies of any plasmids present within  
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the cell are distributed among the daughter cells. In this way, members of the same clonal 
line should have identical plasmid profiles. However, in the serovars Enteritidis and 
Typhimurium, the virulence plasmids are present in many different phage types (Brown et 
al, 1993). Plasmids are mobile and can transfer from one bacterial cell to the next usually 
by means of conjugation, which requires cell-to-cell contact as DNA passes from one 
bacterial cell to another via a sex pilus. Plasmids that transfer antimicrobial resistance by 
conjugation are known as ‘R-factors’ and were first identified by Watanabe in 1963 
(Watanabe, 1963). Plasmids can also be “lost”; the bacterial host may eliminate the 
plasmid from the cell when it is no longer needed, such as in response to the withdrawal of 
antimicrobial selective pressure (Brown et al, 1991). 
 
Pulsed Field Gel Electrophoresis 
Standard electrophoresis is unable to resolve fragments of DNA greater than 120kb 
therefore the technique of pulsed field gel electrophoresis (PFGE) was developed. It first 
used in 1984 in the examination of yeast chromosomal DNA (Schwartz & Cantor, 1984). 
PFGE is a highly reproducible genotypic typing method. It has excellent discriminatory 
power and can be used for almost all bacteria. Depending upon the organism being 
investigated, methods vary, however they all follow basic principles. Bacterial cells are 
embedded in agarose and formed into plugs before being lysed, allowing the isolation of 
the chromosomal DNA. EDTA and detergents are used to inhibit nucleases and Proteinase 
K is used to digest cellular proteins. The plugs are then washed repeatedly to remove 
unwanted cell components, leaving only the chromosomal DNA embedded in the agarose. 
The plugs are cut to the required size and digested by a restriction endonuclease that 
ideally cleaves the chromosomal DNA infrequently.  XbaI is the most frequently used  
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enzyme in the study of Salmonella as it is inexpensive and has good discriminatory power. 
However, some very closely related strains, for example the commonly isolated 
Salmonella Enteritidis PT4, may require a second enzyme such as SpeI and BlnI. These 
enzymes are much more expensive but often they are able to distinguish between those 
strains that give identical XbaI profiles. Once digested, the plug slices are sealed into the 
wells of an agarose gel and subjected to pulsed field electrophoresis. 
The PFGE apparatus CHEF (contour clamped homogenous electric field) separates the 
DNA fragments into straight lines. The gel is placed in the centre of the electrophoretic cell 
between three sets of electrodes that form a hexagon around it. These electric fields 
alternate; flowing from one direction for a set length of time before switching and flowing 
from another for the same period.  This is known as the switch time which, in addition to 
other parameters such as voltage, running time and temperature must be optimized. 
Depending upon the specifications of the CHEF equipment, the angle between the electric 
fields is fixed at 120ºC. Some models with greater specifications allow the angle to be 
varied. When the first electric field is applied, the DNA fragments migrate through the gel 
in the new direction. When the second electric field is applied, the fragments re-orientate in 
that direction. Larger molecules take longer to re-orientate and therefore migrate through 
the gel to a lesser extent. Increasing switch times throughout the run allows increasingly 
larger fragments to migrate, thereby resulting in separation of fragments dependent upon 
size. 
The fragments of DNA can be visualized by staining with a chemical such as ethidium 
bromide and illuminating on an ultraviolet source. They form a pattern of bands that is 
known as the pulsed field profile. These pulsed field profiles can be compared with those 
of other strains for genetic relatedness. Guidelines on the interpretation of the banding  
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patterns have been published (Tenover et al, 1995). The advent of computer software such 
as Bionumerics (Applied Maths, Kortrijk, Belgium) has greatly enhanced the analysis of 
these data. Gel images are converted to TIFF files and analysed by the software using 
statistical formulae. From the results, a Dendrogram may be constructed reflecting the 
degree of similarity between the patterns obtained. 
PulseNet Europe is a collaboration between a number of medical and veterinary 
laboratories around Europe. Its purpose is the harmonization of protocols and running 
parameters for the PFGE of Salmonella. As each country runs PFGE using identical 
protocols data may be shared and compared, allowing epidemiological investigation to be 
run Europe-wide. PulseNet Europe has also established a database to which, the member 
laboratories submit the pulsed field profiles. A central curator checks the pattern and, if it 
is novel, assigns a unique PFGE pattern designation, an example of which would be: 
SENTXB.0001. The letter “S” in the first position designates the genus Salmonella. The 
next three letters, in this case “ENT” representing Enteritidis, designate the serotype using 
codes preordained by PulseNet Europe. The “XB” represents the enzyme used to generate 
the pattern, XbaI. A full stop separates these characters from the final four numerical 
characters which are used to distinguish the individual pattern for any particular serotype 
using any particular enzyme. As a result, laboratories across Europe are able to access this 
database in order to identify their pulsed field profiles and assign agreed pattern 
designations. 
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1:7  History of Quinolones and Fluoroquinolones 
Development of the quinolones began with the accidental discovery by George Y. Lesher 
of a by-product of the synthesis of the anti-malarial drug chloroquine that exhibited some 
antibacterial activity (Lesher et al, 1962). The resulting 1,8-naphthyridine derivative was 
named nalidixic acid and was used to mainly treat Gram-negative urinary tract infections 
after it’s introduction in the U.S.A. in 1963 and the U.K. in 1964. The next ten years saw a 
number of related molecules, termed first-generation quinolones, developed. Based on the 
4-quinolone nucleus, compounds with minor modifications such as pipemidic acid, 
oxolinic acid and cinoxacin were all synthesized. These compounds generally displayed 
increased activity against aerobic Gram-negative bacteria but due to poor serum and tissue 
kinetics were restricted to treatment of urinary tract infections and sexually transmitted 
diseases. They still lacked activity against Gram-positive and anaerobic bacteria.  
In the early 1980’s it was discovered that modifications to the C6 and C7 positions of the 
4-quinolone nucleus significantly enhanced the absorption and the activity of these 
compounds. The addition of a fluorine atom at the C6 position significantly increased the 
DNA gyrase inhibitory activity and facilitated penetration into the bacterial cell (Domagala 
et al, 1986). This, in addition to a cyclic diamine piperazine at position C7, resulted in the 
compound norfloxacin-the first fluoroquinolone, so named because of the fluorine atom at 
C-6 (Hooper & Wolfson, 1985). These modifications resulted in antibacterial activity 
against aerobic Gram-positives and improved activity against Gram-negatives but made no 
difference in the activity against anaerobic bacteria. 
Since this discovery, chemical modification of the quinolone nucleus has resulted in a 
broad variety of useful antimicrobial agents. Ciprofloxacin was the result of replacing the 
N-1 ethyl group of norfloxacin with a cyclopropyl group. This second-generation  
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quinolone was the first to be useful in treating infections other than those of the urinary 
tract and sexually transmitted diseases.  
Third- and fourth-generation quinolones have been developed through increasing structural 
novelty and complexity. These newer compounds have increased activity against Gram-
positive cocci and potent activity against anaerobes (Brightly & Gootz, 2000). 
Although attempts to further chemically modify this class of drugs continues, the number 
of ideas for new compounds appears to be relatively small. One of the most promising new 
ideas is based on the notion of removing the fluorine atom from C6-resulting in “6-
desfluoro” compounds (Moellering Jr., 2005).  Garenoxacin is a 6-desfluoroquinolone that 
has broad spectrum activity against both Gram-negative and Gram-positive bacterial 
infections, including anaerobic organisms (Ameyama et al, 2003, Noviello et al, 2003, 
Hoellman et al, 2001). 
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Figure 1:2: Structure of nalidixic acid, ciprofloxacin, ofloxacin, norfloxacin and 
moxifloxacin. 
All diagrams courtesy of http://www.chemblink.com. 
Nalidixic acid           Ciprofloxacin 
 
   
 
 
 
Norfloxacin            Ofloxacin 
 
   
     
 
        Moxifloxacin 
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1:8  The Use of Fluoroquinolones in the Treatment of Human Infections 
Fluoroquinolones are broad-spectrum antimicrobials effective in the treatment of a wide 
variety of clinical infections. They are highly effective in uncomplicated urinary tract 
infections and gonorrhoea and are the drugs of choice where bacterial resistance 
compromises routine β-lactam therapy (Nicolle, 2000). The modern fluoroquinolones, 
including moxifloxacin and gemifloxacin all possess outstanding activity against 
respiratory pathogens, methicillin-susceptible staphylococci and a variety of important 
Gram-negative bacilli (Moellering Jr., 2005). 
Fluoroquinolones are the drugs of choice for treatment of invasive gastrointestinal 
infections in adults worldwide. Norfloxacin or ciprofloxacin has been found to be 
comparable to trimethoprim-sulphamethoxazole in the treatment of diarrhoea caused by 
Shigella species, enterotoxigenic E. coli or Campylobacter jejuni. Norfloxacin has been 
found to be superior to both trimethoprim-sulphamethoxazole and doxycycline in the 
treatment of Vibrio cholerae infection (Oliphant & Green, 2002). 
The fluoroquinolones have proved to be an invaluable tool in the treatment of moderate to 
severe enteric infections (Akalin, 1995). They are widely used in the oral management of 
typhoid fever, reducing complication, relapse and convalescent excretion rates to a greater 
extent than traditional first-line drugs (Parry et al, 2002). 
Salmonella gastroenteritis is usually a self-limiting diarrhoeal disease and antimicrobial 
therapy is usually only indicated when the patient is immunocompromised, has an enteric 
fever, has an extra-intestinal infection or long-term salmonella carriage. In many such 
cases, ciprofloxacin is often the drug of choice (Moraitou, 2007, Ridha et al, 1996)                                                                 
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1:9  The Use of Fluoroquinolones in Veterinary Medicine 
The fluoroquinolones have been used to treat infections in food-producing animals since 
the early 1990s. The regulation and use of these drugs varies greatly between countries. In 
Europe, none of the fluoroquinolones used in the treatment of human infections are 
licensed for use in infections in animals. Nevertheless, there is still concern regarding any 
usage of this group of antimicrobials in veterinary medicine due to the fear of increasing 
resistance. Several European countries have reported a significant increase in the resistance 
of Salmonella to quinolones after their use in livestock was approved (Frost et al, 1996; 
Malorny et al, 1999; Aarestrup et al, 2000). In vivo studies have shown that enrofloxacin 
selects Salmonella mutants resistant to nalidixic acid and fluoroquinolones. It has been 
hypothesized that animals may act as reservoirs for reduced susceptibility mutants that, 
upon further exposure to fluoroquinolones, may lead to high-level resistance (Giraud et al, 
1999).  
 
1:10  Quinolone Mechanism of Action  
The targets of quinolone action are two bacterial enzymes that are essential for cell growth 
and division-DNA gyrase and topoisomerase IV. Both are tetramers composed of two pairs 
of identical subunits, GyrA and GyrB encoded by gyrA and gyrB in DNA gyrase and ParC 
and ParE encoded by parC and parE in topoisomerase IV (Drlica & Zhao, 1997).  Gyrase 
controls DNA supercoiling and relieves topological stress arising from translocation and 
replication complexes along the DNA; topoisomerase IV is a decatenating enzyme that 
resolves interlinked daughter chromosomes following DNA replication (Drlica & Zhao, 
1997). DNA gyrase is the primary target of quinolones in Gram-negative bacteria with  
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topoisomerase IV acting as a secondary target, the reverse is true for Gram-positive 
bacteria (Li, 2005).  
Quinolones act by binding to complexes that form between DNA and gyrase or 
topoisomerase IV. Shortly after binding, the quinolones induce a conformational change in 
the enzyme. The enzyme breaks the DNA and the quinolone prevents re-ligation of the 
broken DNA strands. The enzyme is trapped on the DNA resulting in the formation of a 
quinolone-enzyme-DNA complex. Quinolone-enzyme-DNA complex formation rapidly 
inhibits DNA replication and is consistent with gyrase acting ahead of replication forks 
(Hawkey, 2003). However, inhibition of replication by quinolone-topoisomerase IV-DNA 
complexes occurs slowly, consistent with the enzyme being located behind the replication 
forks (Khodursky & Cozzarelli, 1998). 
It is thought that cell death arises by more than one mechanism. The release of DNA ends 
from the quinolone-gyrase-DNA complexes, which are the equivalent of double-strand 
breaks are thought to induce bacterial apoptosis. It is also believed that quinolone 
molecules may be able to force gyrase-DNA complexes apart, releasing DNA ends. It is 
thought that this second mode occurs when cells are treated with high concentrations of 
fluoroquinolones such as ciprofloxacin (Drlica & Zhao, 1997). 
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Figure 1:3. DIAGRAMATIC REPRESENTATION OF GYRASE ACTIVITY AND 
QUINOLONE INHIBITION. 
   
 
Diagram modified from www.pharmainfo.net 
 
1:11  Resistance to Fluoroquinolones 
Before the early 1990s, resistance to fluoroquinolones was rarely witnessed in clinical 
isolates of Gram-negative bacteria. Successful treatment outcomes resulted in an increase 
in their use which, in turn, led to an ever increasing rate of resistance (Jacoby, 2005).  In 
the United States an increase in the use of fluoroquinolones of around 40% led to a 
coincident doubling in the rate of resistance to ciprofloxacin among Gram-negative bacilli 
CCC-DNA 
DNA Gyrase 
catalytic Subunits 
DNA Gyrase ATP 
binding subunits 
Fluoroquinolones Four 
stacked molecules  
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isolated from intensive care units in hospitals (Neuhauser et al, 2003). In other parts of the 
world too, increased rates of resistance are being reported. In Spain, fluoroquinolone 
resistance had become such a problem that, by the mid 1990s, they were not first choice in 
the treatment of E. coli urinary tract infections (Oteo et al, 1999). In Beijing during 1997-
1999, approximately 60% of E.coli strains isolated from hospital-acquired infections and 
approximately 50% of community-isolated E.coli strains were resistant to ciprofloxacin 
(Wang et al, 2001).  
Treatment failures attributed to fluoroquinolone resistance have been reported in cases of 
typhoid fever. Strains of S. Typhi with reduced susceptibility to fluoroquinolones have 
been reported from amongst others, Vietnam (Parry et al, 1998), the Indian subcontinent 
(Nath et al, 2000) and Africa (Kariuki, 2004).   
High-level resistance to fluoroquinolones is relatively uncommon among isolates of non-
typhoidal Salmonella, although a Finnish study associated an increase in ciprofloxacin 
MIC in S. enterica isolates with travellers returning from Southeast Asia (Hakanen et al, 
2001). Danish scientists also found that quinolone resistance in isolates from patients with 
a history of foreign travel was more prevalent than those with domestically acquired 
infections (Molbak et al, 2002). 
Despite the early promise that came with the licensing of the fluoroquinolones thirty years 
ago, scientists today are calling for cautious, even restricted, use of these antimicrobials 
(Bakken, 2004). 
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1:12  Mechanisms of Quinolone Resistance 
There are essentially four types of mechanism by which bacteria evade the action of 
quinolone antimicrobial agents. They may work independently or in combination, 
conferring degrees of resistance from reduced susceptibility (not always detected by 
current antimicrobial susceptibility tests) to clinically relevant resistance. 
1:12:1 Mutations in Topoisomerase Genes. 
Resistance to quinolones is mainly mediated by chromosomal mutations that alter the 
targets of these antimicrobials, namely DNA gyrase and topoisomerase IV. In Gram-
negative bacteria, gyrase, or more specifically, the gyrA subunit, is most frequently the 
primary target, with topoisomerase IV being the primary target for Gram-positive 
organisms. The point mutations most often occur within the highly conserved domain of 
the N-terminus of the gyrA gene known as the ‘quinolone resistance-determining region’ 
(QRDR) (Piddock, 1999). This region occurs on the DNA-binding surface of the enzyme 
near the putative active site tyrosine 122 (Piddock, 1999). These mutations give rise to 
amino acid changes and, in E.coli, include amino acids between positions alanine 67 and 
glycine 106 with mutations at serine 83 and asparagine 87 being the most common. A few 
mutations have been detected outside the QRDR. An alanine to valine substitutions has 
been detected in in-vitro mutants at position 51 (Friedman et al, 1997) and in salmonellae, 
mutations at Ala131, Glu139 and asp144 have all been detected (Eaves et al, 2002). 
A few mutations have been mapped to the N-terminus of the gyrB gene located between 
amino acids Asp426-Lys447. This region is known as the QRDR in the gyrB gene and all 
of the mutations give rise to amino acid substitutions. Once a first-step mutation has  
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decreased susceptibility in a Gram-negative organism, additional mutations in gyrB may 
serve to further increase the resistance. 
Point mutations have also been detected in the parC and parE genes of Gram-negative 
bacteria but remain much rarer than gyrA mutations. Although Ling et al detected a parC 
mutation in the absence of a gyrA mutation in a strain of Salmonella (Ling et al, 2003); it is 
generally believed that parC mutations arise later than gyrA mutations because in Gram-
negative bacteria, gyrase rather than topoisomerase IV is the preferred target of quinolones.   
 
1:12:2 Alterations in Efflux 
Increased expression of non-specific, energy-dependant efflux systems allow bacteria to 
prevent the accumulation of effective concentrations of quinolones inside the cell by 
actively pumping out the drug. In E. coli, the AcrAB-TolC efflux pump plays a major role 
in quinolone efflux and studies suggest that this may be the primary mechanism of 
fluoroquinolone resistance in Salmonella (Giraud et al, 2000). It is thought that these 
efflux systems cause low-level resistance to quinolones that can become clinically-relevant 
when combined with mutations in the target enzymes (Hooper, 1999) or alterations in the 
outer membrane (Giraud et al, 2000). 
 
1:12:3 Alterations in the Outer Membrane  
Gram-negative bacteria can regulate membrane permeability by altering expression of 
outer membrane porin (omp) proteins that form channels for passive diffusion. Loss or 
reduced levels of OmpF has been implicated in antimicrobial resistance (Toro et al, 1990),  
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but in later studies the role of OmpF in reduced levels of quinolone accumulation was less 
clear with no loss or reduction in levels detected (Piddock et al, 1993 ; Ruiz et al, 1997).   
1:12:4 Plasmid-mediated Resistance 
A natural transferable plasmid encoding low-level resistance to quinolones was isolated 
from a clinical strain of Klebsiella pneumoniae. The 56kb plasmid, named pMG252, had a 
broad host range that included other members of the Enterobacteriaceae and Pseudomonas 
aeruginosa (Martinez-Martinez et al, 1998). The qnrA gene from the plasmid encodes a 
protein of 218 amino acids that belongs to the pentapeptide repeat family. In vitro studies 
demonstrated that Qnr protected the E. coli DNA gyrase from inhibition by ciprofloxacin 
but did not protect topoisomerase IV (Tran et al, 2005). Further molecular studies 
demonstrated that qnr was collocated with other resistance determinants on sul1-type 
integrons (Rodríguez-Martinez et al, 2007). The presence of qnr has frequently been found 
in strains producing extended spectrum β-lactamases (Hata et al, 2005). 
In 2005, scientists in Japan discovered another qnr gene, qnrS (now designated qnrS1), in a 
plasmid from a strain of Shigella flexneri 2b (Hata et al, 2005), and in 2006 a third qnr 
gene, qnrB1, was isolated from strains of K. pneumoniae from India. These two genes 
share 41% and 59% amino acid identity with the original gene, now designated qnrA1 
(Nordmann & Poirel, 2005). The sixth variant of qnrA1, qnrA6, has recently been 
identified and a variant with 91% homology to qnrS1 has been identified in the United 
States and designated qnrS2 (Gay et al, 2006). qnrB2 and qnrB5 were identified in non-
typhoidal Salmonella enterica isolates from the United States (Gay et al, 2006), and in 
Germany qnrB12 has recently been identified in poultry isolates of Citrobacter werkmanii 
(Kehrenberg et al, 2008).  
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The presence of qnr genes themselves do not appear to confer resistance to quinolones; 
however their importance lies in the augmenting effect of these qnr genes and other 
resistance mutations and facilitating the selection of higher level quinolone resistance from 
strains harbouring the plasmid than those without it (Martinez-Martinez et al, 1998).    
 
 1:13  Aims of this study 
Fluoroquinolones are being increasingly used in the treatment of invasive gastrointestinal 
infections. Reports of treatment failures are also increasing. This study aimed to: 
1.  Determine the levels resistance to quinolone and fluoroquinolone antimicrobials in 
strains of non-typhoidal Salmonella isolated in Scotland.  
2.  To attempt to select fluoroquinolone-resistant mutants following exposure to 
subinhibitory concentrations of these drugs. 
3.  To establish the capacity of susceptible strains of Salmonella to develop resistance 
and to determine whether this capacity is equal in all serotypes examined. 
4.  To investigate the capacity of certain antimicrobials to select for resistance. 
5.  To compare the findings to the results of previous investigations into laboratory-
selected fluoroquinolone-resistant mutants. 
 
 
Chapter 2: Characterisation of strains to point of inclusion in this study  
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2:1  Introduction 
The general procedures for the typing of isolates of Salmonella have been outlined in 
Chapter1. In this chapter, the origin of the strains used in this study is given together with 
the methods used in the Scottish Salmonella Reference Laboratory (SSRL). The 
characterisation of strains used in this study and described in this chapter comprises 
identification to reporting stage with the exception of the antimicrobial sensitivity data 
which are given in Chapter 3.  
All isolates of Salmonella of human, veterinary and environmental origin isolated in 
Scotland are submitted to the SSRL for phenotypic and genotypic characterisation. Each 
isolate is given a unique identifying number. A sweep from this original culture is then 
inoculated onto a MacConkey agar plate that is incubated overnight at 37°C. A single 
colony is selected from this plate and inoculated onto a Dorset’s Egg slope, which is 
incubated overnight at 37°C. Inoculated Dorset’s Egg slopes are stored at room 
temperature for future reference. It is from this Dorset’s Egg that all subsequent work is 
performed. Isolates are routinely serotyped, phage typed (where applicable), tested for 
sensitivity against a panel of fourteen antimicrobials, plasmid profiled and pulse field 
profiled. Data from these procedures are then stored in the SSRL database and appropriate 
portions reported to clinicians, Health Protection Scotland (HPS) and the Pulse Field Gel 
Electrophoresis (PFGE) data are filed with PulseNet Europe. These data were available for 
each strain prior to selection for this study. 
 
 
  
28 
 
2:2  Materials and Methods 
The materials and methods described in this Chapter refer to routine procedures operation 
in the SSRL and of relevance to the study as a whole. They were used to confirm the 
properties on file for the isolates of Salmonella selected in two laboratory studies. 
2:2:1  Isolates of Salmonella  
The procedure for acquisition, identification, reporting and archiving strains of Salmonella 
enterica has been outlined above in the introduction.  
The SSRL received a total of 58,576 isolates in the years 1990-2000. For the purposes of 
this study quality control strains and duplicate samples were excluded and only a single 
isolate from epidemiologically-related outbreaks has been included. 
These isolates were divided into four subsets based on the following criteria:  
·  MDR (resistant to multiple antimicrobials) - those isolates resistant by 
breakpoint method to four or more antimicrobials (two of these being quinolone 
or fluoroquinolones). 
·  FQR (Fluoroquinolone resistant) - those isolates only resistant by breakpoint 
method to nalidixic acid 40mg/L and ciprofloxacin 0.5mg/L. 
·  NCpL (nalidixic acid and low-level ciprofloxacin resistant)–those isolates only 
resistant by breakpoint method to nalidixic acid 40mg/L and to low-level 
ciprofloxacin 0.125mg/L. 
·  FS (Fully susceptible)–those isolates showing no resistance by breakpoint to 
any antimicrobials tested.  
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Inclusion in the final selection was then based on a further set of criteria, namely serotype, 
phage type, source and year received, to give as varied a collection of strains as possible. 
As a result 180 isolates of Salmonella enterica formed the basis of these studies. The 
serotype and source distribution of the selected isolates are shown in Tables 2:1 and 2:2, 
respectively and their original breakpoint designations are given in Appendix I. 
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Table 2:1. Serotype distribution of Salmonella isolates studied. 
Serotype  MDR
a  FQR
b  NlCp
c  FS
d  Total 
Enteritidis  5  45  23  5  78 
Typhimurium  12  1  1  10  24 
Mbandaka  6  13  2  1  22 
Hadar  14  0  1  0  15 
Virchow  3  0  4  1  8 
Dublin  0  0  2  5  7 
Senftenberg  1  0  3  0  4 
Thompson  1  0  3  0  4 
Liverpool  0  0  3  0  3 
Binza  0  0  1  1  2 
Blockley  2  0  0  0  2 
Brandenburg  1  0  0  1  2 
Kottbus  0  0  2  0  2 
Antarctica  0  0  1  0  1 
Bovismorbificans  1  0  0  0  1 
Indiana  1  0  0  0  1 
Java  1  0  0  0  1 
Monophasic Group C1  1  0  0  0  1 
Montevideo  0  0  0  1  1 
Oranienberg  1  0  0  0  1 
Total  50  59  46  25  180 
a Resistant by breakpoint testing to 4 or more antimicrobials including nalidixic acid and ciprofloxacin. 
b Resistant by breakpoint testing to ciprofloxacin 0.5mg/L and nalidixic acid 40mg/L. 
c   Resistant by breakpoint testing to nalidixic acid 40mg/L and ciprofloxacin 0.125mg/L. 
d   Fully sensitive by breakpoint testing. 
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Table 2:2. Source distribution of Salmonella isolates studied. 
Source  MDR
a  FQR
b  NlCp
c  FS
d  Total 
Human  31  25  29  13  98 
Poultry  11  29  11  3  54 
Environmental  4  4  3  0  11 
Bovine  1  0  2  4  7 
Porcine  0  0  0  1  1 
Pheasant  1  0  0  1  2 
Canine  0  0  1  0  1 
Ovine  0  0  0  1  1 
Porpoise  0  0  0  1  1 
Canary  0  0  0  1  1 
Feline  0  1  0  0  1 
Unknown  2  0  0  0  2 
Total  50  59  46  25  180 
a Resistant by breakpoint testing to 4 or more antimicrobials including nalidixic acid and ciprofloxacin. 
b Resistant by breakpoint testing to ciprofloxacin 0.5mg/L and nalidixic acid 40mg/L. 
c   Resistant by breakpoint testing to nalidixic acid 40mg/L and ciprofloxacin 0.125mg/L. 
d   Fully sensitive by breakpoint testing.
 
 
2:2:2  Study 1: Plasmid Profile Analysis of the selected strains 
2:2:2:1  Materials 
Test organisms            detailed in section 2:2:1  
Cysteine Lactose Electrolyte Deficient (CLED) agar    Oxoid    CM0301 
Brain Heart Infusion Broth (Dehydrated)      Oxoid    CM0225  
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TE 50:1: Trizma base           Sigma   T6066 
  Ethylenediaminetetraacetic acid  
disodium salt dihydrate (EDTA)      Sigma   E5134 
10X TBE Buffer            Invitrogen  15581-044  
Phenol Chloroform Isoamyl          Sigma   P2069 
Kado & Liu Lysis Buffer: Trizma base      as above 
      Sodium Dodecyl Sulfate (SDS)  Sigma   L4390 
      Sodium Hydroxide      BDH    191533K 
 
Redipac GP agarose            Mast    GP500 
Ethidium Bromide            Sigma   E1510 
E. coli Control strains, 39R861 & V517      H.P.A. Colindale, England 
Preparation of working solutions can be found in Appendix I. 
 
 
2:2:2:2  Methods 
Preparation of Plasmid DNA 
Four colonies from an overnight CLED plate were inoculated into 5ml BHI and incubated 
shaking at 37°C overnight. 0.8ml culture was dispensed into a Treff tube and centrifuged at 
13,000 rpm for 5 minutes. The supernatant was removed and the pellet was resuspended in 
20µl of TE 50:1 buffer by vortexing. 100µl of Kado and Liu lysis buffer was added and 
mixed by inversion. The tubes were transferred to a 56°C waterbath for 30 minutes. 100µl  
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of phenol-chloroform-isoamyl was added to each tube and vortexed. Tubes were 
transferred to a microcentrifuge and centrifuged at 18,000g for 15 minutes. 40µl of 
supernatant was carefully transferred to a clean Treff tube to which 6µl of gel loading 
solution was added. The control strains of Escherichia coli, 39R861 (Threlfall et al, 1986) 
and V517 (Macrina, 1978), were also prepared in the same way. These contain plasmids of 
known sizes and can be used to size the plasmids of the test isolates. The plasmid 
preparations were stored at 5°C until needed. 
Preparation of Gel 
The gel was prepared by dissolving 0.7g of general purpose agarose in 100ml of 1X TBE 
buffer by heating in a microwave oven and then transferring to a 56°C waterbath.  The 
ends of the gel casting tray were sealed using autoclave tape. A twelve well comb was 
inserted before pouring the cooled agarose into the casting tray. Once the gel was set, the 
comb and the autoclave tape were removed and the gel was placed in an electrophoresis 
tank (Bio-Rad) containing 1X TBE buffer to a level 5mm above the gel surface. 25µl of 
each plasmid preparation was added to wells 2-11, while in wells 1 and 12 the controls, 
39R861 and V517, were loaded. The gel was run for 3 hours at 100V and then stained in a 
1.25µg/ml solution of Ethidium Bromide for 20 minutes. The gel was then de-stained for a 
further 20 minutes before being visualized and photographed using a U.V. transilluminator 
and a Kodak EDAS 120 Digital Camera System (BRL Life Technologies). 
 
Calculation of plasmid sizes 
Plasmids migrate at different speeds due to their molecular size and so included on every 
electrophoresis gel are two standard plasmid preparations with plasmids of known  
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molecular size.  The first, E. coli V517 contains 8 plasmids ranging from 2.1kb up to 54kb 
while the second, E. coli 39R861 has 4 plasmids ranging in size from 7kb up to 147kb. 
Plasmid molecular weights were estimated according to the method of Rochelle et al. 
Briefly, a standard curve of log molecular weight v log relative mobility was generated for 
the reference plasmids. Relative mobility was calculated for the unknown plasmids and 
this was used to extrapolate their molecular weights from the standard curve. 
 
2:2:2:3  Results 
Plasmid profile results are tabulated in Appendix II.  
Seventeen different plasmid profiles were identified among the 78 strains of S. Enteritidis 
examined. The most common profile consisted of a single plasmid of approximately 57kb, 
with 44 strains sharing this profile. Twelve strains harboured a single additional plasmid of 
2.1kb and three strains, a single additional plasmid of 100kb or 110kb. Eight strains 
harboured varying numbers of plasmids that ranged in size from 2.1kb to 70kb in addition 
to the 57kb plasmid while the remaining 11 strains had profiles that did not include the 
57kb plasmid including 4 strains which possessed single plasmids of 120kb, 5.2kb or 2.1kb 
(2), one strain that harboured 3 plasmids of 45; 6.0 and 4.5kb and 6 strains that harboured 
no plasmids and were termed plasmid-free. 
Of the twenty-four strains of S. Typhimurium, twenty possessed a plasmid (or plasmids) of 
approximately 90kb, eight of which had additional plasmids in the range of 2.0-145kb. One 
strain of S. Typhimurium RDNC (Reacts but Does Not Conform) possessed five plasmids 
ranging from 2kb up to 145kb. Three strains were plasmid-free.  
35 
 
The plasmid profiles of the S. Mbandaka strains varied considerably. The twenty-two 
strains yielded nineteen different profiles, ranging from one to six plasmids. Plasmid sizes 
ranged from 2.1kb to 90kb. No strain of S. Mbandaka was plasmid-free. 
Of the seven S. Dublin strains examined, two were plasmid-free and five possessed a single 
plasmid of approximately 80kb.  
The fifteen strains of S. Hadar all possessed a small plasmid of 2.1kb. In addition to this, 
thirteen strains had between one and five larger plasmids ranging from 3.2kb to 45kb. Of 
the remaining thirty-four isolates examined, nine were plasmid-free. With the exception of 
three strains of S. Liverpool which had identical plasmid profiles, all of the serotypes with 
greater than one isolate resulted in different plasmid profiles. 
 
2:2:3  Study 2: Pulsed Field Gel Electrophoresis studies of the selected strains 
2:2:3:1  Materials 
Test organisms            detailed in section 2:2:1  
Cystine Lactose Electrolyte Deficient (CLED) agar    as in section 2:2:2:1 
Sodium Chloride            BDH    102414Y 
ES Buffer  N-lauryl-sarcosine (Sarcosyl
R NL30)   BDH    442753R 
    EDTA           as in section 2:2:2:1   
    Sodium hydroxide solution 40% w/v   BDH    191533K 
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Proteinase K  (stock solution 50mg/ml)      Roche  03 115 852 044 
Pulsed Field Certified Agarose        Bio-Rad  162-0137 
10X TBE Buffer            as in section 2:2:2:1 
TE (PFGE) Wash Buffer  Trizma Base      as in section 2:2:2:1 
        EDTA       as in section 2:2:2:1 
 
Ethidium Bromide (10mg/ml solution)      as in section 2:2:2:1 
XbaI Restriction Enzyme          Invitrogen  15226-038 
React 2 10X Buffer            supplied with XbaI. 
Preparation of working solutions can be found in Appendix III. 
 
2:2:3:2  Method 
Four colonies from an overnight CLED plate were inoculated into 5ml BHI and incubated 
shaking at 37°C overnight. 0.8ml culture was dispensed into a Treff tube and centrifuged 
in a microcentrifuge at 13,000 rpm for 5 minutes. The supernatant was removed and the 
pellet was resuspended in 1ml 0.85% saline. After further centrifugation, the supernatant 
was again removed and the pellet was resuspended in 0.5ml 0.85% saline. The cell 
suspensions were then transferred to a 40°C heating block and left to equilibrate for 15 
minutes.  
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2% agarose was prepared by dissolving 0.4g Pulsed Field Certified agarose in 20ml 0.85% 
saline in a microwave oven and allowing it to cool to 56°C in a waterbath. A plug mould 
was prepared by sealing the underside with autoclave tape. 
Agarose plugs were prepared by adding 0.5ml cooled agarose to the cell suspension and 
mixing well. An aliquot of 120µl was then dispensed into a single well of the plug mould. 
Once all the wells were full, the mould was then placed at 5°C to allow the plugs to set. 
Plugs were lysed by transferring each plug to a Treff tube containing 1ml ES buffer to 
which 20µl of 50mg/ml Proteinase K solution had been added. The tubes were then placed 
in a 56°C waterbath overnight. 
After lysis, the plugs were transferred to sterile disposable 5ml plastic test tubes containing 
3ml TE (PFGE) wash buffer. The test tubes were placed in a shaking waterbath at 56°C for 
30 minutes. Using fresh wash buffer, this step was repeated 6 times after which, the plugs 
were stored in 3ml wash buffer at 5°C until digestion. 
Using a sterile disposable scalpel, a 1mm slice of plug was taken from each plug and 
placed into a Treff tube containing 90µl of sterile water and 10µl React 2 10X buffer, and 
left at room temperature for 1 hour. This was removed and replaced with 85µl sterile 
water, 10µl React 2 10X buffer and 5µl XbaI restriction enzyme. Plugs were incubated for 
4 hours at 37°C. 
The gel was prepared by suspending 1.3g Pulsed Field Certified agarose in 130ml 0.5X 
TBE buffer. The agarose was dissolved by heating in a microwave oven and then placed in 
a waterbath to cool to 56°C. The gel casting mould was assembled and wiped with 
methylated spirits. A thirty-well comb was inserted before the cooled agarose was poured 
into the mould. Approximately 1.5ml agarose was returned to the waterbath for later use.  
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Once the gel was set, the comb was removed and the slices of agarose plugs were removed 
from the restriction mix and inserted into the wells of the gel using two small spatulas. The 
remaining agarose was removed from the waterbath and used to seal the plugs inside the 
wells. 
PFGE was performed using a CHEF-DR II system from Bio-Rad. 2.2L of 0.5X TBE buffer 
was added to the tank. The cooling module and the pump were switched on and set to 14°C 
and 70 - 80 respectively. The gel and the buffer were left for approximately one hour until 
both had reached the running temperature of 14°C. The gel was run for 22 hours using the 
parameters 6V, initial switch 2s and final switch 64s. 
The gel was removed and stained in a 1.25µg/ml Ethidium Bromide solution with gentle 
shaking for approximately 30 minutes and then de-stained in distilled water for a further 30 
minutes. The gel was visualized by U.V. transillumination and photographed as previously 
described. Images of the gel were stored electronically as Tiff files and analysed using 
Bionumerics software. Where possible, they were given designations applied to identical 
banding patterns held in the PulseNet Europe database. Any pulsed field profiles (PFP) that 
failed to match named patterns in this database were given designations unique to this 
study and are preceded with the letters AM. 
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2:2:3:3  Results 
All 180 isolates of Salmonella were analysed by PFGE using the parameters of PulseNet 
Europe and analysed using Bionumerics software. The pulsed field profiles are listed in 
Appendix V. 
Using the Bionumerics software, a Dendrogram was constructed of the 78 strains of S. 
Enteritidis investigated in this study (Figure 2:1). Fifty-five (70%) proved to be identical 
and were given the designation SENTXB.0001, the most common pulsed field pattern 
(PFP). Seven strains gave PFPs that differed from SENTXB.0001 by the deletion of the 
same single band and were assigned the designation SENTXB.0014.  Another strain also 
possessed this deletion but had a smaller single band and was given the designation 
AMENTX7.The remaining 15 strains of S. Enteritidis were divided into a further ten 
groups some of which, for example, SENTXB.0019, had only one representative. The 
SENTXB.0001 designation was common among twelve of the thirteen different phage 
types of Enteritidis.  
A discrepancy arose with the Bionumerics analysis of two strains of S. Enteritidis assigned 
the designation SENTXB.0005. On visual comparison the two PFP looked identical, and 
when analysed they both matched the PulseNet designation SENTXB.0005 and have 98% 
similarity with each other. However when the S. Enteritidis Dendrogram was constructed, 
the two PFPs were separated into different clusters. Various ways of correcting this very 
obvious discrepancy were tried but the two PFP remained in separate clusters. The reason 
for this occurrence is unclear but, as these two strains were run on different gels it may be 
due to temperature fluctuations during the running time, slight differences in DNA content 
of the plugs resulting in heavier or lighter bands or perhaps the normalisation step during 
the Bionumerics analysis where the gels are stretched or compressed to ensure that the  
40 
 
assigned bands of the reference lanes match their corresponding reference positions. 
Despite this, it is highly likely that these two strains are of clonal origin. 
Of the serotypes with multiple examples, S. Enteritidis and S. Dublin showed least 
variation by PFGE using XbaI, with the seventy-eight strains of the former separated into 
just thirteen pulsed field patterns and six of the seven strains of S. Dublin resulting in 
identical profiles with the seventh only differing by a single band (Figure 2:2). 
Twenty-four strains of S. Typhimurium resulted in fourteen different PFPs (Figure 2:3). 
However, among these fourteen different PFPs, there are twelve different phage types, the 
predominant one being DT104, with 9 strains, all of which, when analysed, resulted in the 
most common Typhimurium PFP-STYMXB.0001.  
The Dendrogram for the twenty-two strains of S. Mbandaka resulted in thirteen different 
PFPs the most common of which, was AMMBA3 (a PFP unique to this study) (Figure 
2:4). Only one strain had an identical pattern in the PulseNet Europe database, while 
twelve of the fifteen strains of S. Hadar were identified as SHADXB.0001 (Figure 2:5). 
Discrimination among seven strains of S. Virchow resulted in 4 different PFP with one, 
designated AMVIR1, demonstrating only 60% similarity to the other strains (Figure 2:6). 
In the remaining six serotypes with multiple examples (Figure 2:7), only S. Liverpool 
demonstrated 100% identical PFPs and of those serotypes with only a single example, S. 
Java was the only one to have an identical PFP in the PulseNet database.  
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Figure 2:1  Dendrogram for S. Enteritidis 
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The PFPs of four strains of S. Enteritidis (19901754; 19935599; 19940871; 19992150) are 
not included in this dendrogram as their files were corrupted during analysis in the 
Bionumerics program. 
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Figure 2:2  Dendrogram for S. Dublin 
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Figure 2:3 Dendrogram for S. Typhimurium 
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  Figure 2:4  Dendrogram for S. Mbandaka 
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Figure 2:5  Dendrogram for S. Hadar 
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Figure 2:6  Dendrogram for S. Virchow 
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Figure 2:7  Dendrogram for multiple serotypes 
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Poultry
Poultry
Poultry
Poultry
Poultry
Human
Poultry
Poultry
Poultry
Poultry
Poultry
Human
Human
Bovine
AMBIN2
AMBIN1
AMBRN2
AMLPL1
AMLPL1
AMLPL1
AMANT1
AMBLO1
AMBLO2
SPTJXB.0003
AMSEN2
AMSEN4
AMSEN3
AMSEN1
AMBRN1
AMTHO1
AMTHO1
AMTHO2
AMTHO1a
AMTYMMPC1/1
AMKOT1
AMKOT1
AMMVD1
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2:3  Discussion 
The 180 strains of Salmonella comprised 20 serotypes selected primarily for their 
phenotypic resistance types (R-types). The analyses performed in studies 2:2:2 (Plasmid 
profile analysis) and 2:2:3 (PFGE) provided more information. 
2:3:1  Study 1  Plasmid profile analysis 
In this study 320 plasmids were isolated from 160 strains of Salmonella (20 were plasmid-
free). The plasmids varied widely in terms of number, ranging from strains harbouring 
single sized plasmids to strains harbouring 6 different sized plasmids, and size, from 2.0kb 
up to 160kb however, very few strains possessed a large plasmid and of the thirteen that 
did, eight were resistant to four or more antimicrobials.  
High molecular-mass plasmids (that is, greater than 100kb) represent a considerable 
biosynthetic burden to the organism as they may constitute up to 5% of the total genome 
(Rychlik et al, 2006). These plasmids are potentially unstable in maintenance and 
replication functions. When present, it is most likely that they bestow a selective advantage 
through encoding beneficial phenotypes for the host, such as resistance to antimicrobials 
(R-plasmids) and heavy metals (Martinez et al, 2007; Ghosh et al, 2000).  
A total of 78 of the strains studied harboured at least one low molecular-mass plasmid, 
there appeared to be little correlation between the individual strains. For example, a 2.1kb 
plasmid appeared to be the most frequently isolated small plasmid, being present in 38 of 
the eight-one strains (being the sole plasmid in six instances). Although low molecular-
mass plasmids are more prolific and diverse than high molecular-mass plasmids, little is 
known about their biological function. One such plasmid has been shown to influence 
resistance to phage infection in isolates of S. Enteritidis whilst another, designated as pRF- 
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1, was found to confer resistance to sulphathiazole in isolates of S. Choleraesuis (Rychlik 
et al, 2001; Haneda et al, 2004). As this 2.1kb plasmid was present in seven different 
serotypes (and different phage types where applicable) with various R-types, there is no 
obvious phenotypic marker associated with it.  
Whilst the plasmids of Salmonella enterica have the ability to transfer between organisms, 
the mere presence or absence of these extrachromosomal pieces of DNA can be of 
epidemiological importance. Although the results of plasmid profile analysis can yield 
plasmids of varying size and number, for those strains that are suspected of being part of 
an outbreak, a distinctive plasmid profile can provide an essential link. In one case, the 
absence of a plasmid linked an outbreak of S. Senftenberg in infants to the consumption of 
one brand of baby cereal (Rushdy, 1998). 
The most intensively investigated group of plasmids are the serotype-associated plasmids 
(SAPs-also known as the virulence plasmids) of S. Typhimurium, S. Enteritidis, S. Dublin, 
S. Choleraesuis, S. Gallinarum, S. Pullorum and S. Abortusovis the first three of which 
have been examined in this study.  
The 90kb, 57kb and 80kb plasmids of S. Typhimurium, S. Enteritidis and S. Dublin 
respectively are very stable. A study examining a strain of S. Enteritidis demonstrated that 
there was no loss or genomic rearrangement of the 57kb plasmid during a 2.5 year period 
under different storage conditions (Olsen et al, 1994). Similarly, studies on a collection of 
enterobacteria from the pre-antimicrobial era, known as the “Murray collection”, 
demonstrated no differences to isolates from recent years (Jones & Stanley, 1992); findings 
reflected in this study with 86% of S. Enteritidis strains harbouring the 57kb SAP; 83% of 
S. Typhimuium harbouring the 90kb SAP and 71% of S.Dublin harbouring the 80kb SAP.    
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These plasmids, usually between 50-100kb, are important as they encode genes that 
contribute towards the virulence of these serotypes. For example, when a 22kb region of 
the 90kb virulence plasmid of S. Typhimurium was cloned into a mobilization vector, the 
resulting recombinant plasmid restored full virulence to a plasmidless strain in a mouse 
model (Norel et al, 1989). A 7.8kb region, spv, which is required for bacterial 
multiplication in the reticulo-endothelial system, is common to all the virulence plasmids 
(Rotger, 1999).The virulence plasmids of S. Enteritidis, S. Typhimurium and S. Dublin also 
contribute to the invasiveness of these strains. It has been demonstrated that only the SAP 
containing strains of these serotypes were capable of invading the livers of orally-infected 
mice. The virulence properties of other serotypes with no associated plasmid could not be 
correlated with their heterogeneous plasmid populations (Helmuth, 1985). 
 The ability of some isolates of Salmonella enterica to cause disease, survive in the 
presence of antimicrobials and heavy metals and resist infection by bacteriophages can all 
be attributed to the presence of certain plasmids. It is obvious that the acquisition of 
plasmids allow their host to survive in environments that would otherwise prove fatal and 
that the plasmids must continually evolve to meet this challenge, as demonstrated by the 
140kb self-transferable plasmid of S. Typhimurium encoding both the characteristic 
Salmonella virulence plasmid genes and the genes coding for chloramphenicol and 
tetracycline resistance (Guerra et al, 2002).  
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2:3:2  Study 2  Pulsed Field Gel Electrophoresis 
Nine strains of S. Enteritidis were unable to be subtyped by phage typing. PFGE in this 
instance, using XbaI, was only slightly better at differentiating between the strains, 
separating just 2 strains (SENTXB.0014 & AMENT7) from the others (SENTXB.0001). 
The difference between SENTXB.0001 and SENTXB.0014 was the loss of a single band 
of approximately 57kb, in the latter. This is, in fact, the virulence plasmid of S. Enteritidis 
which is remarkably stable (Olsen, 1994). This then implies that the single band difference 
between SENTXB.0001 and SENTXB.0014 is significant and had this been an outbreak 
situation, this difference may have been interpreted as indicating different strains. 
AMENT7 is also lacking a single band of approximately 57kb; however this strain has an 
additional smaller band compared to SENTXB.0014, resulting in a new PFP designation. 
Discrimination between the remaining 69 strains of S. Enteritidis using only XbaI was not 
much better with only a further 10 PFP being differentiated. This was applicable to some 
of the other serotypes also. Twenty-four strains of S. Typhimurium resulted in 14 different 
PFPs however 9 strains had the commonest PFP STYMXB.0001. Of the fifteen strains of 
S. Hadar, twelve had an identical profile. This was also the situation in S. Dublin where, 
from a total of seven strains, six strains were indistinguishable by PFGE. 
The results for S. Enteritidis and S. Typhimurium DT104 were somewhat expected due to 
the clonal nature of these strains (Davis et al, 2002), although, still an improvement on the 
other typing methods such as plasmid analysis and ribotyping (Ridley et al, 1998). The 
results for S. Hadar and S. Dublin were disappointing. Using a second and perhaps even a 
third restriction endonuclease in combination would increase the discriminatory power of 
this technique. This would especially be an appropriate measure for the previously  
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mentioned common pulsed field types of S. Enteritidis or S. Typhimurium such as 
SENTXB.0001 and STYMXB.0001 as it is imperative to be absolutely certain that the 
high incidence of these strains does not mask a genuine outbreak and for S. Dublin which 
has important economic implications in the farming industry. 
Twenty-two strains of S. Mbandaka were divided into thirteen distinct profiles using XbaI. 
Fourteen strains were divided into twelve separate profiles. This is a good example of the 
discriminatory power of PFGE. As these Mbandaka strains originated mainly from poultry 
sources, the PFGE results provide reassurance that the incidence of Mbandaka is not due to 
clonal spread. Eight strains of S. Mbandaka had a unique PFP, AMMBA3 (Figure 2:4). 
These strains were isolated over a period of 7 years and all were of poultry origin with the 
exception of one environmental isolate which was taken from a poultry farm. All have 
similar R-types which, when added to the unique PFP suggests that these strains were of 
clonal origin. 
The purpose of PFGE in this study was merely to fully characterize the strains and not to 
identify epidemiological relationships. It was therefore considered sufficient to employ 
only a single restriction endonuclease. 
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Chapter 3: Phenotypic determination of resistance 
3:1  Introduction 
Each isolate the Scottish Salmonella Reference Laboratory receives is routinely tested 
against a panel of 14 antimicrobials, including nalidixic acid and ciprofloxacin, by an in-
house breakpoint method. This generates epidemiological and surveillance data which are 
reported to Health Protection Scotland. An agar dilution method was used to confirm these 
breakpoint designations and determine the Minimum Inhibitory Concentrations (MIC) for 
nalidixic acid, ciprofloxacin and 3 other fluoroquinolones, using first Diagnostic 
Sensitivity agar and then Mueller Hinton agar. 
3:1:1:  Study 1 Materials 
Test organisms            detailed in section 2:2:1 
CLED agar              as in section 2:2:2:1 
Diagnostic sensitivity (DST) agar        Oxoid    CM0301 
Mueller Hinton (MH) agar          Oxoid    CM0337 
BHI broth              as in section 2:2:2:1 
Sterile distilled water            In-house 
Antimicrobial powders  Nalidixic acid     Sigma   N-4382 
        Ofloxacin      Sigma   O-8757 
Norfloxacin      Sigma   N-9890 
Ciprofloxacin      provided courtesy of Bayer   
Moxifloxacin      provided courtesy of Bayer  
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3:1:2  Method 
MIC determination was performed using the technique described by Frost, (1994). Stock 
solutions of 1024mg/L were made for each of the five antimicrobials. Nalidixic acid, 
ciprofloxacin, norfloxacin and moxifloxacin were diluted with sterile distilled water to 
achieve the desired concentration. Ofloxacin required the addition of sodium bicarbonate 
before dilution with sterile distilled water. A series of two-fold dilutions was carried out on 
each of the stock solutions until a series of agar plates with final concentrations ranging 
from 512mg/L to 0.03mg/L were prepared for ciprofloxacin, norfloxacin, ofloxacin and 
moxifloxacin by adding an aliquot of each antimicrobial to sterilized Diagnostic Sensitivity 
Agar (DST) that had been cooled to 50ºC. For nalidixic acid the concentration of the agar 
plates ranged from 512mg/L to 8mg/L. Excess stock solution was stored at -85ºC.The 
plates were allowed to set at room temperature before being stored at 4ºC. All agar plates 
were used within one week to ensure stability of the antimicrobial.  
A single colony from an overnight CLED plate was inoculated into 3mls of BHI broth and 
incubated on a shaker at 37ºC for two hours. 0.5ml of sterile saline was aseptically 
dispensed into a well of a Perspex block. 10 l of culture was then added to the well. The 
agar plates containing known concentrations of antimicrobial were placed in an incubator 
at 37ºC for 1 hour before use. They were then inoculated with the cultures from the 
Perspex block using the Lidwell multipoint inoculator and allowed to dry at room 
temperature. The plates were then stacked and incubated at 37ºC overnight. The next day 
the plates were removed from the incubator and the results recorded. The lowest 
concentration at which there was no visible growth on the plate was recorded as the MIC 
for that antimicrobial.  
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3:1:3  Results 
MIC results are tabulated in Table 3:1. All but one of the 25 strains selected as “fully 
susceptible” (FS) by breakpoint method were fully susceptible to nalidixic acid. Twenty-
four strains had an MIC of 8mg/L, the exception had an intermediate MIC of 16mg/L. 
Seventeen had MICs of 0.03mg/L-0.06mg/L of ciprofloxacin; the remaining 8 strains had 
reduced susceptibility at a concentration of 0.125mg/L. The strains showed varying 
degrees of susceptibility to the three remaining fluoroquinolones. The majority of MICs of 
ofloxacin ranged from 0.03-0.5mg/L, with the exception of a single strain of S. Dublin 
which was inhibited at a concentration of 2mg/L. The majority of strains demonstrated 
reduced susceptibility to norfloxacin with 19 strains having an MIC of 0.125mg/L and a 
further 4 with a MIC of 0.25mg/L. The aforementioned strain of S. Dublin was also 
resistant to norfloxacin, again at a concentration of 2mg/L. The MICs of moxifloxacin 
ranged from<0.06-0.25mg/L, with a single strain representing each extreme. The majority 
of strains had MICs of 0.03mg/L. 
Of the 46 strains selected as resistant to nalidixic acid  at 40mg/L and low-level 
ciprofloxacin at 0.125mg/L (NCpL), 44 were resistant to nalidixic acid at MICs of 
256mg/L or above, with two strains showing reduced susceptibility at a concentration of 
16mg/L. The same two strains were fully susceptible to ciprofloxacin with MICs of 
0.06mg/L while the remaining 44 strains had MICs ranging from 0.25-2mg/L. The MICs 
of ofloxacin and norfloxacin ranged from 0.5-4mg/L and 0.25-4mg/L respectively, 
however in both cases, the predominant MIC was 2mg/L. The majority of the strains were 
resistant to moxifloxacin, with 40 being resistant at a concentration of 1mg/L. Two were 
resistant at 2mg/L, with only a single strain susceptible at 0.25mg/L.  
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Fifty-nine strains were selected as both resistant to nalidixic acid and to ciprofloxacin at a 
concentration of 0.5mg/L (FQR). All of the strains examined were resistant to nalidixic 
acid at a concentration of ≥512mg/L. They were also resistant to ciprofloxacin, with MICs 
ranging from 1-8mg/L. The strains were also cross-resistant to the three other 
fluoroquinolones, with MICs ranging from 2-32mg/L for both ofloxacin and norfloxacin, 
and between 1 and 8mg/L for moxifloxacin. 
For the 50 strains selected as resistant to multiple antimicrobials (MDR), the most 
prevalent MIC of nalidixic acid was >512mg/L, with 41 strains being inhibited at this 
concentration. Six strains demonstrated an MIC of only 8mg/L. MICs of ciprofloxacin 
ranged from 0.06-32mg/L however, only 2 strains proved to be susceptible (<0.5mg/L) 
with the majority demonstrating MICs between 1-2mg/L. MICs of ofloxacin and 
norfloxacin ranged from 0.125-256mg/L, while the MICs of moxifloxacin were slightly 
lower at 0.125-32mg/L. The majority of these MDR strains were however, resistant to 
these three fluoroquinolones at concentrations of 8mg/L or 4mg/L respectively. 
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Table: 3.1: MIC results for strains of S. enterica to nalidixic acid, ciprofloxacin, ofloxacin, norfloxacin and moxifloxacin using DST agar. 
 
SSRL 
Reference 
Serotype 
Phage 
type 
Source 
Breakpoint 
designation 
Nalidixic 
acid  Ciprofloxacin  Ofloxacin  Norfloxacin  Moxifloxacin 
19900377  Enteritidis  4  Human  FQR  >512  1  8  8  1 
19900497  Enteritidis  RDNC  Poultry  FQR  >512  4  8  4  2 
19900633  Enteritidis  RDNC  Poultry  FQR  >512  2  8  8  2 
19900813  Enteritidis  4  Human  FQR  >512  1  4  4  1 
19900828  Enteritidis  4  Human  FQR  >512  2  4  8  2 
19901024  Enteritidis  4  Poultry  FQR  >512  1  8  8  1 
19901059  Enteritidis  4  Poultry  FQR  >512  2  4  2  2 
19901127  Enteritidis  Untypable  Poultry  FQR  >512  2  4  4  2  
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SSRL 
Reference 
Serotype 
Phage 
type 
Source 
Breakpoint 
designation 
Nalidixic 
acid  Ciprofloxacin  Ofloxacin  Norfloxacin  Moxifloxacin 
19901135  Enteritidis  Untypable  Poultry  FQR  >512  2  4  4  2 
19901221  Enteritidis  Untypable  Poultry  FQR  >512  2  4  4  2 
19901257  Enteritidis  Untypable  Poultry  FQR  >512  2  8  4  2 
19901259  Enteritidis  4  Poultry  FQR  >512  2  4  4  1 
19901289  Enteritidis  Untypable  Poultry  FQR  >512  2  8  4  2 
19901301  Enteritidis  Untypable  Poultry  FQR  >512  2  4  4  2 
19901442  Enteritidis  RDNC  Poultry  FQR  >512  1  8  8  2 
19901527  Enteritidis  RDNC  Poultry  FQR  >512  2  8  4  2 
19901602  Enteritidis  4  Poultry  FQR  >512  1  8  8  1 
19901733  Enteritidis  Untypable  Poultry  FQR  >512  2  4  4  2  
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SSRL 
Reference 
Serotype 
Phage 
type 
Source 
Breakpoint 
designation 
Nalidixic 
acid  Ciprofloxacin  Ofloxacin  Norfloxacin  Moxifloxacin 
19901754  Enteritidis  Untypable  Poultry  FQR  >512  1  2  4  1 
19901928  Enteritidis  4  Poultry  FQR  >512  1  2  4  2 
19902644  Typhimurium  66  Human  FQR  >512  2  8  8  2 
19903116  Enteritidis  RDNC  Human  FQR  >512  2  4  4  2 
19903865  Bovismorbificans    Human  MDR  >512  4  16  4  8 
19903993  Enteritidis  Untypable  Poultry  FQR  >512  1  8  8  1 
19910646  Mbandaka    Poultry  FQR  >512  4  8  8  4 
19910665  Enteritidis  4  Poultry  FQR  >512  2  4  8  4 
19910748  Virchow    Not stated  MDR  >512  2  8  4  8 
19911165  Enteritidis  4  Poultry  FQR  >512  2  4  4  2  
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SSRL 
Reference 
Serotype 
Phage 
type 
Source 
Breakpoint 
designation 
Nalidixic 
acid  Ciprofloxacin  Ofloxacin  Norfloxacin  Moxifloxacin 
19911537  Enteritidis  4  Human  FQR  >512  1  8  8  1 
19912067  Mbandaka    Poultry  FQR  >512  1  8  8  2 
19921643  Mbandaka    Poultry  FQR  >512  2  8  8  4 
19932001  Oranienburg  Human  Poultry  MDR  >512  8  4  2  4 
19932300  Hadar    Poultry  MDR  8  32  16  16  4 
19933184  Enteritidis  4  Human  FQR  >512  1  4  4  2 
19933339  Enteritidis  4  Human  FQR  >512  1  8  4  1 
19933344  Typhimurium  204c  Human  MDR  8  32  256  256  16 
19933488  Mbandaka    Environment  FQR  >512  2  8  8  4 
19934878  Mbandaka   
Poultry 
environment 
FQR 
>512  2  8  16  2  
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SSRL 
Reference 
Serotype 
Phage 
type 
Source 
Breakpoint 
designation 
Nalidixic 
acid  Ciprofloxacin  Ofloxacin  Norfloxacin  Moxifloxacin 
19935442  Hadar    Human  MDR  256  32  32  32  16 
19935599  Enteritidis  4  Human  FQR  >512  2  4  4  2 
19940240  Hadar    Human  MDR  256  8  32  32  32 
19940784  Enteritidis  4  Human  FQR  >512  1  8  8  2 
19940871  Enteritidis  4  Human  FQR  >512  2  8  8  2 
19940880  Enteritidis  4  Human  FQR  >512  1  4  4  2 
19941463  Typhimurium  204  Environment  MDR  >512  1  4  2  1 
19941804  Mbandaka    Poultry  FQR  >512  2  4  4  2 
19941864  Enteritidis  4  Human  FQR  512  2  32  16  2 
19943026  Enteritidis  4  Human  FQR  512  1  8  4  2  
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SSRL 
Reference 
Serotype 
Phage 
type 
Source 
Breakpoint 
designation 
Nalidixic 
acid  Ciprofloxacin  Ofloxacin  Norfloxacin  Moxifloxacin 
19950004  Typhimurium  2  Human  MDR  >512  2  4  4  4 
19953743  Virchow    Human  MDR  >512  1  4  8  2 
19963399  Brandenburg    Human  MDR  >512  2  8  8  4 
19964025  Enteritidis  5c  Human  FQR  >512  4  8  8  8 
19965081  Enteritidis  1  Human  FQR  >512  4  32  16  4 
19966072  Typhimurium  104b  Bovine  MDR  >512  2  4  16  2 
19970269  Enteritidis  7  Human  FQR  >512  8  32  32  8 
19970646  Typhimurium  104  Human  MDR  >512  2  8  8  4 
19970917  Typhimurium  104  Human  MDR  >512  2  8  8  4 
19972895  Typhimurium  104  Environment  MDR  >512  4  8  8  4  
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SSRL 
Reference 
Serotype 
Phage 
type 
Source 
Breakpoint 
designation 
Nalidixic 
acid  Ciprofloxacin  Ofloxacin  Norfloxacin  Moxifloxacin 
19982543  Enteritidis  4  Human  FS  8  0.125  0.25  0.25  0.25 
19982602 
Monophasic group 
C1 
  Poultry 
MDR 
8  0.06  4  0.25  0.125 
19982854  Liverpool    Poultry  NaCpL  >512  1  4  2  1 
19982886  Mbandaka    Poultry 
environment 
NaCpL  >512  2  4  4  2 
19983032  Senftenberg    Poultry  NaCpL  >512  0.5  4  4  1 
19983155  Dublin    Human  FS  8  0.06  0.25  0.125  0.03 
19983351  Typhimurium  RDNC  Canary  FS  8  0.06  0.25  0.125  0.03 
19983458  Typhimurium  2  Human  FS  8  0.125  0.25  0.125  0.03 
19983717  Virchow    Human  FS  8  0.03  0.125  0.125  0.125  
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SSRL 
Reference 
Serotype 
Phage 
type 
Source 
Breakpoint 
designation 
Nalidixic 
acid  Ciprofloxacin  Ofloxacin  Norfloxacin  Moxifloxacin 
19983922  Binza    Canine  NaCpL  >512  2  2  2  1 
19984026  Enteritidis  1  Human  NaCpL  >512  0.5  2  2  1 
19990031  Typhimurium  104  Human  MDR  >512  4  4  0.125  4 
19990095  Hadar    Human  MDR  >512  4  8  8  4 
19990203  Thompson    Poultry  NaCpL  >512  1  4  2  1 
19990341  Typhimurium  104  Human  FS  8  0.125  0.25  0.125  0.06 
19990380  Enteritidis  4  Poultry  NaCpL  512  0.5  2  2  1 
19990515  Hadar    Human  MDR  >512  2  4  4  8 
19990706  Mbandaka    Poultry 
environment 
FS  8  0.03  0.06  0.06  0.06 
19990807  Enteritidis  8  Not stated  MDR  >512  2  4  8  4  
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SSRL 
Reference 
Serotype 
Phage 
type 
Source 
Breakpoint 
designation 
Nalidixic 
acid  Ciprofloxacin  Ofloxacin  Norfloxacin  Moxifloxacin 
19990838  Blockley    Human  MDR  >512  2  4  2  2 
19990898  Mbandaka    Poultry  MDR  >512  2  8  8  4 
19990970  Mbandaka    Poultry  MDR  >512  2  8  8  2 
19990976  Mbandaka    Poultry  FQR  >512  1  16  16  2 
19990983  Virchow    Poultry  MDR  >512  0.5  2  2  1 
19991026  Hadar    Human  MDR  >512  1  4  4  4 
19991035  Typhimurium  104  Porpoise  FS  8  0.06  0.25  0.125  0.03 
19991073  Brandenburg    Human  FS  8  0.06  0.125  0.125  0.125 
19991308  Enteritidis  4  Human  FQR  >512  1  4  4  1 
19991452  Binza    Pheasant  FS  8  0.03  0.125  0.125  0.125  
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SSRL 
Reference 
Serotype 
Phage 
type 
Source 
Breakpoint 
designation 
Nalidixic 
acid  Ciprofloxacin  Ofloxacin  Norfloxacin  Moxifloxacin 
19991601  Virchow    Poultry  NaCpL  >512  0.5  2  4  1 
19991655  Enteritidis  21  Human  NaCpL  >512  0.5  0.5  1  1 
19991657  Enteritidis  1  Human  NaCpL  >512  0.5  2  2  1 
19991700  Enteritidis  4  Human  FQR  >512  1  4  2  1 
19991711  Blockley    Human  MDR  >512  1  4  4  1 
19991722  Enteritidis  4  Human  FQR  >512  1  4  4  1 
19991746  Thompson    Poultry  MDR  >512  1  8  2  1 
19991815  Enteritidis  1  Human  MDR  >512  2  8  16  4 
19991817  Enteritidis  7  Human  NaCpL  >512  0.5  2  2  1 
19991825  Enteritidis  4  Pheasant  MDR  8  0.25  8  4  0.125  
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SSRL 
Reference 
Serotype 
Phage 
type 
Source 
Breakpoint 
designation 
Nalidixic 
acid  Ciprofloxacin  Ofloxacin  Norfloxacin  Moxifloxacin 
19991870  Enteritidis  5c  Human  FS  8  0.125  0.25  0.125  0.03 
19991929  Enteritidis  1  Human  FS  8  0.125  0.25  0.125  0.03 
19992003  Kottbus    Human  NaCpL  256  0.25  2  2  1 
19992070  Hadar    Human  NaCpL  >512  1  4  2  2 
19992150  Enteritidis  6a  Human  FS  8  0.125  0.5  0.25  0.03 
19992252  Enteritidis  1  Human  FQR  >512  2  4  4  2 
19992491  Senftenberg    Poultry 
environment 
NaCpL  256  0.5  4  2  1  
19992678  Virchow    Human  NaCpL  >512  1  4  2  1 
19992689  Hadar    Human  MDR  >512  2  8  16  8 
19992820  Hadar    Human  MDR  >512  2  8  4  4  
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SSRL 
Reference 
Serotype 
Phage 
type 
Source 
Breakpoint 
designation 
Nalidixic 
acid  Ciprofloxacin  Ofloxacin  Norfloxacin  Moxifloxacin 
19992835  Typhimurium  3  Poultry  NaCpL  16  0.06  2  2  0.25 
19993033  Enteritidis  4  Human  MDR  >512  1  4  2  2 
19993048  Indiana    Human  MDR  >512  32  64  128  16 
19993056  Dublin    Bovine  NaCpL  >512  0.5  2  2  1 
19993085  Thompson    Poultry 
environment 
NaCpL  >512  1  4  2  1 
19993115  Enteritidis  4  Human  NaCpL  >512  0.5  2  2  1 
19993539  Enteritidis  untypable  Human  NaCpL  >512  0.5  1  2  1 
19993805  Dublin    Bovine  FS  8  0.06  2  2  0.125 
19993807  Liverpool    Environment  NaCpL  >512  0.5  2  2  1 
19993849  Typhimurium  104  Human  FS  8  0.06  0.25  0.125  0.03  
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SSRL 
Reference 
Serotype 
Phage 
type 
Source 
Breakpoint 
designation 
Nalidixic 
acid  Ciprofloxacin  Ofloxacin  Norfloxacin  Moxifloxacin 
19993983  Mbandaka    Poultry 
environment 
FQR  >512  2  8  4  2 
19994076  Typhimurium  104  Human  FS  8  0.06  0.25  0.125  0.03 
19994609  Enteritidis  14b  Human  NaCpL  >512  0.5  2  2  1 
19995017  Enteritidis  RDNC  Human  MDR  >512  4  16  8  8 
20000136  Dublin    Bovine  FS  8  0.06  0.125  0.125  0.125 
20000139  Dublin    Bovine  NaCpL  512  0.25  2  2  1 
20000283  Mbandaka    Poultry 
environment 
MDR  >512  2  4  2  2 
20000635  Mbandaka    Poultry 
environment 
FQR  >512  2  8  8  2 
20000672  Liverpool    Poultry 
environment 
NaCpL  512  0.25  2  2  1  
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SSRL 
Reference 
Serotype 
Phage 
type 
Source 
Breakpoint 
designation 
Nalidixic 
acid  Ciprofloxacin  Ofloxacin  Norfloxacin  Moxifloxacin 
20000673  Senftenberg    Poultry 
environment 
MDR  8  0.125  0.5  0.125  1 
20000721  Hadar    Poultry  MDR  >512  2  8  8  4 
20000821  Mbandaka    Environment  FQR  >512  2  8  8  2 
20000918  Typhimurium  104b  Human  MDR  >512  2  8  8  4 
20001054  Mbandaka    Poultry 
environment 
FQR  >512  2  2  8  2 
20001058  Mbandaka    Poultry 
environment 
MDR  >512  1  8  4  4 
20001178  Typhimurium  104  Poultry  FS  16  0.125  0.25  0.25  0.125 
20001314  Enteritidis  4  Human  NaCpL  >512  0.5  2  2  1 
20001526  Virchow    Human  NaCpL  >512  0.5  0.5  2  1 
20001735  Dublin    Ovine  FS  8  0.06  0.25  0.125  0.125  
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SSRL 
Reference 
Serotype 
Phage 
type 
Source 
Breakpoint 
designation 
Nalidixic 
acid  Ciprofloxacin  Ofloxacin  Norfloxacin  Moxifloxacin 
20001797  Montevideo    Bovine  FS  8  0.03  0.125  0.125  0.125 
20002001  Virchow    Human  NaCpL  >512  1  4  4  1 
20002014  Typhimurium  104b  Human  MDR  >512  2  8  8  4 
20002058  Typhimurium  104b  Human  MDR  8  0.06  0.25  4  1 
20002113  Hadar    Human  MDR  >512  1  8  4  4 
20002195  Enteritidis  1  Human  NaCpL  >512  1  2  2  1 
20002257  Typhimurium  RDNC  Human  MDR  >512  1  2  2  1 
20002298  Mbandaka    Poultry 
environment 
NaCpL  512  1  1  2  2 
20002399  Hadar    Poultry  MDR  >512  1  4  8  2 
20002427  Java    Poultry  MDR  >512  1  4  4  1  
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SSRL 
Reference 
Serotype 
Phage 
type 
Source 
Breakpoint 
designation 
Nalidixic 
acid  Ciprofloxacin  Ofloxacin  Norfloxacin  Moxifloxacin 
20002524  Mbandaka    Poultry 
environment 
FQR  >512  2  8  4  2 
20002550  Mbandaka    Poultry 
environment 
FQR  >512  2  4  4  2 
20002563  Mbandaka    Environment  MDR  >512  2  8  8  2 
20002590  Enteritidis  RDNC  Human  NaCpL  >512  0.5  1  2  1 
20002618  Enteritidis  21  Human  NaCpL  >512  0.5  2  4  1 
20002621  Enteritidis  6  Human  NaCpL  16  0.06  0.5  0.25  0.25 
20002660  Enteritidis  1c  Human  NaCpL  >512  0.5  2  2  1 
20003052  Dublin    Bovine  FS  8  0.06  0.125  0.125  0.06 
20003106  Hadar    Human  MDR  >512  2  8  8  8 
20003940  Typhimurium  40  Human  FS  8  0.06  0.25  0.25  0.03  
74 
 
SSRL 
Reference 
Serotype 
Phage 
type 
Source 
Breakpoint 
designation 
Nalidixic 
acid  Ciprofloxacin  Ofloxacin  Norfloxacin  Moxifloxacin 
20003957  Kottbus    Human  NaCpL  256  0.25  2  1  1 
20003962  Typhimurium  10  Human  FS  8  0.06  0.5  0.125  0.06 
20004010  Hadar    Human  MDR  >512  1  8  8  4 
20004028  Hadar    Human  MDR  >512  2  8  8  4 
20004057  Enteritidis  1  Human  NaCpL  >512  0.5  2  2  1 
20004078  Enteritidis  3  Human  NaCpL  >512  0.5  1  2  1 
20004300  Enteritidis  4  Human  FQR  >512  2  8  8  4 
20004338  Enteritidis  1c  Human  NaCpL  >512  0.5  2  2  1 
20004342  Enteritidis  6a  Human  NaCpL  >512  1  2  4  1 
20004447  Enteritidis  21  Human  FS  8  0.125  0.25  0.125  <0.03  
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SSRL 
Reference 
Serotype 
Phage 
type 
Source 
Breakpoint 
designation 
Nalidixic 
acid  Ciprofloxacin  Ofloxacin  Norfloxacin  Moxifloxacin 
20004592  Enteritidis  RDNC  Human  NaCpL  >512  0.5  1  2  1 
20004594  Enteritidis  1  Human  FQR  >512  1  4  4  2 
20004661  Mbandaka    Poultry 
environment 
MDR  >512  1  8  4  2 
20004730  Enteritidis  21  Human  NaCpL  >512  0.5  2  2  1 
20004768  Enteritidis  1  Feline  FQR  >512  2  8  4  4 
20004928  Antarctica    Human  NaCpL  >512  0.5  2  2  1 
20004947  Senftenberg    Poultry  NaCpL  >512  0.5  1  2  1 
20005031  Enteritidis  7  Human  NaCpL  >512  0.5  2  2  1 
20005084  Enteritidis  4  Human  NaCpL  >512  0.5  2  2  1 
20005141  Enteritidis  untypable  Human  NaCpL  >512  0.5  1  2  1  
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SSRL 
Reference 
Serotype 
Phage 
type 
Source 
Breakpoint 
designation 
Nalidixic 
acid  Ciprofloxacin  Ofloxacin  Norfloxacin  Moxifloxacin 
20005189  Typhimurium  170  Porcine  FS  8  0.06  0.5  0.125  0.03 
20005212  Enteritidis  1  Human  FQR  nd  2  4  4  2 
20005300  Enteritidis  1  Human  FQR  nd  2  2  4  2 
20005319  Thompson    Poultry 
environment 
NaCpL  >512  1  4  4  1 
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3:2:1:  Study 2 Materials & Method  
This experiment was performed using the materials and method previously described. 
Mueller Hinton agar (MH) was used instead of DST as the latter was found to give 
inaccurate MIC results (discussed in section 3:3:1).  
3:2:2  Results  
The MIC results are listed in Table 3:2. All FS strains tested were fully susceptible to 
nalidixic acid with MICs of 8mg/L. MICs of ciprofloxacin and moxifloxacin were 0.03 or 
0.06mg/L with those of ofloxacin and norfloxacin measuring slightly higher at 0.125 or 
0.25mg/L for most strains.  
For the NCpL strains, the majority of the strains examined were highly resistant to 
nalidixic acid at a concentration of 128mg/L or above. A single strain of S. Typhimurium 
DT 3 had an MIC of 16mg/L. Most of these strains demonstrated reduced susceptibility to 
ciprofloxacin at concentrations of 0.125-0.25mg/L; 6 strains were susceptible with MICs 
of 0.06mg/L. For the remaining three fluoroquinolones, the MICs ranged from 0.125-
0.5mg/L. An MIC of 1mg/L was recorded for a single strain for ofloxacin and 
moxifloxacin however 8 strains had an MIC of 1mg/L for norfloxacin. 
All FQR strains selected for this experiment were highly resistant to nalidixic acid with 
MICs of 256mg/L or above. The MICs of ciprofloxacin ranged from 0.125-0.5mg/L, the 
majority of strains having MICs of 0.25mg/L. For ofloxacin, the MICs were either 0.5 or 
1mg/L, with MICs of norfloxacin measuring higher at 1 or 2mg/L. MICs of moxifloxacin 
were similar to those of ciprofloxacin with the exception of 5 strains whose MICs were 1-
2mg/L.  
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The MDR strains were all resistant to nalidixic acid with MICs of 512mg/L and 
demonstrated reduced susceptibility to ciprofloxacin with MICs of 0.125 or 0.25mg/L. A 
single strain had an MIC of 0.5mg/L. MICs of ofloxacin and norfloxacin ranged from 
0.125-2mg/L. The MICs of moxifloxacin were considerably higher, ranging from 0.5-
4mg/L.  
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Table 3.2: A Comparison of the MICs of nalidixic acid, ciprofloxacin, ofloxacin, norfloxacin and moxifloxacin for 55 strains of S. enterica 
using Diagnostic Sensitivity agar and Mueller Hinton agar. 
SSRL 
Reference 
Serotype  Phage 
type 
Breakpoint 
Designation 
DST 
Nal 
MH 
Nal 
DST  
Cp 
MH   
Cp 
DST 
Oflox 
MH 
Oflox 
DST 
Norflox 
MH 
Norflox 
DST 
Moxi 
MH 
Moxi 
19900497  Enteritidis  RDNC  FQR  >512  >512  4  0.25  8  1  8  2  2  0.5 
19900633  Enteritidis  RDNC  FQR  >512  >512  2  0.25  8  1  8  1  2  0.5 
19900828  Enteritidis  4  FQR  >512  512  2  0.25  4  0.5  8  1  2  0.5 
19901024  Enteritidis  4  FQR  >512  512  1  0.25  8  0.5  8  1  1  0.5 
19901059  Enteritidis  4  FQR  >512  256  2  0.125  4  0.5  2  1  2  0.5 
19901127  Enteritidis  Untypable  FQR  >512  512  2  0.25  4  1  4  1  2  0.5 
19901135  Enteritidis  Untypable  FQR  >512  512  2  0.25  4  0.5  4  1  2  0.5 
19901259  Enteritidis  4  FQR  >512  512  2  0.125  4  0.5  4  1  1  0.5 
19901289  Enteritidis  Untypable  FQR  >512  512  2  0.25  8  1  4  1  2  0.5  
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SSRL 
Reference 
Serotype  Phage 
type 
Breakpoint 
Designation 
DST 
Nal 
MH 
Nal 
DST  
Cp 
MH   
Cp 
DST 
Oflox 
MH 
Oflox 
DST 
Norflox 
MH 
Norflox 
DST 
Moxi 
MH 
Moxi 
19901442  Enteritidis  RDNC  FQR  >512  512  1  0.25  8  1  8  1  2  0.5 
19901527  Enteritidis  RDNC  FQR  >512  512  2  0.25  8  1  4  1  2  0.5 
19901602  Enteritidis  4  FQR  >512  512  1  0.25  8  1  8  1  1  0.5 
19901928  Enteritidis  4  FQR  >512  512  1  0.25  2  0.5  4  1  2  0.5 
19902644  Typhimurium  66  FQR  >512  512  2  0.5  8  1  8  2  4  2 
19903116  Enteritidis  RDNC  FQR  >512  512  2  0.125  4  0.5  4  2  2  0.5 
19903993  Enteritidis  Untypable  FQR  >512  512  1  0.125  8  0.5  8  1  1  0.5 
19933339  Enteritidis  4  FQR  >512  512  1  0.25  8  0.5  4  1  1  0.5 
19933488  Mbandaka    FQR  >512  512  2  0.5  8  1  8  2  4  1 
19940784  Enteritidis  4  FQR  >512  512  1  0.25  8  0.5  8  1  2  0.5 
19941463  Typhimurium  204  MDR  >512  512  1  0.25  4  0.5  2  1  1  0.5  
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SSRL 
Reference 
Serotype  Phage 
type 
Breakpoint 
Designation 
DST 
Nal 
MH 
Nal 
DST  
Cp 
MH   
Cp 
DST 
Oflox 
MH 
Oflox 
DST 
Norflox 
MH 
Norflox 
DST 
Moxi 
MH 
Moxi 
19940871  Enteritidis  4  FQR  >512  512  2  0.25  8  1  8  1  2  0.5 
19941804  Mbandaka    FQR  >512  512  2  0.25  4  1  4  1  2  1 
19941864  Enteritidis  4  FQR  512  512  2  0.25  32  1  16  1  2  0.5 
19943026  Enteritidis  4  FQR  512  512  1  0.25  8  0.5  4  1  1  0.5 
19964025  Enteritidis  5c  FQR  >512  512  4  0.125  8  0.5  8  1  8  0.5 
19982543  Enteritidis  4  FS  8  8  0.125  0.03  0.25  0.25  0.25  0.25  0.25  0.06 
19982886  Mbandaka    NaCpL  >512  512  2  0.25  4  1  4  1  2  0.5 
19983032  Senftenberg    NaCpL  >512  128  0.5  0.125  4  0.5  4  1  1  0.25 
19984026  Enteritidis  1  NaCpL  >512  512  0.5  0.125  2  0.25  2  1  1  0.25 
19990341  Typhimurium  104  FS  8  8  0.125  0.03  0.25  0.125  0.25  0.125  0.06  0.06 
19990515  Hadar    MDR  >512  512  2  0.5  4  2  4  2  8  4  
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SSRL 
Reference 
Serotype  Phage 
type 
Breakpoint 
Designation 
DST 
Nal 
MH 
Nal 
DST  
Cp 
MH   
Cp 
DST 
Oflox 
MH 
Oflox 
DST 
Norflox 
MH 
Norflox 
DST 
Moxi 
MH 
Moxi 
19990807  Enteritidis  8  MDR  >512  512  2  0.5  4  2  8  2  4  4 
19990976  Mbandaka    FQR  >512  512  1  0.25  16  1  16  2  2  1 
19991655  Enteritidis  21  NaCpL  >512  512  0.5  0.125  0.5  0.25  1  0.125  1  0.25 
19992003  Kottbus    NaCpL  256  128  0.25  0.125  2  0.25  2  1  1  0.25 
19992070  Hadar    NaCpL  >512  512  1  0.25  4  0.5  4  1  2  1 
19992835  Typhimurium  3  NaCpL  16  16  0.5  0.06  2  0.125  2  0.25  0.25  0.125 
19993033  Enteritidis  4  MDR  >512  512  1  0.5  4  1  4  2  2  1 
19993056  Dublin    NaCpL  >512  128  0.5  0.125  2  0.25  2  1  1  0.25 
19993085  Thompson    NaCpL  >512  512  1  0.25  4  0.5  2  1  1  0.5 
19993115  Enteritidis  4  NaCpL  >512  256  0.5  0.125  2  0.25  2  1  1  0.25 
19993983  Mbandaka    FQR  >512  512  2  0.25  8  1  4  1  2  1  
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SSRL 
Reference 
Serotype  Phage 
type 
Breakpoint 
Designation 
DST 
Nal 
MH 
Nal 
DST  
Cp 
MH   
Cp 
DST 
Oflox 
MH 
Oflox 
DST 
Norflox 
MH 
Norflox 
DST 
Moxi 
MH 
Moxi 
19994609  Enteritidis  14b  NaCpL  >512  512  0.5  0.125  2  0.5  2  0.5  1  0.5 
20000283  Mbandaka    MDR  >512  512  2  0.125  4  0.125  2  0.25  2  0.5 
20001178  Typhimurium  104  FS  8  8  0.25  0.03  0.5  0.06  0.5  0.125  0.25  0.06 
20001314  Enteritidis  4  NaCpL  >512  256  0.5  0.125  2  0.5  2  0.5  1  0.25 
20001526  Virchow    NaCpL  >512  256  0.5  0.125  0.5  0.25  2  0.5  1  0.25 
20002195  Enteritidis  1  NaCpL  >512  512  1  0.125  2  0.25  2  0.5  1  0.25 
20002660  Enteritidis  1c  NaCpL  >512  >512  0.5  0.125  2  0.25  2  0.5  1  0.25 
20003940  Typhimurium  40  FS  8  8  0.06  0.03  0.25  0.125  0.25  0.25  0.06  0.03 
20004338  Enteritidis  1c  NaCpL  >512  512  0.5  0.125  2  0.5  2  0.5  1  0.25 
20004592  Enteritidis  RDNC  NaCpL  >512  512  0.5  0.125  1  0.5  2  0.5  1  0.25 
20004928  Antarctica    NaCpL  >512  512  0.5  0.125  2  0.25  2  0.5  1  0.25  
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SSRL 
Reference 
Serotype  Phage 
type 
Breakpoint 
Designation 
DST 
Nal 
MH 
Nal 
DST  
Cp 
MH   
Cp 
DST 
Oflox 
MH 
Oflox 
DST 
Norflox 
MH 
Norflox 
DST 
Moxi 
MH 
Moxi 
20005084  Enteritidis  4  NaCpL  >512  512  0.5  0.125  1  0.5  2  0.5  1  0.25 
20005141  Enteritidis  Untypable  NaCpL  >512  512  1  0.125  1  0.25  2  0.5  1  0.25 
Table abbreviations: DST, Diagnostic sensitivity agar; MH, Mueller Hinton agar; Nal, nalidixic acid; Cp, ciprofloxacin; Oflox, ofloxacin; 
Norflox, norfloxacin; Moxi, moxifloxacin 
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3:3   Discussion 
3:3:1  Agar dilution method using DST 
The SSRL employs a breakpoint method for sensitivity testing as it is a very efficient 
method of screening large numbers of isolates with minimal time and effort. The data 
generated are used for epidemiological surveillance purposes and therefore it is perfectly 
sufficient to know whether an isolate is sensitive, resistant or intermediate. Breakpoints are 
determined by organisations such as the British Society for Antimicrobial Chemotherapy 
(BSAC) or CLSI (Clinical Laboratory Standards Institute). Recently national susceptibility 
testing committees from Britain, France, The Netherlands, Norway, Sweden and Germany 
have collaborated on a project to harmonise antimicrobial breakpoints including previously 
established MIC values that differed between countries. The result is EUCAST (European 
Committee on Antimicrobial Susceptibility Testing) which has produced a list of MIC 
breakpoints for antimicrobials for which there has been international agreement. It is the 
breakpoints produced by EUCAST that have been used for the interpretation of the results 
of  this  experiment;  resistant  at  ≥1mg/L  for  ciprofloxacin,  ofloxacin,  norfloxacin  and 
moxifloxacin. 
For the strains selected from the SSRL database as “fully-susceptible”, the agar dilution 
experiment confirmed the breakpoint results for nalidixic acid, as all of the strains were 
fully susceptible at 40mg/L. The current recommended breakpoint for nalidixic acid is 
32mg/L; some strains in this study date back to 1990 when the SSRL employed a 
breakpoint of 40mg/L, therefore this value was chosen for the sake of consistency 
throughout the experiment. The MIC results for ciprofloxacin confirmed the susceptibility 
of the majority of the strains however 8 strains that were susceptible by breakpoint had 
reduced sensitivity to ciprofloxacin at a concentration of 0.125mg/L. With the exception of  
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a single strain of S. Dublin which was resistant to ofloxacin and norfloxacin at a 
concentration of 2mg/L, all the strains were susceptible to ofloxacin, norfloxacin and 
moxifloxacin at the breakpoint of 0.5mg/L. With the exception of the 8 strains with 
reduced susceptibility to ciprofloxacin, the breakpoint data for the 25 “fully susceptible” 
strains were confirmed by this experiment. 
Two strains selected as resistant to nalidixic acid and low-level ciprofloxacin by breakpoint 
had reduced susceptibility to nalidixic acid with MICs of 16mg/L. One was also 
susceptible to all four fluoroquinolones, while the other was additionally susceptible to 
ciprofloxacin and moxifloxacin only. The remaining forty-four strains were as expected, 
resistant to nalidixic acid at a concentration, for the majority of these strains, of >512mg/L. 
The MICs of ciprofloxacin were slightly higher than anticipated. As they had been selected 
on the basis of reduced susceptibility, MICs of 0.125mg/L were expected. Instead, 38 of 
the 46 strains had MICs of ≥0.5mg/L and 37 of these strains were resistant to ofloxacin at 
≥2mg/L while 43 were resistant to norfloxacin at ≥2mg/L.  
The MICs for the strains selected as resistant to both nalidixic acid and ciprofloxacin 
(0.5mg/L) confirmed that all 59 strains were resistant to both antimicrobials and that they 
also exhibited cross-resistance to ofloxacin, norfloxacin and moxifloxacin.  
For the last group of strains, selected on the basis of their multi-drug resistance, 44 of the 
50 strains were resistant to nalidixic acid at concentrations of 256- >512mg/L; 6 were 
found to be fully susceptible with MICs of 8mg/L. Details of these 6 can be found in Table 
3:3. 
The strain of S. Typhimurium DT204c was resistant to an additional 8 antimicrobials and 
had very high MICs for three of the four fluoroquinolones, while a strain of monophasic  
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group C1 Salmonella, resistant to 13 of the 14 antimicrobials tested was only additionally 
resistant to ofloxacin with an MIC of 4mg/L. Four of these 6 strains are fully susceptible to 
ciprofloxacin. On the basis of their MIC for nalidixic acid it could be assumed that these 
six strains do not have mutations in their gyrA genes as usually even a single point 
mutation is sufficient to confer reduced susceptibility to quinolones (Levy et al, 2004). 
This does not explain the high MIC to ciprofloxacin demonstrated in two of the strains. 
MICs of this level are generally thought to require the presence of gyrase mutations and 
not be solely the result of increased efflux pump activity (Chen et al, 2007). The MICs for 
ofloxacin and norfloxacin were extensive and ranged from 0.25-256mg/L and 0.125-
256mg/L respectively. The MICs for moxifloxacin were slightly lower ranging from 
0.125-32mg/L. The “higher-than-expected” ciprofloxacin MIC results for the NCpL strains 
coupled with the very high MICs for ofloxacin and norfloxacin in the MDR strains 
highlighted some discrepancies in this experiment. Why were these MIC results so 
different from the breakpoint results? In case of any experimental error, the experiment 
was repeated but the same results were obtained. After consulting a member of the BSAC 
committee (Dr. Jennifer Andrews), it was concluded that Diagnostic sensitivity agar may 
not be suitable for use with fluoroquinolones as the high concentrations of magnesium and 
calcium ions may have an inhibitory effect on the fluoroquinolones causing raised MICs. 
In light of this information, a random selection of 55 strains from the collection was 
investigated for MIC on Mueller Hinton agar. 
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3:3:2  Study2 Agar dilution method using MH 
Of the 55 strains studied, 26 were from the group resistant to nalidixic acid and 
ciprofloxacin at a concentration of 0.5mg/L, FQR; 20 were from the nalidixic acid and 
low-level ciprofloxacin (0.125mg/L) group NCpL; 5 were from the multi-resistant group 
MDR and 4 were from the “fully susceptible” group FS. 
Once again the FS strains investigated were shown to be sensitive to all five 
antimicrobials. The strain of S. Typhimurium DT 104, with the intermediate MIC of 
16mg/L for nalidixic acid using DST agar, proved to have the same MIC of 8mg/L as the 
other FS strains using Mueller Hinton agar.  
Nineteen of the 20 NCpL strains were confirmed as resistant to nalidixic acid and had at 
least reduced susceptibility to the four fluoroquinolones. A single strain of S. Typhimurium 
DT 3 was susceptible to nalidixic acid and ciprofloxacin but had reduced susceptibility to 
ofloxacin, norfloxacin and moxifloxacin. This suggests that the results of the breakpoint 
testing were wrong and that this strain, since it is susceptible to all the antimicrobials at 
EUCAST breakpoints, should be classed as “fully susceptible”.  
All 26 (FQR) strains exhibited resistance to nalidixic acid, ofloxacin, norfloxacin and 
moxifloxacin. Only one strain was cross-resistant to ciprofloxacin with an MIC of 
0.5mg/L; the other 25 classed as having reduced susceptibility with MICs of 0.125-
0.25mg/L. Although the majority of these strains are classed as resistant by EUCAST 
standards, the highest MIC recorded was 2mg/L in only five strains; not nearly as high as 
those recorded when using DST agar. This is a good indication of the inhibitory effect of 
the DST agar when fluoroquinolone antimicrobials are incorporated for the purposes of 
MIC determination.  
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On the basis of these findings, the Scottish Salmonella Reference Laboratory conducted a 
study into the agar used in the breakpoint method of susceptibility testing. The results 
indicated that Mueller Hinton and Isosensitest agar gave indistinguishable results therefore 
the agar used in the routine susceptibility testing by breakpoint method was changed from 
Diagnostic Sensitivity agar to Isosensitest agar as recommended by the BSAC 
organisation. 
The MDR strains investigated were all resistant to nalidixic acid with MICs of 512mg/L 
and, although the majority of the strains were categorised as resistant to the 
fluoroquinolones (with the exception of ciprofloxacin which exhibited reduced 
susceptibility), they were not highly resistant. These results mirror those of a previous 
study which found that a single point mutation in gyrA resulted in resistance to nalidixic 
acid (MIC ≥128mg/L) and reduced susceptibility in ciprofloxacin (MIC between 0.125 and 
0.25mg/L). It was also discovered that the parental clone of the strains of S. Virchow under 
investigation overproduced the AcrAB efflux pump which, in this study would account for 
the multiple resistances to the non-fluoroquinolone antimicrobials (Solnik-Isaac et al, 
2007). 
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Table 3:3: Additional resistances of the six nalidixic acid-susceptible multi-drug resistant strains of Salmonella. 
 
SSRL 
Reference  Serotype  Phage 
type  Additional resistances
a  Nalidixic 
acid  Ciprofloxacin  Ofloxacin  Norfloxacin  Moxifloxacin 
19932300  Hadar    St;Te  8  32  16  16  4 
19933344  Typhimurium  204c  Ap;Cl;Ka;Sp;St;Sx;Te;Tm  8  32  256  256  16 
19982602 
Monophasic 
group C1 
  Ap;Cl;Cp;Fz;Gm;Ka;Ne;Sp;St;Sx;Te;Tm  8  0.06  4  0.25  0.125 
19991825  Enteritidis  4  Fz,Tm  8  0.25  8  4  0.125 
20000673  Senftenberg    Ka;Te  8  0.125  0.5  0.125  1 
20002058  Typhimurium  104b  Ap;St;Sx;Tm  8  0.06  0.25  4  1 
a Antimicrobials: Ap, ampicillin; Cl, chloramphenicol; Cp, ciprofloxacin; Fz, furazolidone; Gm, gentamicin; Na, nalidixic acid; Ne, 
netilmycin; Sp, spectinomycin; St, streptomycin; Sx, sulphamethoxazole; Te, tetracycline; Tm, trimethoprim. 
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Chapter 4: Selection and study of Spontaneous Mutants I 
4:1  Introduction 
With the incidence of treatment failures with fluoroquinolones increasing, the occurrence 
of Salmonella with reduced susceptibility to these drugs has become a real concern 
(Hakanen et al, 2001; Mehta et al, 2001). The Luria-Delbruck dogma states that resistant 
mutants occur spontaneously before the exposure of bacteria to the antimicrobial. If this is 
true, then Salmonella deemed susceptible to antimicrobials may potentially harbour a 
subpopulation of mutants with reduced susceptibility. 
In Staphylococcus aureus, the presence in some strains, of heterogeneous resistance to 
vancomycin has been noted. Hetero-Van-resistant-Staphylococcus aureus (hVRSA) strains 
are defined as those strains that contain non-susceptible subpopulations at a frequency of 
10
-6 or higher (Jung, 2002). It is possible that these hVRSA strains are precursors of 
vancomycin-intermediate-susceptible Staphylococcus aureus strains, and therefore the 
early detection of these strains is imperative. Similarly, the early detection of non-
susceptible subpopulations of bacteria in otherwise susceptible strains of Salmonella is 
imperative if an even higher incidence of treatment failures is to be avoided.  
The purpose of these experiments was to investigate the possibility that resistant 
subpopulations of bacteria exist in ostensibly susceptible strains of Salmonella. If so, then 
to calculate the frequency with which they appear and to characterize the mutations, if any, 
that are present.  
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4:2  Study 1:  Population analysis experiment 
4:2:1  Materials 
Test organisms           Strains of Salmonella susceptible to 
fluoroquinolones 
as detailed previously in section 2:2:1 
MH agar              as in section 3:1:1 
CLED agar              as in section 2:2:2:1 
BHI broth              as in section 2:2:2:1 
Glycerol              Sigma Aldrich  G-6279 
Sterile distilled water            as in section 3:1:1 
Etests (ciprofloxacin)           Biostat-51000686 
 
Antimicrobials:   
Ciprofloxacin powder           as in section 3:1:1 
Ofloxacin              as in section 3:1:1   
Norfloxacin              as in section 3:1:1   
Moxifloxacin              as in section 3:1:1 
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4:2:2:1  Method 
MH agar plates were prepared by adding a 0.25ml aliquot of 1000mg/L antimicrobial stock 
solution to 500ml of sterilized molten agar that had been cooled to 50ºC. From this 20 
plates with a final antimicrobial concentration of 0.5mg/L were poured and allowed to set 
at room temperature. In addition, plates with final concentrations of 0.125mg/L 
ciprofloxacin and 1mg/L norfloxacin were similarly prepared, as were non-selective plates 
with no added antimicrobial. 
Several colonies were taken from an overnight CLED plate, inoculated into 5 ml Brain 
Heart Infusion (BHI) broth and incubated with shaking at 37°C overnight. The broths were 
centrifuged at 18,000g for 5 minutes and the pellet was resuspended in 1ml BHI broth. The 
culture was adjusted to an optical density of 0.15 at 540nm, which is approximately 
10
8colony forming units (cfu) per ml.  
Viable cell counts were determined by performing a series of 1:10 dilutions. 0.1ml aliquots 
of the dilutions were inoculated onto two non-selective MH agar plates for each dilution 
and incubated overnight. The number of colonies from the non-selective plates where the 
inoculum had yielded growth that was easily quantifiable was recorded and an average 
cfu/ml was determined from the two plates.  
Aliquots of 0.1ml were inoculated onto the antimicrobial-containing MH agar plates in 
duplicate and incubated at 37ºC. The plates were examined after 24 hours. If no growth 
was detected then the plates were replaced in the incubator for a further 24 hours and re-
examined. If colonies were detected, they were considered to be mutants and were 
subcultured onto MH agar containing the same concentration of relevant antimicrobial to 
confirm resistance. The plates were incubated at 37°C and examined for growth 24 hours  
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later. If the mutants had grown on the confirmatory plates then the MIC of the selecting 
antimicrobial was determined before being inoculated  into 5mls BHI and incubated with 
shaking at 37ºC overnight before being stored at -80°C in 15% glycerol. These were later 
recovered and subjected to PFGE to ensure they were unchanged from the wild-type strain 
before being sequenced.  
The MICs of ciprofloxacin were determined by Etest for a number of mutants selected on 
ofloxacin, norfloxacin and moxifloxacin. 
4:2:2:2  Determination of MIC by Etest 
Colonies taken from a fresh overnight CLED plate were resuspended in 3mL of sterile 
0.85% saline to a turbidity of 0.5 McFarland units and inoculated onto Mueller-Hinton 
agar plates using a cotton wool swab and a RP 454 rotary plater (Denley, England). 
Ciprofloxacin Etest strips were placed onto the plates, which were then incubated at 37°C 
for 18 hours. MIC values were determined according to the manufacturer’s instructions. 
4:2:2:3  Determining the frequency of spontaneous fluoroquinolone-selected 
mutants. 
The mutants were counted and the rate of spontaneous mutation was determined with 
regards to the total cell population inoculated onto the antimicrobial-containing agar plates 
determined by the viable cell count. 
 
4:2:3  Results 
A total of 46 spontaneous mutants with raised fluoroquinolone MICs were recovered from 
6 strains of Salmonella enterica. An isolate of S. Typhimurium DT104 yielded the highest  
95 
 
number of mutants (n=33) recovered using norfloxacin (n=16), ofloxacin (n=10) and 
moxifloxacin (n=7). A strain of S. Dublin was the only other organism to have mutants 
recovered using all three of these fluoroquinolones; the numbers were smaller yielding just 
2, 1 and 1 respectively. Five ofloxacin-selected mutants were obtained from a strain of S. 
Typhimurium DT40 with a further single mutant obtained from each of the strains of S. 
Typhimurium DT10 and S. Virchow. Two S. Typhimurium DT170 mutants were selected 
using moxifloxacin (n=1) and ofloxacin (n=1). No mutants were obtained when using 
ciprofloxacin as the selecting fluoroquinolone. 
Table 4.1 shows the frequencies of spontaneous mutants with raised MICs to norfloxacin, 
ofloxacin and moxifloxacin. In the strain of S. Dublin, the frequency of mutants resistant to 
norfloxacin was 4x10
-9 which was the lowest frequency detected. Conversely, the highest 
frequency of 1x10
-6was detected in the mutants spontaneously resistant to ofloxacin in the 
strain of S. Typhimurium DT104. 
All of the mutants selected on ofloxacin, norfloxacin and moxifloxacin exhibited a 
decrease in susceptibility to ciprofloxacin. Results are tabulated in Table 4:2.  
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Table 4:1. Frequencies of spontaneous mutants resistant to ofloxacin, norfloxacin and moxifloxacin. 
SSRL No.  Organism 
Wild-type 
MIC 
(mg/L) 
No. Cells per 
ml inoculum 
Selecting 
antimicrobial
a 
Total No. 
Mutants 
obtained 
Mutant MIC 
(mg/L) 
Frequency of 
spontaneous FQ 
mutation
b 
19993849  S. Typhimurium DT104  0.06  1x10
8  ofloxacin  10  1  1x10
-6 
    0.094  1x10
8  moxifloxacin  7  1-2  7x10
-7 
    0.25  1x10
8  norfloxacin  16  >2  1.6x10
-6 
20003940  S. Typhimurium DT 40  0.06  5x10
9  ofloxacin  5  1-2  1x10
-8 
20005189  S. Typhimurium DT170  0.03  8x10
7  moxifloxacin  1  1  1.25x10
-7 
    0.06  8x10
7  ofloxacin  1  1  1.25x10
-7 
20003962  S. Typhimurium DT 10  0.06  6.35x10
9  ofloxacin  1  1  1.6x10
-9 
19993805  S. Dublin  0.25  5x10
9  norfloxacin  2  1-2  4x10
-9 
    0.125  5x10
9  ofloxacin  1  1  2x10
-9 
    0.06  5x10
9  moxifloxacin  1  2  2x10
-9 
19983717  S. Virchow  0.06  5x10
9  ofloxacin  1  2  2x10
-9 
a All concentrations of selecting antimicrobial are 0.5mg/L except norfloxacin at 1mg/L 
b Mutants resistant to fluoroquinolones at BSAC/EUCAST breakpoints. 
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Table 4:2. Ciprofloxacin MICs of spontaneous fluoroquinolone-resistant mutants selected on ofloxacin, norfloxacin and moxifloxacin. 
SSRL 
Reference  Mutant  Organism  Selecting 
antimicrobial  WT Cp MIC (mg/L)  Mutant Cp 
MIC (mg/L) 
19993849  P13  S. Typhimurium 104  Moxifloxacin  0.012  0.38 
20003940  P35  S. Typhimurium 40  Ofloxacin  0.023  0.19 
  P36  -  -  -  0.38 
2005189  P41  S. Typhimurium 170  Ofloxacin  0.016  0.19 
  P42  -  -  -  0.25 
20003962  P43  S. Typhimurium 10  Ofloxacin  0.016  0.25 
19993805  P47  S. Dublin  Ofloxacin  0.016  0.38 
  P48  -  Norfloxacin  -  0.19 
  P50  -  Moxifloxacin  -  0.5 
19983717  P53  S. Virchow  Ofloxacin  0.016  0.5 
Cp-ciprofloxacin 
    Dashes indicate identity to parameter above 
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4:3  Study 2: Amplification and Sequencing of gyrA and parC genes in selected 
mutants exhibiting decreased susceptibility to fluoroquinolones. 
4:3:1  Materials 
Test organisms           
5 wild-type strains of Salmonella      as detailed in section 2:2:1 
9 mutants exhibiting decreased resistance to ciprofloxacin isolated in study 4.2: 
 (19993849, S. Typhimurium 104 (n=2); 20003940, S. Typhimurium 40; 20005189,  
S. Typhimurium 170; 20003962, S. Typhimurium 10; 19993805, S. Dublin (n=3);  
19983717, S. Virchow) 
 
Preparation of Template DNA 
CLED agar            as detailed in section 2:2:2:1 
PCR grade water          Sigma Aldrich-W3500   
     
Polymerase Chain Reaction 
Deoxynucleotide triphosphates (dNTPs)    ABgene  AB-0196 
Taq polymerase          GE Healthcare27-0799-04 
10X Reaction Buffer          supplied with Taq 
PCR grade water          as detailed above   
Redipac GP Agarose          as detailed in section 2:2:2:1  
10X TBE buffer          as detailed in section 2:2:2:1 
Ethidium Bromide          as detailed in section 2:2:2:1  
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Superladder-Low 100bp         ABgene  SLL-100 
6X Loading buffer          supplied with ladder 
 
Primers  
The primers used in this experiment for the detection of the gyrA and parC genes were 
made by MWG Biotech (Milton Keynes, U.K.) and were as follows: 
gyrA Primer 1   Forward-[5’-TGTCCGAGATGGCCTGAAGC-3’]   
gyrA Primer 2   Reverse-[5’-CGTTGATGACTTCCGTCAG-3’] 
parC Primer 1   Forward-[5’-ATGAGCGATATGGCAGAGCG-3’]  
parC Primer 2   Reverse-[5’-TGACCGAGTTCGCTTAACAG-3’] 
These primers were described previously by Giraud et al 1999. 
 
DNA Purification 
QIAquick PCR Purification Kit.      Qiagen 28104 
 
4:3:2  Methods 
4:3:2:1  Preparation of Template DNA 
The organisms under investigation were inoculated onto CLED agar plates and incubated 
at 37°C overnight. A single colony was then suspended in a 1.5ml microcentrifuge tube 
containing 1ml of sterile distilled water and placed on a heating block at 100°C for 12  
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minutes. The tubes were then centrifuged at 18,000g for 10 minutes. 80 l of supernatant 
was transferred to a clean tube and stored at -20ºC until needed. 
 
4:3:2:2  Polymerase Chain Reaction 
Reagents were prepared as a master mix in a “clean laboratory”, i.e. one that was free from 
possibly contaminating DNA. This master mix comprised: 25pmoles of both forward and 
reverse primer; 200µM dNTPs; 0.5U Taq polymerase; 10X Reaction buffer (that included 
1.5mM MgCl2) and sterile water. 
In the “dirty” laboratory, 20µl of the PCR master mix was aliquoted to 0.5ml PCR tubes. 
After adding 5µl of template DNA the tubes were immediately stored on ice. To the 
negative control, 5µl of sterile water was added to the tube in place of DNA. This would 
confirm that any amplification was the target DNA and not contaminating DNA. The tubes 
were immediately transferred to the GeneAmp PCR System 9700, which had been pre-
programmed with the relevant parameters. 
 
PCR Parameters 
Following an initial denaturation step of 3 minutes at 94°C, amplification was performed 
over 30 cycles, each one consisting of 1 minute at 94°C, 1 minute at hybridisation 
temperature specific to the target gene (55°C for gyrA, and 52°C for parC) and 1 minute at 
72°C, with a final extension step of 10 minutes at 72°C. 
Gel electrophoresis was performed on the resulting amplicons using a 1.5% agarose gel in 
1X TBE buffer at 80V for approximately 45 minutes. 100bp molecular weight marker was  
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added to wells at regular intervals and used to size the 470-bp and 412-bp products of the 
QRDR regions of gyrA, and parC respectively. The amplicons were visualised using 
ethidium bromide. 
 
4:3:2:3  DNA Purification 
The PCR product was purified using the QIAquick Purification Kit according to the 
manufacturer’s instructions. 
 
4:3:2:4  DNA Sequencing 
Sequencing of the PCR product was performed in both directions by GATC-Biotech, Lake 
Constanz, Germany on an ABI 3730XL capillary sequencer. 
4:3:2:5  Analysis of the sequence data 
GATC-Biotech provided chromatogram files containing the sequence data in addition to 
FAS files. The chromatogram files were checked using the software provided by GATC-
Biotech to ensure the correct oligonuclotide was assigned. 
Both the forward and reverse complement sequences were compared to the published gyrA 
or parC sequences of an Enteritidis isolate (Accession No. AM933172.1) and Salmonella 
Typhimurium LT2 (Accession No.AE006468.1) respectively, using BLAST software 
(available at http://blast.ncbi.nlm.nih.gov/Blast.cgi).  
A point mutation was accepted as genuine if it was present in both the forward and reverse 
complement sequences of the isolate.  
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4:3:3  Results 
The results of the sequence analysis are listed in Table 4.3. The 5 wild-type sequences 
were identical to published gyrA and parC sequences. All 9 mutants examined in this 
experiment had amino acid substitutions as a result of point mutations within the QRDR of 
gyrA. Four within Ser83 encoded phenylalanine residues, 4 within Asp87 resulted in 
substitutions to asparagine (2) and tyrosine (2) residues and one at Asp82 encoded an 
asparagine residue. These substitutions have been described previously. No mutants 
selected contained mutations within the QRDR of parC. 
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Table 4.3: MICs for wild-types and mutants and nucleotide changes in the QRDR region of gyrA with deduced amino acid 
substitutions. 
SSRL 
Reference  Mutants  Serotype  Phage 
type 
Selecting 
antimicro
bial 
WT 
MIC 
(mg/L) 
Mutant 
MIC 
(mg/L) 
    gyrA  sequencing results         
  Codons            80  81  82  83  84  85  86  87  88 
              CAC 
(His) 
GGC 
(Gly) 
GAT 
(Asp) 
TCC 
(Ser) 
GCA 
(Ala) 
GTG 
(Val) 
TAT 
(Tyr) 
GAC 
(Asp) 
ACC 
(Thr) 
19983717  P53  Virchow  n/a  Oflox  0.06  2  -  -  -  -  -  -  -  TAC 
(Tyr)  - 
19993849  P13  Typhimurium  104  Moxi  0.125  2  -  -  - 
TTC 
(Phe)   -   -        -         -   -    
-  P20  -  -  Norflox  0.25  >2  -  -  - 
TTC 
(Phe)    -   -        -      -  - 
20003940  P36  Typhimurium  40  Oflox  0.06  2  -  -  AAT(
Asn)  -    -         -  -  -  - 
20005189  P41  Typhimurium  170  Ofllox  0.06  1  -  -  -  -   -         -  -  AAC 
(Asn)  - 
20003962  P43  Typhimurium  10  Oflox  0.06  1  -  -  -  -  -   -   -    AAC 
(Asn)  - 
19993805  P47  Dublin  n/a  Oflox  0.125  1  -  -  -  TTC 
(Phe)     -   -         -         -         -     
104 
 
SSRL 
Reference  Mutants  Serotype  Phage 
type 
Selecting 
antimicro
bial 
WT 
MIC 
(mg/L) 
Mutant 
MIC 
(mg/L) 
    gyrA  sequencing results         
-  P48  -  -  Norflox  0.25  1  -  -  -  TTC 
(Phe)     -   -         -       -       - 
-  P50  -  -  Moxi  0.06  2  -  -  -        -     -   -   -  TAC 
(Tyr)  - 
Antimicrobial abbreviations: Cp, ciprofloxacin; Oflox, ofloxacin; Norflox, norfloxacin; Moxi, moxifloxacin 
Dashes indicate identity to parameter above 
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4:4  Discussion 
 
4:4:1  Study 1 Population analysis 
Spontaneous quinolone-resistant mutants were recovered from only 6 out of 25 strains of 
Salmonella enterica. This may be explained by a previous study which demonstrated that 
in vivo, resistance mechanisms resulting in  high-level fluoroquinolone-resistance may be 
deleterious, as in vitro high-level fluoroquinolone resistant mutants exhibited drastically 
altered growth on solid media relative to the wild-type organism (Giraud et al, 1999).  The 
46 mutants that were selected were obtained from strains that were ostensibly susceptible 
by the breakpoint and agar dilution methods of susceptibility testing, to norfloxacin, 
ofloxacin and moxifloxacin, and were selected on concentrations of antimicrobial at least 
twice their MIC. A selection of these mutants was sequenced to determine the mechanisms 
responsible for the resistance and will be discussed in the next section. Whatever the 
mechanism, their existence clearly has serious implications for the use of these 
antimicrobials in clinical therapy. Suboptimal dosing can enrich these resistant 
subpopulations resulting in overall resistance which in turn, has been shown to reduce the 
efficacy of other members of the same class of antimicrobial compound (Drlica , 2003). 
All three fluoroquinolones elicited low frequencies of spontaneous mutation. Among the 
six strains from which mutants were obtained, selection rates were between 1x10
-6 and 
4x10
-9. Previous studies have reported that spontaneous bacterial mutants usually arise at a 
low frequency between 10
-6 and 10
-8 (Zhao & Drlica, 2001). Mutation rates can be 
variable, and the lower frequencies of spontaneous mutation obtained in this experiment 
may have been a result of differences in experimental process, as previous studies have 
demonstrated. Experimental parameters such as the antimicrobial, the concentration of the  
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antimicrobial, physiological conditions, bacterial stress, the existence of mutations that 
produce mutator phenotypes and the capability of some antimicrobials to increase 
mutability are all inconsistent factors that can have a significant effect on the rate of 
selection making it difficult to achieve an accurate evaluation (Martinez & Baquero, 2000). 
The increase in cross-resistance to ciprofloxacin exhibited by the spontaneous ofloxacin-, 
norfloxacin- and moxifloxacin-resistant mutants confirms earlier reports that resistance in 
one fluoroquinolone confers resistance to all other fluoroquinolones (Hopkins et al, 2005). 
4:4:2   Study 2 Amplification and Sequencing of gyrA and parC genes  
The mutants characterised were selected from an ostensibly susceptible population as 
previously discussed. All were selected on agar plates containing at least 3 doubling 
dilutions of antimicrobial above their measured MIC. The mutations have all been 
observed in previous studies examining clinical isolates (Escribano et al, 2004; Eaves et al, 
2004), however one of these strains was of porcine origin and another of bovine origin.  
Ser83→Phe, found in the strains S. Typhimurium and S. Dublin, is the most common 
mutation described and is frequently associated with fluoroquinolone resistance (Ruiz et al, 
1995). In this instance, it was responsible for resistance to ofloxacin, norfloxacin and 
moxifloxacin. Asp87→Asn and Asp87→Tyr, the mutations described in the strains of S. 
Typhimurium DT 10, S. Typhimurium DT170 and S. Virchow were responsible for 
resistance to ofloxacin, as was the less frequently described mutation Asp82→Asn 
responsible for resistance in a strain of S. Typhimurium DT40. It may be noted that no 
mutants were selected using ciprofloxacin which has been the drug of choice in the 
treatment of severe or systemic Salmonella infections. This may be due to the fact that 
resistance to fluoroquinolones usually requires the acquisition of a number of mutations in  
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gyrA (Casin et al, 2003). Perhaps the single mutations described in this study were just first 
step mutations that required additional mutations, possibly in another of the topoisomerase 
genes, before clinical resistance to ciprofloxacin could be achieved.  
No mutants were selected from any strain of S. Enteritidis examined. It has been noted in a 
previous study that this serotype has the least capacity to generate mutants (Cebrían et al, 
2003).  
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Chapter 5: Selection and study of Spontaneous Mutants II 
 
5:1  Study 1: Selection of ciprofloxacin-resistant mutants using an antimicrobial 
concentration gradient. 
5:1:1  Introduction 
Due to the increase of multi-resistant isolates of Salmonella, fluoroquinolones are 
considered to be the drugs of choice in the treatment of infections where antimicrobial 
intervention is warranted. Unfortunately in recent years, resistance to this class of drugs 
has developed and treatment failures are being reported with increasing regularity (Boswell 
et al, 1997; Chandel & Chaudhry, 2001). 
In Salmonella, one mechanism of resistance is a result of a sequential accumulation of 
mutations in the topoisomerase genes. Most to date have been found to occur in a specific 
region of the gyrA gene of topoisomerase II which encodes the A subunit of gyrase, the 
primary target of fluoroquinolones; parC and parE genes of topoisomerase IV are 
considered to be secondary targets for fluoroquinolone action in Salmonella and a number 
of mutations have now been documented in these genes. 
The following two experiments were designed to illustrate the progressive accumulation of 
mutations and the concomitant decrease in susceptibility to fluoroquinolones by repeated 
exposure of a susceptible isolate of Salmonella, to subinhibitory concentrations of 
antimicrobial. The third experiment characterized the mutations of the selected mutants. 
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5:1:2  Materials 
Test Organisms  21 fully sensitive strains of Salmonella enterica as 
  detailed in section 2:2:1 
DST agar            as in section 3:1:1   
Ciprofloxacin powder         as in section 3:1:1 
Sterile distilled water          as in section 3:1:1 
CLED agar             as in section 2:2:2:1 
BHI broth            as in section 2:2:2:1 
Glycerol            as in section 4:2:1 
Etests (ciprofloxacin)         as in section 4:2:1 
Mueller Hinton agar           as in section 3:1:1 
 
5:1:3  Method 
Antimicrobial gradient plates were prepared using a modified version of the technique of 
Szybalski and Bryson (Szybalski & Bryson, 1952). A 0.1ml aliquot of a 100mg/L stock 
solution of ciprofloxacin was added to a glass universal containing sterilized molten DST 
agar that had been cooled to 50°C, to give a final concentration of 0.5mg/L. This was then 
poured into a square Petri dish, 15cm x 15cm, that had been raised to an angle of 5° at one 
side and allowed to solidify at room temperature in the angled position. The Petri dish was 
then levelled and a second 20ml amount of DST agar containing no antimicrobial was 
poured over the bottom layer. This was also allowed to solidify at room temperature. Plates 
were left overnight to allow diffusion of antimicrobial concentration gradients. Gradient  
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plates with final concentrations of 0.25mg/L, 0.75mg/L and 1.0mg/L were also prepared in 
this way. 
Several colonies were taken from an overnight CLED plate and inoculated into 5 ml BHI 
broth and incubated on a shaker at 37°C overnight. Using a sterile cotton swab, the 
bacterial culture was plated across the gradient plate in the direction of low to high 
antimicrobial concentration. The plates were allowed to dry and then incubated at 37°C 
overnight. If strains failed to grow on the 0.5mg/L gradient plates, they were re-inoculated 
into BHI and again shaken at 37°C overnight for plating out onto a 0.25mg/L gradient 
plate the next day. From those strains in which growth occurred, colonies growing nearest 
the high concentration end of the plate were subcultured into 5ml BHI and incubated 
overnight on a shaker at 37°C. If no individual colonies were present, a small sweep was 
taken using a plastic loop at the highest concentration end of the growth streak. This 
procedure was repeated until there was confluent growth along the entire concentration 
gradient. At this point a plastic loop was used to sample the growth at the high 
concentration end of the plate and subcultured into 5ml BHI, which was incubated on a 
shaker at 37°C overnight. This was then plated onto a gradient plate with a final 
concentration of 0.75mg/L ciprofloxacin. Plates were incubated at 37°C overnight. The 
experiment was repeated as many times as required to obtain confluent growth along the 
concentration gradient. Once this was achieved, the experiment was repeated using 
gradient plates with a final concentration of 1.0mg/L ciprofloxacin. 
Once growth had been established at least 25% along the concentration gradient of the agar 
plate MICs were determined using Etests for a number of mutants selected on 0.25mg/L 
(after 1 exposure), 0.5mg/L (after 1 and 2 exposures), 0.75mg/L (after 2 exposures) and 
1.0mg/L (after 2 exposures) gradient plates.  
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Throughout the experiment, colonies that were subcultured for plating out onto the 
gradient plates were also stored at -85°C in 15% glycerol. These were later recovered and 
characterised using PFGE to ensure the strains remained unchanged. 
 
Determination of ciprofloxacin MIC by Etest 
As detailed in section 4:2:2:2 
 
5:1:4  Results 
Results can be found in Table 5.1. On the first exposure on the 0.5mg/L gradient plate, 4 
of the 21 strains examined grew near to the lowest ciprofloxacin concentration end. From 
these, 5 individual mutant colonies and light confluent growth from the strain of S. 
Typhimurium DT40 were selected for further exposure on 0.5mg/L plates. The 17 strains 
that failed to grow were inoculated onto a 0.25mg/L gradient plate. As a result individual 
colonies were obtained from a further 5 strains, while a sweep of confluent growth in 
addition to single colonies was taken from the other 12 strains. 
Upon exposure on the 0.75mg/L gradient plates, no individual colonies were obtained and 
the growth was slight near the low concentration end of the plate. On the second exposure, 
good confluent growth was obtained along at least 1/3 of the gradient plate for all the 
strains. 
The same pattern of growth was observed following exposure on the 1.0mg/L gradient 
plates. Initially the strains failed to grow well with only slight growth, but upon the second 
exposure, confluent growth was obtained along at least ¼ of the gradient plate for most of  
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the strains with only a single strain of S. Dublin still only growing slightly at the low 
concentration end. 
All mutants subjected to PFGE had pulsed field profiles indistinguishable from their parent 
strains. 
The ciprofloxacin MICs were determined for the mutants selected from each of the 21 
strains. These results can be found in Table 5.2. In every case, the MIC of the mutant was 
greater than that of the wild-type strain. For 3 strains the difference is very slight with 
wild-type MICs of 0.012-0.023 increasing to 0.094mg/L in the mutants. Considerable 
differences were seen in strains of S. Enteritidis PT21, S. Typhimurium DT RDNC and S. 
Dublin, with mutant MICs of 0.75-1mg/L 10-fold greater than the original wild-type MICs 
of 0.016, 0.008 and 0.023mg/L respectively. The majority of mutants had MICs ranging 
between 0.125-0.5mg/L with their wild-type MICs ranging between 0.008-0.047mg/L. 
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Table 5.1: Mutants recovered from gradient plates using ciprofloxacin as the selecting antimicrobial 
 
 
 
  Growth from 
0.5mg/L plates 
Growth from 
0.25mg/L plates 
Growth from 
0.75mg/L plates 
Growth from 
1mg/L plates 
SSRL Reference  Serotype  Phage type  Exp
1 
Exp
2 
Exp
3  Exp 1  Exp 2  Exp 1  Exp 2  Exp 1  Exp 2 
19991929  Enteritidis  1  ng  1/g  1/g  g  G  g  G 
19982543  Enteritidis   4  ng  1/g  1/g  g  G  g  G 
19992150  Enteritidis  6a  ng  2/g  2g  g  G  g  G 
20004447  Enteritidis  21  ng  1/g  1/g  g  G  g  G 
19990341  Typhimurium  104  ng  1/g  1/g  g  G  g  G 
19993849  Typhimurium  104  ng  1/g  1/g  g  G  g  G 
20001178  Typhimurium  104  ng  1  G  g  G  g  G 
19983458  Typhimurium  2  ng  3  2/g  g  G  g  G 
19983155  Dublin    ng   1  G  g  G  g  G 
19993805  Dublin    ng  1/g  1/g  g  G  g  G  
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  Growth from 
0.5mg/L plates 
Growth from 
0.25mg/L plates 
Growth from 
0.75mg/L plates 
Growth from 
1mg/L plates 
SSRL Reference  Serotype  Phage type  Exp
1 
Exp
2 
Exp
3  Exp 1  Exp 2  Exp 1  Exp 2  Exp 1  Exp 2 
20000136  Dublin    ng  1/g  1/g  g  G  g  ng 
20001735  Dublin    ng  1/g  1/g  g  g  g  G 
20003052  Dublin    ng  1  g  g  G  g  G 
19983717  Virchow    ng  1/g  1/g  g  G  g  G 
19990706  Mbandaka    ng  1  G  g  G  g  G 
19991073  Brandenburg    ng  1/g  1/g  g  G  g  ng 
19991452  Binza    ng  1/g  1/g  g  G  g  g 
19994076  Typhimurium  104  1  1  3  -  g  G  g  G 
19983351  Typhimurium  RDNC  1  1  3  -  g  G  g  G 
20003962  Typhimurium  10  3  3  3  -  g  G  g  G 
20003940  Typhimurium 40  40  g  1  1  -  g  G  g  G 
Numerical value indicates number of single colonies recovered from the gradient plate. 
Exp, exposure; ng, no growth; g, light confluent growth; G, heavy confluent growth. 
  
115 
 
Table 5.2: MICs of mutants selected across ciprofloxacin concentration gradient 
determined by Etest (mg/L). 
SSRL 
Reference  Serotype   Phage 
type 
Wild type 
MIC  0.25mg/L  0.5mg/L 0.75mg/L  1.0mg/L 
20003940  Typhimurium   40  0.023  n/d  0.047   0.094   0.094  
19994076  Typhimurium   104  0.016  n/d  0.047  0.25   0.5  
20003962  Typhimurium   10  0.016  n/d  0.047   0.064   0.094  
19983351  Typhimurium  RDNC  0.023  n/d  0.125   1   0.5  
19993849  Typhimurium   104  0.012  0.064  -  -  0.38 
19983155  Dublin    0.008  0.012  -  -  0.75 
1999 0706  Mbandaka    0.008  0.064  -  -  0.19 
19992543  Enteritidis   4  0.016  0.064  -  -  0.25 
19983717  Virchow    0.016  0.047  -  -  0.38 
19991452  Binza    0.012  0.047  -  -  0.125 
19991929  Enteritidis   1  0.012  0.064  -  -  0.094 
19983458  Typhimurium   2  0.016  0.125  -  -  0.5 
19992150  Enteritidis   6a  0.047  0.064  -  -  0.125 
20004447  Enteritidis   21  0.016  0.125  -  -  0.75 
19990341  Typhimurium   104  0.023  0.06   -  -  0.125  
20001178  Typhimurium   104  0.023  0.125  -  -  0.19  
19993805   Dublin    0.016  0.06   -  -  0.19  
20001735  Dublin    0.016  0.06   -  -  0.125  
20003052  Dublin    0.016  0.06   -  -  0.5  
19991073  Brandenburg    0.032  0.125   -  -  ng 
20000136  Dublin    0.023  0.06   -  -  ng 
ng: no growth 
-: mutants not stored  
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5:2  Study 2: Selection of mutants by exposure to subinhibitory concentrations of 
fluoroquinolones. 
5:2:1  Materials 
Test organisms: 20000041, strain of S. Typhimurium DT104 R-type ACSSxT [Tym
R]  
  3 “FS” strains previously detailed in section 2:2:1 
(19991929, S. Enteritidis PT1; 19994076, S. Typhimurium DT104 [Tym
S];       
19990706, S. Mbandaka) 
DST agar              as detailed in section 3:1:1 
CLED agar               as detailed in section 2:2:2:1 
PCR grade water            as detailed in section 4:3:1 
BHI broth              as detailed in section 2:2:2:1 
Glycerol              as detailed in section 4:2:2 
 
Antimicrobials: 
Ciprofloxacin              as detailed in section 3:1:1 
Ofloxacin              as detailed in section 3:1:1 
Norfloxacin              as detailed in section 3:1:1 
Moxifloxacin              as detailed in section 3:1:1 
 
5:2:2  Method 
For each individual antimicrobial, an aliquot of stock solution was added to a glass 
universal containing sterilized molten DST agar that had been cooled to 50ºC to give final 
concentrations of 0.125mg/L and 0.5mg/L and ⅛ the measured MIC for each antimicrobial  
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determined for each one of the Salmonella isolates. Plates with no antimicrobial added 
were also prepared as control plates. Experiments were performed in duplicate. 
Several colonies were taken from an overnight CLED plate and inoculated into 5ml BHI 
broth and incubated on a shaker at 37°C overnight. The culture was adjusted to an optical 
density of 0.15 at 540nm, containing approximately 10
8 colony forming units (cfu). 0.1ml 
aliquots of culture were plated out using a plastic spreader over the surface of a non-
selective DST plate and plates containing 0.5mg/L, 0.125mg/L and the subinhibitory 
concentration of antimicrobial. These were allowed to dry at room temperature and 
incubated overnight at 37°C. The entire growth was harvested from the subinhibitory plate 
using a sterile cotton swab and resuspended in 3ml sterile saline. After vortexing to ensure 
thorough resuspension, the culture was again adjusted to 0.15 at 540nm. 0.1ml aliquots 
were again plated out onto new plates and incubated overnight at 37°C after drying. The 
0.125mg/L and 0.5mg/L plated were examined for growth. When growth was observed on 
either plate, the complete population was subcultured into 5mls BHI and incubated on a 
shaker overnight at 37ºC. The MIC was measured at various points and if determined to be 
at least twice the original MIC value, was subjected to three exposures in the absence of 
antimicrobial to ensure stability of the mutation. This mutant was then characterized using 
PFGE and stored at –85ºC in 15% glycerol to await further investigation. This experiment 
was repeated 18 times or if less, as many times as required to obtain growth on the 
0.125mg/L and 0.5mg/L concentration plates, indicating a reduction in susceptibility to the 
antimicrobial. 
5:2:3  Results 
Antimicrobial susceptibility was found to be reduced following repeated exposure to 
subinhibitory concentrations of fluoroquinolones. Results for the selection of mutants are  
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recorded for growth on both 0.125mg/L and 0.5mg/L ciprofloxacin. The MIC results for a 
selection of these mutants are shown in Table 5:3 and Figure 5:1. 
Confluent growth was obtained on each of the agar plates containing the subinhibitory 
concentrations of antimicrobial. Repeated exposure on these plates resulted in a decrease in 
fluoroquinolone susceptibility in each of the 4 strains examined. Two strains of S. 
Typhimurium were included in this experiment. Both were indistinguishable by PFGE and 
plasmid profile analysis. One was fully susceptible to antimicrobials (Tym
S) whilst the 
other had the pentaresistant R-type (Tym
R) common to S. Typhimurium DT104. Both 
strains showed a decrease in susceptibility to each of the 4 fluoroquinolones (Figures 5:2 
& 5:3). For ciprofloxacin, Tym
R required the shortest time before growing on the 
0.125mg/L plates, taking just three exposures to display a reduction in susceptibility from 
an initial MIC of 0.012 to 0.25mg/L. After eighteen exposures, 0.5mg/L was the highest 
MIC recorded for the mutants tested. Although the initially susceptible Tym
S had a slightly 
higher initial MIC of 0.016mg/L, it took five subinhibitory exposures before an increase in 
MIC to 0.19mg/L was observed, however MICs of 1.5mg/L, 0.5mg/l, and 1.0mg/L were 
recorded in mutants isolated from further subinhibitory exposures. For moxifloxacin and 
ofloxacin, the MICs of both Tym
S and Tym
R increased from 0.064mg/L and 0.047mg/L 
respectively, to 0.38mg/L after 16 exposures in Tym
S and only 9 exposures in Tym
R 
(0.25mg/L for moxifloxacin). The MIC of Tym
S rose from 0.047mg/L to 0.25mg/L, while 
that of Tym
R rose from 0.125mg/L to 0.38mg/L, each after 11 exposures to subinhibitory 
concentrations of norfloxacin. The strain of S. Enteritidis PT1 increased from an initial 
MIC of 0.012mg/L for ciprofloxacin to 0.38mg/L in 4 subinhibitory exposures, rising to 
1mg/L after just 5 exposures.  The MIC of the S. Kottbus, already resistant to low-level 
ciprofloxacin (0.125mg/L) upon its introduction to this experiment, increased to 0.25mg/L  
119 
 
after only 4 subinhibitory exposures. Despite this, the MIC failed to increase beyond 
0.25mg/L, with no colonies recovered from the 0.5mg/L plates. 
All of the mutants were characterised by PFGE and were confirmed as having profiles 
indistinguishable from those of the parent strains except for those of S. Mbandaka, which 
had several band differences that appeared to be a result of contamination and were 
therefore disregarded for the remainder of the experiment.  
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Table 5.3. Selection of mutants using subinhibitory concentrations of fluoroquinolones and the MICs achieved. 
SSRL 
Reference 
Organism  Selecting 
Antimicrobia
l 
Selecting 
Concentration 
(mg/L) 
Number of 
subinhibitory 
subcultures 
Number of 
colonies 
isolated 
Parent strain 
MIC(mg/L) 
Mutant MIC 
(mg/L) 
19991929  S. Enteritidis PT1  Ciprofloxacin  0.125  4  6  0.012  0.38 
-  -  -  -  5  8  -  0.38 
-  -  -  0.5  5  4  -  0.75-1.0 
19994076  S. Typhimurium DT 104  Ciprofloxacin  0.125  4  2  0.016  0.19 
-  -  -  -  5  2  -  0.19 
-  -  -  0.5  10  2  -  1.5 
-  -  -  -  12  2  -  1.0 
-  -  -  -  16  1  -  0.5 
-  -  -  -  18  1  -  1.0 
-  -  Moxifloxacin  0.125  2  1  0.064  0.064 
-  -  -  -  3  1  -  0.19 
19994076  S. Typhimurium DT104  Moxifloxacin  0.5  16  1  0.064  0.38 
-  -  Ofloxacin  0.125  2  1  0.047  0.047 
-  -  -  0.5  16  1  -  0.38 
19994076  S. Typhimurium DT104  Norfloxacin  0.125  1  1  0.047  0.047  
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SSRL 
Reference 
Organism  Selecting 
Antimicrobia
l 
Selecting 
Concentration 
(mg/L) 
Number of 
subinhibitory 
subcultures 
Number of 
colonies 
isolated 
Parent strain 
MIC(mg/L) 
Mutant MIC 
(mg/L) 
-  -  -  0.5  11  1  -  0.25 
20030041  S. Typhimurium DT 
104
a 
Ciprofloxacin  0.125  3  1  0.012  0.25 
20030041  S. Typhimurium DT 
104
a 
Ciprofloxacin  0.125  5  2  -  0.25 
- 
-  -  -  6  2  -  0.25 
-  -  -  -  18  1  -  0.5 
-  -  Moxifloxacin  0.125  4  2  0.064  0.064 
-  -  -  -  9  1  -  0.25 
-  -  Ofloxacin  0.125  4  1  0.047  0.047 
-  -  -  -  9  1  -  0.38 
-  -  -  0.5  9  1  -  0.25 
-  -  Norfloxacin  0.125  1  1  0.125  0.125 
-  -  -  0.5  11  1  -  0.38 
19992003  S. Kottbus  Ciprofloxacin  0.125  4  16  0.125  0.25 
-  -  -  -  8  29  -  0.25 
a Resistant to ampicillin, chloramphenicol, streptomycin, sulphamethoxazole, tetracycline.;  Dashes indicate identity to the parameter above  
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Figure 5:1 
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Diagramatic representation of the decrease in suceptibility of 4 strains of S. enterica following 
exposure to subinhibitory concentrations of ciprofloxacin.
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Figure 5:2 
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Figure 5:3 
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5:3  Study 3: Amplification and Sequencing of gyrA and parC genes in selected 
mutants exhibiting decreased susceptibility to fluoroquinolones.  
5:3:1  Materials 
Test organisms 
6 wild-type strains of Salmonella        as detailed in section 2:2:1 
12 mutants exhibiting decreased susceptibility to ciprofloxacin isolated in experiment 5:1: 
(19994076, S. Typhimurium DT104 (n=3); 19983351, S. Typhimurium RDNC (n=3); 
20004447, S. Enteritidis PT21 (n=2); 19982543, S. Enteritidis PT4 (n=2); 19983155, S. 
Dublin; 19983717, S.Virchow). 
All other materials as described in section 4:3:1 
5:3:2  Methods 
All methods previously described in section 4:3:2 
5:3:3  Results 
The sequencing results can be found in Table 5.4. Mutations resulting in amino acid 
changes in gyrA were found in 5 of the 12 mutants examined; the remaining 7 had 
sequences that were identical to the gyrA of the wild-type S. Enteritidis. Two mutations 
within the Asp87 codon of a strain of S. Typhimurium DT104 encoded glycine residues 
and 2 mutations in a strain of S. Typhimurium DT RDNC encoded tyrosine residues. A 
fifth mutation at Ser83 in a strain of S. Dublin encoded a phenylalanine residue. All of 
these substitutions have been described previously. 
Only a single mutant of a strain of S. Virchow contained a mutation that encoded an amino 
acid substitution at Thr57→Ser within the QRDR of parC 
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Table 5.4: MICs for wild-types and mutants and nucleotide changes in the QRDR region of gyrA with deduced amino acid substitutions. 
SSRL 
Reference  Mutant  Organism  Selecting 
antibiotic 
WT 
MIC 
(mg/L) 
Mutant 
MIC 
(mg/L) 
    gyrA  sequencing results         
          Codons  80  81  82  83  84  85  86  87  88 
            CAC 
(His) 
GGC 
(Gly) 
GAT 
(Asp)  TCC (Ser)  GCA 
(Ala) 
GTG 
(Val) 
TAT 
(Tyr) 
GAC 
(Asp) 
ACC 
(Thr) 
19994076  M2  Typhimurium 104  Cp  0.016  0.047  -  -  -  -  -  -  -  -  - 
  M10        0.25  -  -  -  -  -  -  - 
GGC 
(Gly)  - 
  M52        0.5  -  -  -  -  -  -  - 
GGC 
(Gly)  - 
19983351  M3  Typhimurium 
RDNC    0.023  0.064  -  -  -  -  -  -  -  -  - 
  M14        1  -  -  -  -  -  -  - 
TAC 
(Tyr)  - 
  M54        1  -  -  -  -  -  -  - 
TAC 
(Tyr)  - 
20004447  M27  Enteritidis 21    0.016  0.125  -  -  -  -  -  -  -  -  - 
  M66        0.75  -  -  -  -  -  -  -  -  - 
19982543  M22  Enteritidis 4    0.016  0.064  -  -  -  -  -  -  -  -  -  
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SSRL 
Reference  Mutant  Organism  Selecting 
antibiotic 
WT 
MIC 
(mg/L) 
Mutant 
MIC 
(mg/L) 
    gyrA  sequencing results         
19982543  M64  Enteritidis 4  Cp  0.016  0.25  -  -  -  -  -  -  -  -  - 
19983155  M72  Dublin    0.008  0.75  -  -  -  TTC(Phe)  -  -  -  -  - 
19983717*  M77  Virchow    0.016  0.38  -  -  -  -  -  -  -  -   
Antimicrobial abbreviation: Cp, ciprofloxacin; 
Dashes indicate identity to wild-type codons above; 
*Mutation Thr57→Ser detected in QRDR of parC 
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5:4  Discussion 
5:4:1: Selection of ciprofloxacin-resistant mutants using an antimicrobial 
concentration gradient. 
The EUCAST MIC breakpoint for resistance to ciprofloxacin in strains of Salmonella 
enterica is 1mg/L, with a reduced susceptibility breakpoint of ≥0.5mg/L. Previous 
susceptibility testing by breakpoint method and Etest had categorised the strains as 
susceptible to ciprofloxacin. Heterogeneous populations of bacteria usually demonstrate 
slight variations in susceptibility to antimicrobial compounds. This study has demonstrated 
that by exposing these susceptible strains to a concentration gradient of ciprofloxacin, 
mutants could be selected that demonstrated sufficiently increased MICs to be categorised 
as intermediately-resistant and in one case resistant to ciprofloxacin. This phenomenon 
may account for the increasing number of reports of treatment failures with ciprofloxacin 
in purportedly susceptible strains of S. Typhi and other strains of Salmonella (Rupali et al, 
2004; Chang et al, 2006). In these reports however, the strains that failed to be resolved 
with ciprofloxacin therapy were resistant to nalidixic acid at a concentration of 32mg/L. 
This is a well-documented occurrence in that these strains usually have reduced 
susceptibility to ciprofloxacin that is overlooked by current routine laboratory testing 
methods (Oteo et al, 2000; Albayrak et al, 2004). Nevertheless, the strains in this study 
were susceptible to nalidixic acid, which suggests that a minority of mutants with reduced 
susceptibility to ciprofloxacin exist within the susceptible population. This has clinical 
implications in that it would be imperative that the correct dosage of ciprofloxacin be given 
in order to eradicate the less susceptible mutants. This would also be an argument in favour 
of using the “mutant prevention concentration” (MPC) when administering ciprofloxacin 
for the treatment of Salmonella infections. The MPC is defined as “no colony recovery  
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when 10
10 cells are applied to an agar plate” (Zhao & Drlica, 2001). A recent study has 
proposed an MPC value of 0.25mg/L ciprofloxacin for fully susceptible strains of S. 
Typhimurium and S. Enteritidis (Randall et al, 2004). 
 
5:4:2:  Selection of mutants by exposure to subinhibitory concentrations of 
fluoroquinolones 
Resistance to fluoroquinolones mainly occurs as a result of an accumulation of mutations 
in the topoisomerase genes of Salmonella. Mutants were selected following the repeated 
exposure of susceptible strains of Salmonella to subinhibitory concentrations of a 
fluoroquinolone. The strain of S. Enteritidis required the same number of exposures to 
show a reduction in susceptibility to ciprofloxacin as the three other strains examined. 
Additionally, the MIC increased to 1mg/L in just five exposures, making this serotype the 
fastest to achieve resistance. This is contrary to a previous study, which found that the 
strain of S. Enteritidis required more exposures than the other serotypes studied (Cebrian et 
al, 2003).  
Of the two strains of S. Typhimurium DT104 examined, the one with the pentaresistant R-
type (Tm
R) was the first to show a decrease in susceptibility to ciprofloxacin but over 
eighteen subinhibitory exposures the MIC did not increase beyond 0.5mg/L, whereas the 
fully susceptible S. Typhimurium (Tm
S) took slightly longer to display a decrease in 
susceptibility but the MIC increased to 1.5mg/L in just eleven exposures. It may be that the 
initial decrease in ciprofloxacin susceptibility in the pentaresistant strain of S. 
Typhimurium was due to increased efflux as a previous study has demonstrated that 
increased efflux resulting in multidrug resistance in a strain of S. Typhimurium also  
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resulted in an increase in unrelated antimicrobials such as quinolone/fluoroquinolones 
(Abouzeed et al, 2008). 
The MIC of the S. Kottbus, although resistant to low-level ciprofloxacin at the beginning 
of the experiment, did not rise beyond 0.25mg/L despite being subjected to eighteen 
exposures. This is reflected in the clinical strains of S. Kottbus received by the SSRL. 
From a total of eighteen isolates received between the years of 1990 and 2000, only one 
additional isolate was classed as resistant to low-level ciprofloxacin. 
Subinhibitory exposure of the two strains of S. Typhimurium to the three other 
fluoroquinolones all resulted in a decrease in susceptibility. With the exception of an 
increase in moxifloxacin MIC for Tm
S in four exposures, each the strains required more 
exposures to the subinhibitory concentrations of each of the fluoroquinolones than for 
ciprofloxacin, before displaying an increase in MIC, which did not reach resistance levels. 
This experiment was an attempt to mimic the conditions bacteria are sometimes subjected 
to in vivo when dosing regimens are inadequate. In an attempt to determine the order in 
which bacteria acquire the mutations that result in resistance, the QRDR regions of the 
gyrA and parC genes of the mutants recovered were sequenced. 
5:4:3: Sequencing of gyrA and parC genes in selected fluoroquinolone-resistant 
mutants. 
Exposure of these susceptible strains of Salmonella to either a concentration gradient or 
subinhibitory concentrations of fluoroquinolones resulted in mutants being recovered with 
reduced susceptibility to these antimicrobials. Sequencing of the QRDR of the gyrA gene 
revealed five strains to each have one of the most commonly isolated mutations associated 
with reduced susceptibility to fluoroquinolones; either Asp87→Tyr or Ser83→Phe (Griggs  
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et al, 1996) or Asp87→Gly (Ling et al, 2003). Compared to the wild-type MICs, the 
elevated MICs for the mutants were cause for concern in that they were determined to be 
≥0.5mg/L; further, the S. Typhimurium RDNC mutants with MICs of 1.0mg/L were 
considered resistant by EUCAST breakpoints. Perhaps in this instance, the overproduction 
of an active efflux pump worked synergistically with gyrA mutations to result in 
ciprofloxacin resistance (Giraud et al, 2000). Alternatively it may be that additional 
mutations were present in one or more of the other topoisomerase genes not examined.   
The mutant of S. Virchow which did not exhibit a mutation in the gyrA gene was the only 
mutant to have a parC mutation. The Thr57→Ser mutation is considered somewhat 
unusual in that single point mutations in topoisomerase IV genes are more common in 
Gram-positive species and in Gram-negative species, second-step mutations after those of 
gyrase leading to high-level fluoroquinolone resistance (Heisig, 1996). It may be that there 
are mutations within the gyrB and parE genes which were not examined, however this 
single mutation has been described previously in a strain of S. Virchow and no mutations 
were detected in any other topoisomerase gene. The Thr57→Ser mutation of parC has 
been thought not to be responsible for the decrease in susceptibility to quinolones as it has 
been detected in nalidixic acid-susceptible isolates (Weill et al, 2006). This would suggest 
that perhaps the increase in resistance to ciprofloxacin may be a result of a different 
mechanism of resistance such as the previously mentioned increased efflux or altered 
membrane permeability. 
Overall, these studies have demonstrated that strains of Salmonella enterica susceptible to 
fluoroquinolones by both breakpoint and agar dilution method of sensitivity testing do 
harbour mutants with decreased susceptibility to these antimicrobials. If exposed to 
subinhibitory concentrations of these same antimicrobials, the bacteria will not be inhibited  
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but will survive due to an enhanced fitness as a result of previous acquisition of first-step 
mutations and may, with prolonged exposure, continue to acquire mutations ultimately 
resulting in resistance to fluoroquinolone antimicrobials. 
 
 
 
 
 
 
 
 
 
 
 
 
  
133 
 
Chapter 6: Amplification and Sequencing of plasmid-mediated resistance genes 
qnrA, qnrB and qnrS. 
6:1  Introduction 
In Salmonella, quinolone resistance is mostly attributed to point mutations within the 
quinolone resistance-determining region (QRDR) of the gyrA gene and to a lesser extent 
the gyrB and topoisomerase IV genes. Other resistance mechanisms include alterations in 
efflux systems and outer membrane porins. 
Plasmid-mediated resistance was first reported in 1998 in a clinical strain of Klebsiella 
pneumoniae which carried a plasmid termed pMG252 (Martinez-Martinez, et al, 1998). 
This plasmid was found to contain the gene, now termed qnrA1 that is responsible for 
quinolone resistance. Since then a number of genes with varying degrees of similarity to 
qnrA1 have been discovered: qnrA1-6; qnrB1-20; qnrC; qnrD and qnrS1-4. Many qnr 
genes have been associated with strains of Salmonella that produce extended-spectrum β-
lactamases (ESBLs) and have been identified collocated with other resistance determinants 
on sul1-type integrons (Lavigne et al, 2006; Garnier et al, 2006). This is cause for concern 
as these mobile genetic elements could greatly increase the dissemination of qnr genes 
whose clinical importance lies in their ability to facilitate the selection of quinolone 
resistance mutations in the presence of bactericidal levels of antimicrobial. 
This purpose of this study was to determine the prevalence of qnr genes among Salmonella 
isolates  submitted  to  the  Scottish  Salmonella  Reference  Laboratory  from  human, 
veterinary and environmental sources in the years 1997-2007. 
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6:2  Materials 
 
Test organisms:   Detailed in Table 6:1. 53 strains of Salmonella enterica 
susceptible to nalidixic acid (40mg/L) but with reduced 
susceptibility to ciprofloxacin (0.125mg/L) by breakpoint 
method; 
  Detailed in Table 6:2. 17 strains of Salmonella enterica 
resistant to ciprofloxacin (0.125mg/L) and cefotaxime 
(1mg/L) by breakpoint method.  
Determination of MIC by Etest 
Etests (ciprofloxacin)         as detailed in section 4:2:2:2 
Mueller Hinton agar          as detailed in section 3:1:1 
 
Preparation of template DNA 
CLED agar              as detailed in section 2:2:2:1 
PCR grade water            as detailed in section 4:3:1 
 
Polymerase Chain Reaction 
Illustra PureTaq Ready-To-Go Beads        GE Healthcare 27-9558-01 
PCR grade water            as detailed in section 4:3:1   
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Gel Electrophoresis 
Redipac GP Agarose            as detailed in section 2:2:2:1 
10X TBE buffer            as detailed in section 2:2:2:1 
Ethidium Bromide            as detailed in section 2:2:2:1 
Superladder-Low 100bp ladder        as detailed in section 4:3:1 
6X Loading buffer            supplied with ladder 
 
Primers 
The primers used for the detection of the qnr genes were manufactured by VH Bio 
(Gateshead, U.K.) and have been described previously (Gay et al, 2006) and were as 
follows: 
qnrA    Forward  5’-ATTTCTCACGCCAGGATTTG-3’ 
    Reverse 5’-GATCGGCAAAGGTTAGGTCA-3’ 
qnrB    Forward 5’-GATCGTGAAAGCCAGAAAGG-3’ 
    Reverse 5’-ACGATGCCTGGTAGTTGTCC-3’ 
qnrS    Forward  5’-ACGACATTCGTCAACTGCAA-3’ 
    Reverse 5’-TAAATTGGCACCCTGTAGGC-3’ 
 
DNA Purification 
QIAquick PCR Purification Kit.        as detailed in section 4:3:1 
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Table 6:1  Strains of Salmonella enterica with reduced susceptibility to ciprofloxacin (0.125mg/L) but susceptible to nalidixic acid (40mg/L)  
 
SSRL No. 
Isolate 
Source 
Organism Name  PT  Ap  Cx
1  Cl  Cp  Fz  Gm  Ka  Na  Ne  Sp  St  Sx  Te  Tm  LCp 
19973002  Human  Typhimurium  104  R    R  S  S  S  S  S  S  R  R  R  R  S  R 
19974670  Human  Hadar    R    S  S  S  S  S  S  S  S  R  S  R  S  R 
19990154  Porcine  Typhimurium  RDNC  R  S  S  S  S  S  S  S  S  S  R  S  R  S  R 
19991811  Human  Enteritidis  1  S  S  S  S  S  S  S  S  S  S  S  S  S  S  R 
20003353  Human  Braenderup    S  S  S  S  S  S  S  S  S  S  S  S  S  S  R 
20003619  Human  Braenderup    S  S  S  S  S  S  S  S  S  S  S  S  S  S  R 
20011005  Human  Mucoid : eh :1,5    S  S  S  R  S  S  S  S  S  S  S  S  S  R  R 
20013147  Human  Virchow    R  S  S  I  R  R  R  S  R  R  R  R  R  R  R  
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SSRL No. 
Isolate 
Source 
Organism Name  PT  Ap  Cx
1  Cl  Cp  Fz  Gm  Ka  Na  Ne  Sp  St  Sx  Te  Tm  LCp 
20014543  Human  Braenderup    S  S  S  S  S  S  S  S  S  S  S  S  S  S  R 
20023201  Poultry  Non-motile groupC4    R  R  R  S  S  S  S  S  S  S  S  S  S  R  R 
20023466  Human  Braenderup    S  S  S  I  S  S  S  S  S  S  S  S  S  S  R 
20023518  Human  Enteritidis  4  S  S  S  S  S  S  S  S  S  S  S  S  S  S  R 
20030081  Environment  Typhimurium  104b  R  S  R  R  S  S  S  S  S  R  R  R  R  R  R 
20032653  Environment  Non-motile groupC4    S  S  S  S  S  S  S  S  S  S  S  S  S  S  R 
20040636  Human  Corvallis    S  S  S  R  S  S  S  S  S  S  R  R  R  S  R 
20041345  Environment  Rough :k :-    S  S  S  S  S  S  S  S  S  S  S  S  S  R  R 
20042428  Human  Enteritidis  13a  S  S  S  S  S  S  R  S  S  S  S  S  S  R  R 
20050040  Human  Typhimurium  RDNC  S  S  S  R  S  S  S  S  S  S  R  R  R  S  R  
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SSRL No. 
Isolate 
Source 
Organism Name  PT  Ap  Cx
1  Cl  Cp  Fz  Gm  Ka  Na  Ne  Sp  St  Sx  Te  Tm  LCp 
20050075  Ovine  Typhimurium  Untypable  R  S  R  I  S  S  S  S  S  S  R  R  R  R  R 
20050123  Human  Typhimurium  Untypable  R  S  R  R  S  S  S  S  S  S  R  R  R  R  R 
20050192  Ovine  Typhimurium  Untypable  R  S  R  R  S  S  S  S  S  S  R  R  R  R  R 
20050193  Ovine  Typhimurium  Untypable  R  S  R  R  S  S  S  S  S  S  R  R  R  R  R 
20050275  Bovine  Typhimurium  Untypable  R  S  R  R  S  S  S  S  S  S  R  R  R  R  R 
20050378  Human  Corvallis    S  S  S  I  S  S  S  S  S  S  R  R  R  S  R 
20050446  Human  Corvallis    S  S  S  R  S  S  S  S  S  S  S  S  S  S  R 
20050669  Human  Stanley    S  S  S  S  S  S  S  S  S  R  R  R  R  R  R 
20050682  Human  Typhimurium  RDNC  S  S  S  R  S  S  S  S  S  S  R  R  R  S  R 
20050875  Human  Corvallis    S  S  S  S  S  S  S  S  S  S  R  R  R  S  R  
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SSRL No. 
Isolate 
Source 
Organism Name  PT  Ap  Cx
1  Cl  Cp  Fz  Gm  Ka  Na  Ne  Sp  St  Sx  Te  Tm  LCp 
20051150  Human  Corvallis    S  S  S  R  S  S  S  S  S  S  R  R  R  S  R 
20051267  Human  Corvallis    S  S  S  R  S  S  S  S  S  S  S  S  S  S  R 
20052136  Human  Corvallis    S  S  S  R  S  S  S  S  S  S  S  R  S  S  R 
20052260  Human  Corvallis    S  S  S  R  S  S  S  S  S  S  S  S  S  S  R 
20052592  Human  Stanley    S  S  R  R  S  R  R  S  S  R  R  R  R  S  R 
20060113  Human  Newport    S  S  S  S  S  S  S  S  S  S  S  S  S  S  R 
20060787  Human  Corvallis    S  S  S  R  S  S  S  S  S  S  R  R  R  S  R 
20060807  Human  Corvallis    S  S  S  S  S  S  S  S  S  S  R  R  R  S  R 
20060845  Human  Typhimurium  120  R  S  S  R  S  S  S  S  S  S  R  R  R  S  R 
20062459  Human  Braenderup    S  S  S  S  S  S  S  S  S  S  S  S  S  S  R  
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SSRL No. 
Isolate 
Source 
Organism Name  PT  Ap  Cx
1  Cl  Cp  Fz  Gm  Ka  Na  Ne  Sp  St  Sx  Te  Tm  LCp 
20062576  Human  Corvallis    S  S  S  I  S  S  S  S  S  S  R  R  R  S  R 
20062603  Human  Braenderup    S  S  S  S  S  S  S  S  S  S  S  S  S  S  R 
20063292  Human  Enteritidis  RDNC  R  S  S  R  S  S  S  S  S  S  S  S  S  S  R 
20070289  Human  Typhimurium  120  S  S  S  R  S  S  S  S  S  S  R  R  R  S  R 
20070308  Human  Reading    S  S  S  R  S  S  S  S  S  S  S  S  S  S  R 
20070317  Human  Corvallis    S  S  S  R  S  S  S  S  S  S  R  R  R  S  R 
20070339  Human  Bareilly    S  S  S  S  S  S  S  S  S  S  S  S  S  S  R 
20070467  Environment  Gaminara    S  S  S  R  S  S  S  S  S  S  S  S  S  S  R 
20070484  Human  Blockley    R  S  S  R  S  S  S  S  S  S  S  S  S  S  R 
20070485  Human  Corvallis    S  S  S  I  S  S  S  S  S  S  R  R  R  S  R  
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SSRL No. 
Isolate 
Source 
Organism Name  PT  Ap  Cx
1  Cl  Cp  Fz  Gm  Ka  Na  Ne  Sp  St  Sx  Te  Tm  LCp 
20070494  Bovine  Typhimurium  104b  S  R  R  S  S  S  S  S  S  S  S  R  R  S  R 
200700598  Human  Typhimurium  Untypable  S  S  S  R  S  S  S  S  S  S  R  R  R  S  R 
20071604  Human  Mbandaka    R  S  R  S  S  S  S  S  S  S  S  R  R  R  R 
20071727  Human  Java    R  S  S  S  S  S  S  S  S  S  S  S  S  S  R 
20071810  Human  Mbandaka    R  S  R  S  S  R  S  S  S  R  R  R  S  R  R 
1Cefotaxime sensitivity testing began in SSRL in 1999 
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Table 6:2  Strains of Salmonella enterica with reduced susceptibility to ciprofloxacin (0.125mg/L), resistant to cefotaxime (1mg/L). 
SSRL 
No.  Isolate Source  Organism Name  PT  Ap  Cx  Cl  Cp  Fz  Gm  Ka  Na  Ne  Sp  St  Sx  Te  Tm  LCp 
19992535  Human  Virchow    R  R  S  S  S  S  R  R  S  R  R  R  R  R  R 
20021751  Human  Virchow    R  R  S  S  S  S  S  R  S  S  R  R  S  R  R 
20022460  Human  Virchow    R  R  S  S  S  S  S  R  S  S  R  R  S  R  R 
20022461  Human  Virchow    R  R  S  S  S  S  S  R  S  S  R  R  S  R  R 
20023201  Poultry  Non-motile group C4    R  R  R  S  S  S  S  S  S  S  S  S  S  R  R 
20023730  Environment  Non-motile group C4    R  R  R  S  S  S  S  S  S  S  S  S  S  R  R 
20031051  Poultry  Non-motile group C4    R  R  R  S  R  S  S  S  S  S  S  S  S  R  R 
20032581  Human  Haifa    R  R  R  R  S  R  R  R  S  R  R  R  R  R  R 
20032864  Human  Enteritidis  1b  R  R  R  R  S  S  S  R  S  S  S  S  S  R  R 
20050127  Human  Haifa    R  R  R  R  S  R  R  R  S  R  R  R  R  R  R  
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SSRL 
No.  Isolate Source  Organism Name  PT  Ap  Cx  Cl  Cp  Fz  Gm  Ka  Na  Ne  Sp  St  Sx  Te  Tm  LCp 
20061399  Poultry  Java    R  R  S  R  S  S  S  R  S  R  R  S  S  R  R 
20061425  Human  Agona    R  R  S  R  S  R  R  R  S  R  R  R  R  R  R 
20062244  Human  Virchow    R  R  S  S  R  S  R  R  S  R  R  R  R  R  R 
20070145  Human  Typhimurium  RDNC  R  R  R  R  S  R  S  R  S  R  R  R  R  S  R 
20070591  Human  Rissen    R  R  R  I  S  R  I  S  S  S  R  R  R  S  R 
20071213  Human  Typhimurium  193  R  R  R  R  R  R  S  R  S  R  R  R  R  R  R 
20072161  Human  Colindale    R  R  S  S  S  S  S  R  S  S  S  S  S  S  R 
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6:3  Methods 
Determination of MIC by Etest 
Method previously described in section 4:2:2:2 
Preparation of Template DNA 
Method previously described in section 4:3:2:1 
Polymerase Chain Reaction 
All six primers, each at a concentration of 25pmol, were added to Illustra PureTaq Ready-
To-Go beads. After adding 1µl of template DNA and sterile PCR grade water to give a 
final volume of 25µl, the tubes were immediately stored on ice. To the negative control, an 
additional 1µl of sterile PCR grade water was added to the tube in place of DNA; this 
would confirm that any amplification was the target DNA and not contaminating DNA. A 
touchdown PCR was carried out on a GeneAmp PCR System 9700, with denaturation at 
94°C for 45 seconds followed by 32 cycles of 94°C for 45seconds, a ramped annealing 
step of 45seconds at 67.4°C to 53°C for 12 cycles, 53°C for 20 cycles and elongation at 
72°C for 60seconds. A final extension step of 72°C for 7 minutes was carried out. 
Gel electrophoresis was performed on the resulting amplicons using a 1.5% agarose gel in 
1X TBE buffer at 80V for approximately 45 minutes. 100bp molecular weight marker was 
added to wells at regular intervals and used to size the 516bp qnrA, 469bp qnrB and 417bp 
qnrS products. The amplicons were visualised using ethidium bromide. 
Purification 
As detailed in section 4:3:2:3. 
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DNA Sequencing 
As detailed in section 4:3:2:4 
Analysis of the sequence data 
As detailed in section 4:3:2:5 
 
6:4  Results 
Thirty-four of the 70 strains were found to harbour qnr genes. The MICs of ciprofloxacin 
for these strains ranged from 0.125-1mg/L; thus all were categorized as having either 
reduced susceptibility or resistance to ciprofloxacin, despite being susceptible to nalidixic 
acid. These results can be found in Table 6.3.  
The majority of these strains were of human origin; one strain of S. Gaminara was of 
environmental origin and three strains of S. Typhimurium, untypable by phage typing, 
were from ovine (2) and bovine sources. Of the strains from human sources, 58% of 
patients had a history of foreign travel.  
qnr genes were identified in twelve different serotypes. S. Corvallis was the most common 
with thirteen strains accounting for 38%, followed by nine S. Typhimurium (26%), and two 
S. Stanley and S. Enteritidis (6%). The eight remaining serotypes, S. Virchow, S. Haifa, S. 
Agona, S. Gaminara, S. Blockley, S. Rissen, S. Colindale and a strain of S. Java were 
represented by a single strain (3%). 
qnrA1 was identified in strains of S. Virchow and S. Stanley. qnrB1 was identified in S. 
Colindale, with qnrB2 being identified in S. Agona and S. Haifa. qnrB5 was identified in S. 
Gaminara . With the exception of these six strains, all other qnr genes were identified as 
qnrS1. Four of the seventeen cefotaxime-resistant strains harboured qnr genes.  
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Table 6:3. Details of qnr-positive strains of Salmonella enterica 
Salmonella 
serotype 
Phage 
type 
Number 
of 
isolates 
Source  Foreign travel  Year of 
isolation 
Range of Cp 
MICs 
(mg/L) 
Additional resistances 
qnr 
gene 
isolated 
Virchow  -  1  human  Oman  2001  0.125  ApFzGmKaNeSpStSxTeTm  A1 
Haifa  -  1  human  -  2003  1  ApCxClGmKaNaSpStSxTeTm  B2 
Corvallis    9  human 
Malaysia(4), 
Cambodia (1), 
Thailand (2), 
Brazil/Chile(1) 
2004-2007  0.125-0.5  StSxTe  S1 
Corvallis  -  3  human  Bali/Singapore(1)  2005  0.25  -  S1 
Corvallis  -  1  human  Thailand  2005  0.25  Sx  S1 
Enteritidis  13a  1  human  -  2004  0.25  ApGmSpStSxTmKa  S1 
Enteritidis  RDNC  1  human  -  2006  0.5  Ap  S1 
Typhimurium  RDNC  2  human  Malaysia(1)  2005  0.25-0.38  StSxTe  S1 
Typhimurium  Untypable  4  human,ovine(2) 
bovine 
-  2005  0.25-0.5  ApClSpStSxTeTm  S1 
Typhimurium  Untypable  1  human  Singapore/Thailand  2007  0.38  StSxTe  S1  
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Salmonella 
serotype 
Phage 
type 
Number 
of 
isolates 
Source  Foreign travel  Year of 
isolation 
Range of Cp 
MICs 
(mg/L) 
Additional resistances 
qnr 
gene 
isolated 
Typhimurium  120  1  human  Singapore  2006  0.75  ApStSxTe  S1 
Typhimurium  120  1  human  -  2007  0.38  StSxTe  S1 
Stanley  -  1  human  -  2005  0.125  SpStSxTeTm  A1 
Stanley  -  1  human  Thailand  2005  0.19  ClGmKaSpStSxTe  S1 
Agona  -  1  human  Egypt  2006  1  ApCxGmKaNaSpStSxTeTm  B2 
Gaminara  -  1  environment  -  2007  0.25  -  B5 
Blockley  -  1  human  Nigeria/Angola  2007  0.5  Ap  S1 
Rissen  -  1  human  Thailand  2007  0.125  ApCxClGmStSxTeKa  S1 
Java  -  1  human  -  2007  0.19  Ap  S1 
Colindale  -  1  human  -  2007  0.19  ApCx  B1 
Antimicrobials in bold indicate intermediate susceptibility 
Additional resistances: Ap, ampicillin; Cx, cefotaxime; Cl, chloramphenicol; Cp, ciprofloxacin; Fz, furazolidone; Gm, gentamicin; Ka, kanamycin; Na, 
nalidixic acid; Ne, netilmycin; Sp, spectinomycin; St, streptomycin; Sx, sulphamethoxazole; Te, tetracycline; Tm, trimethoprim.  
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6:5  Discussion 
The majority of strains harboured qnrS1 genes, with qnrA1, qnrB1, qnrB2 and qnrB5 
identified in only six strains. The thirty-four qnr-positive strains belonged to twelve 
serotypes, including S. Gaminara, S. Rissen, S. Agona S. Haifa, S. Blockley, S. Colindale 
and a strain of S. Java which, at this time, have not previously been found to harbour qnr 
genes.  
Of the eighteen strains isolated from patients with a history of foreign travel, sixteen were 
identified as qnrS1, one was qnrA1 and another was qnrB2. With the exception of one 
from Brazil, all qnrS1-positive strains originated from Thailand or Malaysia 
Plasmid-mediated quinolone resistance has serious implications for the use of this group of 
antimicrobials in the future. More importantly, the fact that these genes have been found on 
integrons together with ESBLs supports the requirement for ongoing surveillance of 
resistance. Surveillance will be problematic and it was thought that this problem could be 
addressed by the recommendation that nalidixic acid disk screening was indicative of 
fluoroquinolone susceptibility (Hakenen, 1999). However, as this experiment has shown, 
isolates that are nalidixic acid-susceptible can possess qnr genes and have a MIC as high as 
0.75mg/L for ciprofloxacin. 
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Chapter 7:  General Discussion 
7:1  General Discussion 
This study was the first investigation into the incidence of resistance to quinolone and 
fluoroquinolone antimicrobials in strains of Salmonella enterica isolated from human, 
veterinary and environmental sources in Scotland; to determine the capacity of the 
fluoroquinolones to select resistant mutants in these isolates and to characterize some of 
the genetic mechanisms through which any such resistance arises. In this chapter the 
experimental results of this study and others will be compared and discussed. 
All fluoroquinolones, whether used in clinical or veterinary medicine, have an identical 
mechanism of action in that they inhibit the action of bacterial topoisomerase genes, 
topoisomerase II (DNA gyrase) in Gram-negative species and in Gram-positive species, 
topoisomerase IV, leading to the inhibition of DNA replication and ultimately resulting in 
cell death. 
The emergence of resistance in Salmonella to this class of antimicrobials was first reported 
in 1990 in strains of S. Typhimurium (Piddock et al, 1990). Since then reports of resistance 
to quinolones and fluoroquinolones have continued to increase from around the world 
(Frost et al, 1996; Hakenen et al, 2001; Herikstad, 1997; Molbak et al, 2002). Reasons 
behind this increase in resistance are thought to include previous treatment with 
ciprofloxacin (Muder et al, 1991) and the licensing of enrofloxacin (a ciprofloxacin 
analogue specifically for use in animal medicine) for use in animal husbandry in 1993 in 
the U.K. (Threlfall et al, 1999).   
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At the start of this study in 2001, relatively little was known about the mechanisms of 
quinolone and fluoroquinolone resistance in the genus Salmonella. Point mutations in the 
quinolone resistance-determining region (QRDR) of the GyrA subunit of the 
topoisomerase II enzyme DNA gyrase (Yoshida et al, 1990) were well documented and 
were shown to result in high-level resistance to nalidixic acid in addition to cross-
resistance to the fluoroquinolones (Crumplin, 1990; Reyna et al, 1995), with the GyrB 
subunit being implicated to a lesser degree (Yamagishi et al 1981). Despite several studies 
(Ruiz, 1997; Piddock et al, 1998; Giraud et al, 1999) no mutations had been detected in the 
subunits of topoisomerase IV, parC and parE.  
In the following years, additional mutations both within and outwith the QRDR of the 
topoisomerase genes were described. Mutations outside the QRDR of gyrA at codons, 
Ala131, Glu139 and Asp144 have been described (Eaves et al, 2002) in addition to 
mutations within the QRDR regions of the parC and parE genes (Casin et al, 2003; Ling et 
al, 2003). These mutations, and those of gyrB are frequently isolated second to either one 
or two gyrA mutations and are therefore considered second-step mutations thought to be 
required before high-level fluoroquinolone resistance can be achieved (Hansen & Heisig, 
2003; Baucheron et al, 2004). Some of the mutations to date are listed in Table 7:1. 
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Table7:1. Some of the mutations previously detected in the topoisomerase genes of 
Salmonella isolates 
Gene  Amino acid substitution  Reference
a 
gyrA  Ala67→Pro  Reyna, 1995 
  Asp72→Gly  Eaves, 2002 
  Val73→Ile  Eaves, 2004 
  Gly81→Ser  Reyna, 1995 
  Gly81→Cys  Yoshida, 1990 
  Gly81→Asp  Piddock, 1998 
  Gly81→His  Lindstedt, 2004 
  Asp82→Gly  Allen, 2002 
  Asp82→Asn  Eaves, 2002 
  Ser83→Phe  Casin, 2003 
  Ser83→Tyr  Eaves, 2002 
  Ser83→Ala  Levy, 2004 
  Asp87→Asn  Casin, 2003 
  Asp87→Tyr  Eaves,  2002 
  Asp87→Gly  Eaves, 2002 
  Asp87→Lys  Mirό, 2004 
  Leu98→Val  Eaves, 2004 
  Ala119→Gly  Eaves, 2002 
  Ala119→Ala  Eaves, 2002 
  Ala131→Gly  Eaves, 2002 
  Glu139→Ala  Eaves, 2002 
gyrB  Tyr420→Cys  Eaves, 2004 
  Arg437→Leu  Eaves, 2004 
  Ser464→Tyr  Gensberg, 1995 
  Ser464→Phe  Casin, 2003  
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Gene  Amino acid substitution  Reference
a 
parC  Tyr57→Ser  Ling, 2003 
parC  Thr66→Ile  Eaves, 2004 
  Gly78→Asp  Hansen, 2003 
  Ser80→Arg  Casin, 2003 
  Ser80→Ile  Baucheron, 2002 
  Glu84→Lys  Casin, 2003 
  Glu84→Gly  Mirό, 2004 
parE  Glu453→Gly  Eaves, 2004 
  Ser458→Pro  Ling, 2003 
  His461→Tyr  Eaves, 2004 
  Ala498→Thr  Eaves, 2004 
  Val512→Gly  Eaves, 2004 
a Reference list is not exhaustive 
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Other mechanisms of resistance to have been identified include decreased accumulation 
mediated by the active efflux pump AcrAB which uses the outer membrane protein TolC 
as an extrusion channel with one study showing that the quinolone resistance and 
decreased fluoroquinolone susceptibility of the strains studied were highly dependent on 
the AcrAB-TolC efflux system and that the single gyrA mutations had little effect in 
determining the resistance levels (Baucheron et al, 2004); and plasmid-mediated quinolone 
resistance (PMQR). New variants of the gene qnr have been described and a website at the 
Lahey Clinic in the U.S.A has been set up to keep track as new qnr sequences are 
published (http://www.lahey.org/qnrStudies).  
One hundred and eighty strains of Salmonella enterica were characterised using plasmid 
profile analysis and PFGE. These techniques performed in isolation give limited 
information about the strains being examined. It is useful to know that strains harbour 
multiple plasmids as this may prompt further investigations such as antimicrobial 
resistance determination but, if the strains only possess the serotype-associated plasmid 
(SAPs-as discussed in Chapter 2) then this knowledge may be of less value. This also holds 
true for PFGE. Standardisation of protocol and the enhanced analysis software now 
available helps generate banding patterns that are both replicable and easily analyzed; and 
while a unique pulsed field profile reflects genomic diversity; certain serotypes such as S. 
Enteritidis are clonal and very often result in indistinguishable pulsed field profiles. 
Seventy-eight strains of S. Enteritidis were examined; forty-four possessed a single 
plasmid of approximately 57kb. Since this is the approximate size of the serotype 
associated plasmid (SAP), the 57kb plasmid of this study will be referred to as the SAP. 
Thirty-four of these strains had the most common S. Enteritidis pulsed field profile (PFP) 
of SENTXB.0001, with a further twelve strains with the same PFP harbouring an  
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additional plasmid of approximately 2.1kb. In this case the additional plasmid has had no 
obvious effect on the PFP. In the instance of the SAP being absent from the strain, as is the 
case for nine of the S. Enteritidis examined, the PFP changes to SENTXB.0014 were due 
to a single band deletion (this being the approximate size of 57kb). The PFP can also be 
different independent of possession of the 57kb plasmid. Nine strains possessed the SAP 
yet had PFPs other than SENTXB.0001. This is an example of the benefits of pairing these 
two genotypic methods together to fully characterize the strains so that in subsequent 
experiments, these profiles can be used as reference standards. While these data provided 
details of genetic relationship, there was no information about the phenotypic resistance 
levels to quinolone or fluoroquinolone antimicrobials, therefore investigations into the 
MICs were performed using an agar dilution method. 
In 1990, 2% of all human, veterinary and environmental isolates of Salmonella enterica 
received by the Scottish Salmonella Reference Laboratory (SSRL) were found to be 
resistant to nalidixic acid at a concentration of 40mg/L. During 1997, the laboratory 
introduced the testing of strains for cross-resistance to low-level ciprofloxacin at a 
concentration of 0.125mg/L, by which time the levels of nalidixic acid resistance had risen 
to 4.2%. Of these, 51.5% were cross-resistant to low-level ciprofloxacin. By 2000-01, 
nalidixic acid resistance was demonstrated in 392 isolates, with 88% of these resistant to 
low-level ciprofloxacin. Since 2003, any isolate found to be resistant to nalidixic acid at a 
concentration of 40mg/L and/or low-level ciprofloxacin at a concentration of 0.125mg/L, 
has been subjected to Etests to determine the ciprofloxacin MIC. 
Diagnostic Sensitivity agar (DST) or Mueller Hinton agar is the preferred basal medium 
for the determination of MIC in some laboratories particularly in the United States (Frost, 
1994); therefore investigations to determine MICs were performed using DST agar also in  
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accordance with SSRL standard operating procedures. The fluoroquinolone MIC results, 
listed in Table 3:1, obtained for the NCpL and MDR strains in particular, were inconsistent 
with the breakpoint designations assigned to them and therefore further investigation was 
warranted. No literature could be found advising against the use of DST with 
fluoroquinolones. On the contrary, the International Centre for Science and High 
Technology (ICS) recommended using DST in agar diffusion susceptibility tests of 
norfloxacin (Grimm, 1983) but information from BSAC suggested that the high 
concentration of magnesium and calcium ions present in DST may have an inhibitory 
effect on the fluoroquinolones resulting in raised MICs (Dr. Jennifer Andrews, personal 
communication). Previous studies used Mueller Hinton agar when determining the MIC 
values for quinolone and fluoroquinolones (Giraud et al, 2003; Kumar, 2002). Therefore, 
the MIC by agar dilution method was determined on Mueller Hinton agar for a random 
selection of fifty-five of the strains previously examined. 
These results confirmed the breakpoint designations for the FS strains as being fully 
susceptible to nalidixic acid and the four fluoroquinolones tested. With the exception of a 
single strain of S. Typhimurium DT3 (MIC of 16mg/L), all of the other strains were 
confirmed as resistant to nalidixic acid with MICs of ≥ 128mg/L. The NCpL strains 
demonstrated reduced susceptibility to ciprofloxacin and the three other fluoroquinolones. 
The majority of FQR strains did not confirm the breakpoint designation in that they 
exhibited only reduced susceptibility to ciprofloxacin and moxifloxacin; however 
resistance to ofloxacin and norfloxacin was confirmed. The breakpoint designations of the 
MDR strains were also not corroborated for ciprofloxacin. As with the FQR strains, 
reduced susceptibility was demonstrated for ciprofloxacin, but the majority were resistant 
to the other fluoroquinolones tested.   
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Cross-resistance to fluoroquinolones is a well documented phenomenon in multi-drug 
resistant isolates. One study demonstrated that mutants selected with tetracycline or 
chloramphenicol were cross-resistant to norfloxacin and ciprofloxacin. (Cohen et al, 1989). 
In that study norfloxacin MICs were higher than those of ciprofloxacin and overall 
resistance of the mutants was attributed to decreased drug accumulation due to outer 
membrane changes and loss of OmpF. Since the MICs of norfloxacin were also higher than 
those of ciprofloxacin, it may be that the mechanism of resistance of the MDR strains is 
also decreased drug accumulation. Later studies have confirmed that active efflux pumps 
such as the AcrAB-TolC system are responsible for decreased susceptibility to 
fluoroquinolones and that their increased expression may serve as an initial step in 
allowing the isolate to survive environmental exposures to fluoroquinolone selection 
pressures (Chen et al, 2007). 
None of the 31 strain that were resistant to high-level ciprofloxacin by breakpoint method 
exhibited resistance to ciprofloxacin at EUCAST values. These results reflect the findings 
of a recent study which suggested that high-level fluoroquinolone resistance is rare in 
clinical strains of Salmonella enterica isolated in Scotland (Murray et al, 2005), however 
all 31 were resistant to at least one of the other fluoroquinolones tested, which reinforces 
the need for surveillance of these antimicrobials in the  treatment of Salmonella infections. 
Nalidixic acid-resistance has been extensively used as an indicator of decreased 
fluoroquinolone susceptibility in clinical isolates of Salmonella (Hakanen et al, 1999) and 
the MIC data from this study appear to confirm this. While there was a consistent 
relationship between the nalidixic acid MICs and those of the fluoroquinolones studied in 
that those strains resistant to nalidixic acid exhibited at least reduced susceptibility to the 
fluoroquinolones, all of the MIC values for high-level ciprofloxacin indicated that the  
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assigned breakpoint designations were incorrect. This would corroborate the data that were 
demonstrated in the original agar dilution experiment, where the MICs for all the strains 
examined were very much higher than expected, which lead to the conclusion that DST 
agar is inappropriate for the sensitivity testing of fluoroquinolones. It appears to give 
accurate results for low-level ciprofloxacin but at higher concentrations the agar in some 
way inhibits the action of the antimicrobial, resulting in inflated MIC.  This is also 
applicable to the sensitivity testing by breakpoint method that is employed by the SSRL, in 
that the breakpoint designations would result in false positives at the high-level 
ciprofloxacin concentrations. 
On the basis of these findings the SSRL has changed the agar used in its breakpoint 
method for sensitivity testing and now uses Isosensitest agar. 
Comparison between the MIC values for these antimicrobials and the source of the 
Salmonella isolate does not reveal any significant correlation between the two. MIC values 
were generally identical or within one doubling dilution on Mueller Hinton agar when 
isolates from different sources were compared within the same R-type category. 
These MIC results for nalidixic acid and the fluoroquinolones complete the 
characterization of the strains of Salmonella by both the phenotypic methods of serotyping 
and phage typing and genotypic typing methods of plasmid profile analysis and PFGE. 
There is no apparent relationship between either the plasmid- or the pulsed field profiles 
and the MIC results, nor do they give any indication as to the mechanism of resistance. 
In order to investigate the mechanism of resistance, this experiment (see chapter 4) was 
performed from pure cultures that were assumed to be populations of identical cells. It is 
possible that through spontaneous mutation, some cells within a susceptible population  
158 
 
acquire slightly elevated resistance to an antimicrobial even in the absence of the drug. 
Without selection pressure these mutants may co-exist within the larger susceptible 
population to the point of being undetected during routine sensitivity testing. Once 
selection pressure is applied by exposing the culture to an antimicrobial, these mutants are 
able to out-compete the susceptible cells which are inhibited whilst the mutants grow and 
multiply. In this instance it is useful to assess the presence of spontaneous mutants within 
ostensibly susceptible populations of Salmonella under the selection pressure of different 
fluoroquinolones and the frequency with which these mutants are selected. 
Spontaneous mutants were selected on ofloxacin, norfloxacin and moxifloxacin, but no 
mutants were recovered on ciprofloxacin. Four strains of S. Typhimurium, one of S. Dublin 
and one of S. Virchow all yielded mutants with MICs more than twice those of their wild-
type. The frequency with which these mutants were selected varied between 4x10
-9 and 
1x10
-6 for the six strains; there was little difference between the rates of selection of the 
three fluoroquinolones (Table 4:1). Previous studies have suggested that it can be difficult 
to achieve an accurate assessment of mutation frequencies as many parameters such as 
antimicrobial agent, concentration of antimicrobial, bacterial stress and physiological 
conditions among others, need to be factored into the experiment (Martinez, 2000); one 
study reports that spontaneous mutants arise at the low frequency of 1 in 10
6 to 1 in 10
8 
cells (Zhao & Drlica, 2001). Two of the strains exhibited lower frequencies than this but 
this may be due to the previously-mentioned difficulties such as concentration of 
antimicrobial, physiological conditions, bacterial stress etcetera. 
Each of the spontaneous mutants examined in this experiment resulted in a single gyrA 
mutation (Table 4:2), which have been previously described (Griggs, et al 1996; Eaves et 
al, 2002). The resulting increases in MICs of these mutants, although demonstrative of  
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reduced susceptibility, are not highly resistant. It therefore seems reasonable to conclude 
that these are all first-step mutations. This may also explain the failure to select any 
spontaneous mutants on ciprofloxacin as previous studies have suggested that double 
mutations in gyrA or one additional mutation in another of the topoisomerase genes are 
required before ciprofloxacin resistance can be detected (Casin et al, 2003; Ling et al, 
2003). 
It was not possible to select any mutants exhibiting reduced susceptibility to ciprofloxacin 
from the majority of serotypes examined, including S. Enteritidis. This may be due to the 
selecting concentration of fluoroquinolones being too high as high-level fluoroquinolone 
resistance in clinical isolates of Salmonella is uncommon (Giraud et al, 2006); 
alternatively it may be that fluoroquinolone resistance mechanisms have a prohibitive 
fitness cost and thus limit the emergence of resistant strains (Lindgren et al, 2005; Giraud 
et al, 2006). This may also explain why there are so few published reports regarding 
spontaneous fluoroquinolone-resistant mutants. 
The overall result of the inability to select spontaneous fluoroquinolone resistant mutants 
from the majority of strains coupled with the relatively low frequencies of those that were 
selected reinforces the previous conclusion that there was little fluoroquinolone resistance 
in strains of Salmonella isolated in Scotland in the period of this study. 
To determine the capacity of the fluoroquinolones to select resistant mutants, 
fluoroquinolone-resistant mutants were selected by exposing susceptible isolates to 
numerous cultures on subinhibitory concentrations of antimicrobial and determining any 
accompanying decrease in susceptibility (see Chapter 5). As has been previously 
discussed, high-level fluoroquinolone resistance is rare in strains of Salmonella isolated in 
Scotland however; elsewhere treatment failures have been reported to occur during 
ongoing treatment with these drugs (Piddock et al, 1990; Boswell et al, 1997). Although an  
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in vitro experiment cannot replicate in vivo conditions accurately, these experiments 
attempted to detect and characterize the initial decrease in susceptibility of the isolate. 
The susceptible strains were exposed to subinhibitory concentrations of fluoroquinolones 
in two ways. Firstly, by exposure along an increasing concentration gradient of 
antimicrobial where only the growth at the highest concentration end was selected for 
further examination and secondly, by exposure to subinhibitory concentrations of 
antimicrobial where the entire plate population was repeatedly cultured on successive days. 
The former method only selected mutants with the highest resistance as they were taken 
from the growth at the highest concentration but the latter method repeatedly exposed the 
entire population to subinhibitory concentrations of the antimicrobial, thus potentially 
selecting mutants with only slightly reduced susceptibility in addition to the more resistant 
mutants.  
One difference between these results and those of the previous experiment was that 
mutants were selected on ciprofloxacin. It may be that the lower concentrations of 
ciprofloxacin the strains were exposed to in these experiments, while inhibiting the 
susceptible cells, allowed mutants with slightly decreased susceptibilities to grow and 
increase resistance gradually whereas the higher concentrations of ciprofloxacin (0.5mg/L) 
used in the previous experiment may have been too high and inhibited the entire cell 
population. 
From the 12 mutants examined only 5 gyrA mutations were detected (Table 5:4); with one, 
Asp87→Gly, being selected for the first time in this study although this has, like the other 
mutations, been described previously (Eaves et al, 2002). As in the previous section, only a 
single mutation was determined in each of the mutants. Although noteworthy increases in 
MIC were determined, none reached high-level resistance. Once again, first-step mutations 
appear to have been detected, although in the case of the mutants of S. Typhimurium  
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RDNC, an MIC of 1mg/L suggests that perhaps an additional mechanism of resistance 
such as an increase in active efflux, which has been shown to be a primary mechanism of 
resistance to ciprofloxacin in strains of S. Typhimurium (Giraud et al, 2000), may be 
involved. 
The Thr57→Ser mutation detected in the S. Virchow mutant was the only parC mutation 
detected in any of the experiments. This is somewhat unusual in that parC mutations are 
usually second-step mutations in the acquisition of high-level resistance to 
fluoroquinolones in Gram-negative organisms (Bachoual et al, 1998) or first-step 
mutations in Gram-positive organisms. Ling et al found that the presence of Thr57→Ser in 
addition to a gyrA mutation resulted in higher resistance (Ling et al, 2003) and a previous 
study demonstrated that transformation of parC mutants with wild-type parC resulted in a 
partial reversal of ciprofloxacin resistance. It has also been reported that this single 
mutation in an in vitro mutant had no effect on the quinolone susceptibility of the resulting 
strain; although Bagel et al postulated that Thr57→Ser is a stabilizing mutation that allows 
high-level fluoroquinolone resistance to develop but does not itself confer a higher level of 
resistance (Bagel et al, 1999).  In this instance the MIC of the mutant was determined to be 
0.38mg/L, an increase from 0.016mg/L for the wild-type strain which suggests that, in the 
absence of a gyrA mutation, the Thr57→Ser mutation is a least partly responsible for the 
decrease in fluoroquinolone susceptibility exhibited by this mutant.  
No correlation between the mutation selected and the fluoroquinolone on which it was 
selected could be found as, with the exception of Asp82→Asn which was selected only 
once on ofloxacin, more than one fluoroquinolone selected for the same mutation. 
Similarly, increased MIC could not be correlated to any one of the antimicrobials as 
different fluoroquinolones selected for the same mutation which resulted in the same  
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increase in MIC. Only the identical Ser83→Phe mutations selected on norfloxacin in a 
strain of S. Typhimurium DT104 and a strain of S. Dublin resulted in different increases in 
MIC; the MIC of the S.Typhimurium mutant was more than double that seen in the S. 
Dublin mutant. 
Mutations at codon Asp87 were the most commonly detected but these resulted in three 
different amino acid changes amongst three different serotypes.   
Overall, the frequently isolated serotypes of S. Enteritidis and S. Typhimurium developed a 
decrease in susceptibility to ciprofloxacin far more readily than less frequently isolated 
serotypes such as S. Kottbus, exhibiting increased MICs of 1mg/L and 1.5mg/L, with the 
latter only demonstrating an increased MIC of 0.25mg/L. 
Plasmid-mediated mechanisms have resulted in resistance to most classes of clinically 
important antimicrobials, such as the sulphonamides, aminoglycosides and β-lactams 
(Normark & Normark, 2002); and in 1998, the 56kb plasmid pMG252 was implicated in 
the first report of plasmid-mediated resistance to quinolones. It was 2002 before the 
complete molecular mechanism of qnr-mediated resistance was determined. The 218 
amino acid protein product of the gene qnr belonged to the pentapeptide repeat family 
(Tran & Jacoby, 2002). In vitro studies demonstrated that purified Qnr protected E. coli 
DNA gyrase from inhibition by ciprofloxacin, by binding to gyrase holoenzyme and its 
respective subunits GyrA and GyrB. This protection was shown to be proportional to Qnr 
concentration and inversely proportional to the concentration of ciprofloxacin (Tran & 
Jacoby, 2002). 
qnr itself confers little resistance and strains carrying pMG252 would be classed as 
fluoroquinolone-susceptible (Rodríguez-Martínez et al, 2003); nevertheless its clinical 
importance lies in the fact that it facilitates the selection of higher level quinolone  
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resistance mutations that allow isolates to survive concentrations of antimicrobial that 
would be otherwise be inhibitory.  
Early studies suggested that qnr plasmids might be limited and remain uncommon (Jacoby 
et al, 2003; Rodriguez-Martinez et al, 2003) however this has proved incorrect. The 
incidence of qnr-mediated resistance has continued to increase worldwide (Cheung et al, 
2005; Jonas et al, 2005; Murray, 2008; Karlsson et al, 2009).  
Previous studies have examined isolates resistant to nalidixic acid and reduced 
susceptibility to fluoroquinolones for qnr. However this study investigated a more unusual 
resistance phenotype- nalidixic acid susceptible isolates with reduced susceptibility to 
fluoroquinolones.  This R-type has been previously described (Monoit-Ville et al, 1991; 
Hakanen et al, 2005) but until now, never investigated for the presence of qnr (see Chapter 
6). 
Seventy strains of Salmonella with reduced susceptibility to ciprofloxacin and nalidixic 
acid resistance (n=53) and resistance to cefotaxime (1mg/L) (n=17) were investigated for 
the presence of qnr. Thirty-four strains comprising 12 serotypes were found to harbour the 
genes; qnrS1 (28), qnrA1(2), qnrB1(1), qnrB2 (2) and qnrB5 (1); of these serotypes, 7 have 
not previously been found to harbour qnr genes (Table 6:1). With the exception of one 
environmental and 3 veterinary isolates, all were of human origin, 58% of which were 
isolated from patients with a history of foreign travel. 
The high incidence and wide range of serotypes harbouring qnr genes in this study 
confirmed that the prevalence of plasmid-mediated quinolone resistance is increasing. 
Recent studies have shown that new qnr genes, such as qnrB10, qnrB12 and qnrD, are 
being continually described (Quiroga et al, 2007; Kehrenberg et al, 2008; Cavaco et al, 
2009), with the most recent qnrS4, being described by Danish scientists (Torpdahl et al,   
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2009). 
In addition to these new qnr genes, other plasmid-mediated resistance determinants have 
recently been described. aac(6’)-Ib-cr is a variant of the gene encoding an aminoglycoside 
acetyltransferase aac(6’)-Ib that is responsible for resistance to the aminoglycosides 
kanamycin, amikacin and tobramycin. The enzyme reduces the activity of ciprofloxacin by 
N-acetylation at the amino nitrogen on its piperazinyl substituent (Robicsek et al, 2006). 
As in the case of qnr, the level of resistance conferred is small but has been shown to act 
additively with other plasmid-mediated resistance mechanisms such as qnr, and also 
facilitates the selection of more resistant mutants among a fluoroquinolone-exposed 
population of bacteria (Robicsek et al, 2006).   
The qepA gene was identified in a plasmid, pHPA (Yamane et al, 2007), which encodes a 
14-transmembrane-segment putative efflux pump that increases resistance to norfloxacin 
and ciprofloxacin and enrofloxacin by decreasing the accumulation of antimicrobial in the 
bacterial cell, whilst the MIC of other antimicrobials and dyes known to be substrates for 
efflux pumps remained unchanged (Périchon et al, 2007). 
Previous experiments in this investigation have demonstrated that high-level resistance to 
fluoroquinolones was rare in strains of Salmonella isolated in Scotland from 1990-2000, 
however these new plasmid-mediated mechanisms of resistance which are easily 
transmissible, may pose the biggest threat to the future of this class of antimicrobial. 
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7:2  Limitations of this study 
Despite several attempts, I was unable to gain access to the veterinary antimicrobial 
enrofloxacin. It would have been useful to include this fluoroquinolone in addition to the 
other fluoroquinolones used in the various investigations of this study. The results may 
have helped gain an insight into how the use of fluoroquinolones in veterinary medicine 
impacts on human medicine.   
The number of mutations selected by either examining the entire population for 
spontaneous mutants or those selected upon exposure to subinhibitory concentration of 
fluoroquinolone were fewer than expected when considering the increased MIC of the 
mutant compared to the wild-type. It would therefore have been useful to examine all of 
the topoisomerase genes to determine whether any second-step mutations were present in 
gyrB or parE. It may also have been useful to examine the selected mutants for any 
increase in the levels of efflux to determine whether this was a factor in the increases in 
MIC determined. This would be especially important for those mutants with elevated MICs 
but no mutations detected in either the gyrA or parC genes. It would have helped if the 
mechanism of resistance in the MDR and FQR strains had been determined as this would 
have provided a means of comparison between mutants selected in vivo and those selected 
in this study. 
Further investigations into the Thr57→Ser amino acid substitution detected in the parC 
gene of the strain of S. Virchow might confirm whether or not it was responsible for the 
increase in MIC exhibited by the mutant. 
It may have been useful to perform growth studies on the mutants selected, to determine 
whether or not there was a fitness cost of increased resistance to fluoroquinolones.  
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Further investigations may have been made into the incidence of qnr genes in strains 
exhibiting resistance to nalidixic acid as many studies have done previously. This may 
have provided a more accurate assessment of the incidence of qnr in strains of Salmonella 
enterica in Scotland. 
 
7:3  Final conclusions 
The increasing reports of treatment failures with fluoroquinolones and the discoveries of 
new mechanisms of resistance, suggested that an investigation into the incidence of 
resistance in strains of Salmonella enterica isolated in Scotland was urgently required. 
Comparison between MIC results obtained on DST agar and Mueller Hinton agar revealed 
that DST agar is unsuitable for use with fluoroquinolones. Determination of the MIC 
values of nalidixic acid, ciprofloxacin, ofloxacin, norfloxacin and moxifloxacin for the 
strains examined demonstrated that although no clinical resistance to ciprofloxacin was 
present in any of the R-types selected, reduced susceptibility was exhibited by all but the 
FS group. Resistance to the other three fluoroquinolones was confined to strains exhibiting 
multi-drug resistances or those designated as resistant to 0.5mg/L ciprofloxacin by 
breakpoint method of susceptibility testing. 
The isolates of S. Mbandaka all thought to be of clonal origin (see Chapter 2), exhibited 
MIC values within one doubling dilution, however plasmid and pulsed field profiles did 
not indicate any significant correlation between genotype, MIC value and source of isolate 
for any of the other serotypes studied.  
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Spontaneous fluoroquinolone-resistant mutants were selected for the serotypes S. 
Typhimurium and S. Dublin on each of the four fluoroquinolones, while only ciprofloxacin 
was capable of selecting for resistant mutants of S. Enteritidis. This contrasts with the 
population analysis study where ciprofloxacin failed to select any mutants. This suggests 
that resistance to ciprofloxacin requires more than the single first-step mutations 
characterized by sequence analysis of the mutants selected on the other three 
fluoroquinolones; and that these three fluoroquinolones, especially ofloxacin which 
selected mutants from different serotypes from different sources in the population analysis 
study, may be more capable at selecting for mutants during treatment.  
There was no correlation between the mutation selected and the fluoroquinolone used. The 
increased MIC could not be correlated to any one of the antimicrobials as different 
fluoroquinolones selected for the same mutation which resulted in the same increase in 
MIC.  
As spontaneous fluoroquinolone-resistant mutants were selected from less than 50% of the 
FS strains, it seems reasonable to conclude that the capacity to develop resistance to 
fluoroquinolones is not equal in all serotypes. 
 The  prevalence  of  qnr  genes  was  higher  in  strains  of  Salmonella  enterica  isolated  in 
Scotland than had been demonstrated in previous studies in other parts of the world. There 
is  also  a  wider  distribution  of  these  genes  among  different  serotypes  than  has  been 
previously demonstrated.   
 
This study has demonstrated that for the period investigated, fluoroquinolone resistance in 
strains of Salmonella enterica isolated in Scotland reflected the findings of similar studies 
from other parts of the world in that, although resistance to nalidixic acid was common and  
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reduced susceptibility to fluoroquinolones was linked to this resistance, clinical resistance 
to  fluoroquinolone  was  rare.  With  the  relatively  recent  advent  of  plasmid-mediated 
quinolone resistance, this may not apply for much longer and surveillance of this class of 
antimicrobial is needed more than ever. 
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Appendix I:  Original breakpoint designations 
Strains termed “MDR” 
 
SSRL 
No.  Isolate Source  Epidemiology  Organism Name  PT  Ap  Cx
1  Cl  Cp  Fz  Gm  Ka  Na  Ne  Sp  St  Sx  Te  Tm  LCp
2 
19903865  Human  Sporadic  S.Bovismorbificans  -  S    R  R  S  S  S  R  S  S  S  S  R  S   
19910748   Human   Sporadic  S.Virchow  -  R    S  R  R  S  S  R  S  R  R  R  R  R   
19932001  Human  Sporadic  S.Oranienburg  -  R    R  R  S  S  R  R  R  R  S  R  R  R   
19932300  Human  Sporadic  S.Hadar  -  S    S  R  S  S  S  R  S  S  R  S  R  S   
19933344  Human  Sporadic  S.Typhimurium  204c  R    R  R  S  S  R  R  S  R  R  R  R  R   
19935442  Human  Sporadic  S.Hadar  -  S    S  R  S  S  S  R  S  S  R  R  R  S   
19940240  Human  Sporadic  S.Hadar  -  S    S  R  S  S  S  R  S  S  R  S  R  S   
19941463  Environmental    S.Typhimurium  204  R    R  R  S  S  R  R  S  S  R  R  R  R   
19950004  Human  Sporadic  S.Typhimurium  2  S    S  R  S  S  S  R  S  S  R  S  S  R   
19953743  Human  Sporadic  S.Virchow  -  R    S  R  R  S  S  R  S  S  S  S  S  S    
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SSRL 
No.  Isolate Source  Epidemiology  Organism Name  PT  Ap  Cx
1  Cl  Cp  Fz  Gm  Ka  Na  Ne  Sp  St  Sx  Te  Tm  LCp
2 
19963399  Human  Sporadic  S.Brandenburg  -  S    R  R  R  S  R  R  S  S  S  S  R  S   
19966072  Bovine    S.Typhimurium  104b  R    R  R  S  S  S  R  S  S  S  R  S  R   
19970646  Human   Sporadic  S.Typhimurium  104  R    R  R  S  S  S  R  S  R  R  R  R  S   
19970917  Human  Sporadic  S.Typhimurium  104  R    R  R  S  S  S  R  S  R  R  R  R  S  R 
19972895  Environmental    S.Typhimurium  104  R    R  R  S  S  S  R  S  R  R  R  R  S  R 
19982602  Poultry    Monophasic group 
C1 Salmonella  -  R  S  R  R  R  R  R  R  R  R  R  R  R  R  R 
19990031  Human  Sporadic  S.Typhimurium  104  R  S  S  R  S  S  S  R  S  R  R  R  S  R  R 
19990095  Human  Sporadic  S.Hadar  -  S  S  S  R  S  S  S  R  S  S  R  S  R  S  R 
19990515  Human  Sporadic  S.Hadar  -  R  S  S  R  S  S  S  R  S  S  R  R  R  S  R 
19990807  Not stated    S.Enteritidis  8  R  S  R  R  S  S  S  R  S  S  S  R  S  S  R 
19990838  Human  Sporadic  S.Blockley  -  S  S  R  R  S  S  R  R  S  S  R  S  R  S  R 
19990898  Poultry    S.Mbandaka  -  S  S  S  R  S  S  S  R  S  S  R  S  S  S  R 
19990970  Poultry    S.Mbandaka  -  S  S  S  R  S  S  S  R  S  S  S  S  R  S  R  
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SSRL 
No.  Isolate Source  Epidemiology  Organism Name  PT  Ap  Cx
1  Cl  Cp  Fz  Gm  Ka  Na  Ne  Sp  St  Sx  Te  Tm  LCp
2 
19990983  Poultry    S.Virchow  -  S  S  S  R  S  S  S  R  S  S  S  R  S  R  R 
19991026  Human  Tunisia  S.Hadar  -  R  S  S  R  S  S  S  R  S  S  R  S  R  S  R 
19991711  Human  Egypt  S.Blockley  -  S  S  S  R  S  S  R  R  S  S  R  S  R  S  R 
19991746  Poultry    S.Thompson  -  S  S  S  R  S  S  S  R  S  S  S  R  S  S  R 
19991815  Human  Sporadic   S.Enteritidis  1  R  S  R  R  S  S  S  R  S  S  S  S  S  S  R 
19991825  Pheasant    S.Enteritidis  4  S  S  S  R  R  S  S  R  S  S  S  S  S  R  R 
19992689  Human  Sporadic  S.Hadar  -  R  S  S  R  S  S  S  R  S  S  R  S  R  S  R 
19992820  Human  Spain  S.Hadar  -  R  S  S  R  S  S  S  R  S  S  R  R  R  S  R 
19993033  Human  Sporadic  S.Enteritidis  4  S  S  S  R  S  S  S  R  S  S  S  R  S  S  R 
19993048  Human  Sporadic  S.Indiana  -  S  S  S  R  R  S  R  R  S  R  R  R  R  R  R 
19995017  Human  Sporadic  S.Enteritidis  RDNC  S  S  S  R  S  S  S  R  S  R  R  S  R  R  R 
20000283  Poultry    S.Mbandaka  -  S  S  S  R  S  S  S  R  S  S  S  S  S  R  R 
20000673  Poultry    S.Senftenberg  -  S  S  S  R  S  S  R  R  S  S  S  S  S  S  R 
20000721  Poultry    S.Hadar  -  R  S  S  R  S  S  S  R  S  S  R  S  R  S  R  
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SSRL 
No.  Isolate Source  Epidemiology  Organism Name  PT  Ap  Cx
1  Cl  Cp  Fz  Gm  Ka  Na  Ne  Sp  St  Sx  Te  Tm  LCp
2 
20000918  Human   Sporadic  S.Typhimurium  104b  R  S  R  R  S  S  S  R  S  R  R  R  R  S  R 
20001058  Poultry    S.Mbandaka  -  R  S  S  R  S  S  S  R  S  S  R  S  R  S  R 
20002014  Human  Sporadic  S.Typhimurium  104b  R  S  R  R  S  S  S  R  S  R  R  R  R  S  R 
20002058  Human  Sporadic  S.Typhimurium  104b  R  S  S  R  S  S  S  R  S  S  R  R  S  R  R 
20002113  Human  Sporadic   S.Hadar  -  R  S  S  R  S  S  S  R  S  S  S  S  S  S  R 
20002257  Human  Sporadic  S.Typhimurium  RDNC  R  S  R  R  S  S  R  R  S  R  R  R  R  R  R 
20002399  Poultry    S.Hadar  -  S  S  S  R  S  S  S  R  S  S  R  S  R  S  R 
20002427  Poultry    S.Java  - S    S  S  R  S  S  S  R  S  R  R  S  S  R  R 
20002563  Environmental    S.Mbandaka  -  S  S  S  R  S  S  S  R  S  S  R  S  S  S  R 
20003106  Human  Spain  S.Hadar  -  R  S  S  R  S  S  S  R  S  S  R  R  R  S  R 
20004010  Human  Sporadic  S.Hadar  -  R  S  S  R  S  S  S  R  S  S  R  S  R  S  R 
20004028  Human  Spain  S.Hadar  -  R  S  S  R  S  S  S  R  S  S  R  S  R  S  R 
20004661  Environmental    S.Mbandaka  -  S  S  S  R  S  S  S  R  S  S  S  R  S  R  R 
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Strains termed “FQR” 
 
SSRL 
No.  Isolate Source  Epidemiology  Organism Name  PT  Ap  Cx
1  Cl  Cp  Fz  Gm  Ka  Na  Ne  Sp  St  Sx  Te  Tm  LCp
2 
19900377  Human  Sporadic  S.Enteritidis  4  S    S  R  S  S  S  R  S  S  S  S  S  S   
19900497  Poultry    S.Enteritidis  RDNC  S    S  R  S  S  S  R  S  S  S  S  S  S   
19900633  Poultry    S.Enteritidis  RDNC  S    S  R  S  S  S  R  S  S  S  S  S  S   
19900813  Human  Sporadic  S.Enteritidis  4  S    S  R  S  S  S  R  S  S  S  S  S  S   
19900828  Human  Sporadic  S.Enteritidis  4  S    S  R  S  S  S  R  S  S  S  S  S  S   
19901024  Poultry    S.Enteritidis  4  S    S  R  S  S  S  R  S  S  S  S  S  S   
19901059  Poultry    S.Enteritidis  4  S    S  R  S  S  S  R  S  S  S  S  S  S   
19901127  Poultry    S.Enteritidis  Untypable  S    S  R  S  S  S  R  S  S  S  S  S  S   
19901135  Poultry    S.Enteritidis  Untypable  S    S  R  S  S  S  R  S  S  S  S  S  S   
19901221  Poultry    S.Enteritidis  Untypable  S    S  R  S  S  S  R  S  S  S  S  S  S   
19901257  Poultry    S.Enteritidis  Untypable  S    S  R  S  S  S  R  S  S  S  S  S  S   
19901259  Poultry    S.Enteritidis  4  S    S  R  S  S  S  R  S  S  S  S  S  S    
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SSRL 
No.  Isolate Source  Epidemiology  Organism Name  PT  Ap  Cx
1  Cl  Cp  Fz  Gm  Ka  Na  Ne  Sp  St  Sx  Te  Tm  LCp
2 
19901289  Poultry    S.Enteritidis  Untypable  S    S  R  S  S  S  R  S  S  S  S  S  S   
19901301  Poultry    S.Enteritidis  Untypable  S    S  R  S  S  S  R  S  S  S  S  S  S   
19901442  Poultry    S.Enteritidis  RDNC  S    S  R  S  S  S  R  S  S  S  S  S  S   
19901527  Poultry    S.Enteritidis  RDNC  S    S  R  S  S  S  R  S  S  S  S  S  S   
19901602  Poultry    S.Enteritidis  4  S    S  R  S  S  S  R  S  S  S  S  S  S   
19901733  Poultry    S.Enteritidis  Untypable  S    S  R  S  S  S  R  S  S  S  S  S  S   
19901754  Poultry    S.Enteritidis  Untypable  S    S  R  S  S  S  R  S  S  S  S  S  S   
19901928  Poultry    S.Enteritidis  4  S    S  R  S  S  S  R  S  S  S  S  S  S   
19902644  Human  Sporadic  S.Typhimurium  66  S    S  R  S  S  S  R  S  S  S  S  S  S   
19903116  Human  Sporadic  S.Enteritidis  RDNC  S    S  R  S  S  S  R  S  S  S  S  S  S   
19903993  Poultry    S.Enteritidis  Untypable  S    S  R  S  S  S  R  S  S  S  S  S  S   
19910646  Poultry    S.Mbandaka    S    S  R  S  S  S  R  S  S  S  S  S  S   
19910665  Poultry    S.Enteritidis  4  S    S  R  S  S  S  R  S  S  S  S  S  S   
19911165  Poultry    S.Enteritidis  4  S    S  R  S  S  S  R  S  S  S  S  S  S    
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SSRL 
No.  Isolate Source  Epidemiology  Organism Name  PT  Ap  Cx
1  Cl  Cp  Fz  Gm  Ka  Na  Ne  Sp  St  Sx  Te  Tm  LCp
2 
19911537  Human  Sporadic  S.Enteritidis  4  S    S  R  S  S  S  R  S  S  S  S  S  S   
19912067  Poultry    S.Mbandaka    S    S  R  S  S  S  R  S  S  S  S  S  S   
19921643  Poultry    S.Mbandaka    S    S  R  S  S  S  R  S  S  S  S  S  S   
19933184  Human  Sporadic  S.Enteritidis  4  S    S  R  S  S  S  R  S  S  S  S  S  S   
19933339  Human  Sporadic  S.Enteritidis  4  S    S  R  S  S  S  R  S  S  S  S  S  S   
19933488  Environmental    S.Mbandaka    S    S  R  S  S  S  R  S  S  S  S  S  S   
19934878  Poultry    S.Mbandaka    S    S  R  S  S  S  R  S  S  S  S  S  S   
19935599  Human  Sporadic  S.Enteritidis  4  S    S  R  S  S  S  R  S  S  S  S  S  S   
19940784  Human  Sporadic  S.Enteritidis  4  S    S  R  S  S  S  R  S  S  S  S  S  S   
19940871  Human  Sporadic  S.Enteritidis  4  S    S  R  S  S  S  R  S  S  S  S  S  S   
19940880  Human  Sporadic  S.Enteritidis  4  S    S  R  S  S  S  R  S  S  S  S  S  S   
19941804  Poultry    S.Mbandaka    S    S  R  S  S  S  R  S  S  S  S  S  S   
19941864  Human  Sporadic  S.Enteritidis  4  S    S  R  S  S  S  R  S  S  S  S  S  S   
19943026  Human  Sporadic  S.Enteritidis  4  S    S  R  S  S  S  R  S  S  S  S  S  S    
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SSRL 
No.  Isolate Source  Epidemiology  Organism Name  PT  Ap  Cx
1  Cl  Cp  Fz  Gm  Ka  Na  Ne  Sp  St  Sx  Te  Tm  LCp
2 
19964025  Human  Sporadic  S.Enteritidis  5a  S    S  R  S  S  S  R  S  S  S  S  S  S   
19965081  Human  Sporadic  S.Enteritidis  1  S    S  R  S  S  S  R  S  S  S  S  S  S   
19970269  Human  Sporadic  S.Enteritidis  7  S    S  R  S  S  S  R  S  S  S  S  S  S   
19990976  Poultry    S.Mbandaka    S  S  S  R  S  S  S  R  S  S  S  S  S  S  R 
19991308  Human  Sporadic  S.Enteritidis  4  S  S  S  R  S  S  S  R  S  S  S  S  S  S  R 
19991700  Human  Spain  S.Enteritidis  4  S  S  S  R  S  S  S  R  S  S  S  S  S  S  R 
19991722  Human  Gran Canaria  S.Enteritidis  4  S  S  S  R  S  S  S  R  S  S  S  S  S  S  R 
19992252  Human  Sporadic   S.Enteritidis  1  S  S  S  R  S  S  S  R  S  S  S  S  S  S  R 
19993983  Poultry    S.Mbandaka    S  S  S  R  S  S  S  R  S  S  S  S  S  S  R 
20000635  Poultry    S.Mbandaka    S  S  S  R  S  S  S  R  S  S  S  S  S  S  R 
20000821  Environmental    S.Mbandaka    S  S  S  R  S  S  S  R  S  S  S  S  S  S  R 
20001054  Poultry    S.Mbandaka    S  S  S  R  S  S  S  R  S  S  S  S  S  S  R 
20002524  Environmental    S.Mbandaka    S  S  S  R  S  S  S  R  S  S  S  S  S  S  R 
20002550  Environmental    S.Mbandaka    S  S  S  R  S  S  S  R  S  S  S  S  S  S  R  
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No.  Isolate Source  Epidemiology  Organism Name  PT  Ap  Cx
1  Cl  Cp  Fz  Gm  Ka  Na  Ne  Sp  St  Sx  Te  Tm  LCp
2 
20004300  Human  Tenerife  S.Enteritidis  4  S  S  S  R  S  S  S  R  S  S  S  S  S  S  R 
20004594  Human  Sporadic  S.Enteritidis  1  S  S  S  R  S  S  S  R  S  S  S  S  S  S  R 
20004768  Feline    S.Enteritidis  1  S  S  S  R  S  S  S  R  S  S  S  S  S  S  R 
20005212  Human  Sporadic  S.Enteritidis  1  S  S  S  R  S  S  S  R  S  S  S  S  S  S  R 
20005300  Human  Sporadic  S.Enteritidis  1  S  S  S  R  S  S  S  R  S  S  S  S  S  S  R 
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Strains termed “NaCpL” 
SSRL 
No.  Isolate Source  Epidemiology  Organism Name  PT  Ap  Cx
1  Cl  Cp  Fz  Gm  Ka  Na  Ne  Sp  St  Sx  Te  Tm  LCp
2 
19982854  Poultry    S.Liverpool    S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
19982886  Poultry    S.Mbandaka    S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
19983032  Poultry    S.Senftenberg    S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
19983922  Canine    S.Binza    S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
19984026  Human  Sporadic   S.Enteritidis  1  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
19990203  Poultry    S.Thompson    S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
19990355  Canine    S.Newport    S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
19990380  Poultry    S.Enteritidis  4  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
19990905  Human  Spain  S.Enteritidis  1  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
19991305  Human  Sporadic  S.Enteritidis  1  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
19991378  Human  Family outbreak  S.Enteritidis  1  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
19991459  Human  Sporadic  S.Enteritidis  21  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
19991601  Poultry    S.Virchow    S  S  S  S  S  S  S  R  S  S  S  S  S  S  R  
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No.  Isolate Source  Epidemiology  Organism Name  PT  Ap  Cx
1  Cl  Cp  Fz  Gm  Ka  Na  Ne  Sp  St  Sx  Te  Tm  LCp
2 
19991605  Human  Sporadic  S.Enteritidis  21  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
19991655  Human  Mediterranean  S.Enteritidis  21  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
19991657  Human  Sporadic  S.Enteritidis  1  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
19991668  Human  Sporadic  S.Enteritidis  21  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
19991697  Human  Sporadic  S.Virchow    S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
19991754  Human  Sporadic  S.Enteritidis  1  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
19991760  Human  Diarrhoea since T in 
the Park 
S.Enteritidis  4  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
19991817  Human  Majorca  S.Enteritidis  7  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
19991915  Human  Sporadic  S.Enteritidis  1  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
19991939  Human  Turkey  S.Virchow    S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
19992003  Human  Sporadic  S.Kottbus    S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
19992070  Human  Spain  S.Hadar    S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
19992196  Human  Family outbreak  S.Enteritidis  1  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R  
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SSRL 
No.  Isolate Source  Epidemiology  Organism Name  PT  Ap  Cx
1  Cl  Cp  Fz  Gm  Ka  Na  Ne  Sp  St  Sx  Te  Tm  LCp
2 
19992245  Human  North Africa  S.Enteritidis  Untypable  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
19992327  Human  Malta  S.Virchow    S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
19992365  Poultry    Non-motile group 
C4 Salmonella 
  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
19992434  Human  Majorca  S.Enteritidis  1  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
19992465  Poultry    Non-motile group 
C4 salmonella 
  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
19992491  Poultry    S.Senftenberg    S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
19992678  Human  Sporadic  S.Infantis    S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
19992835  Poultry    S.Typhimurium  3  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
19992934  Human  Sporadic  S.Hadar    S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
19993007  Human  Sporadic  S.Enteritidis  1  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
19993056  Bovine    S.Dublin    S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
19993084  Environmental    S.Thompson    S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
19993085  Environmental    S.Thompson    S  S  S  S  S  S  S  R  S  S  S  S  S  S  R  
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SSRL 
No.  Isolate Source  Epidemiology  Organism Name  PT  Ap  Cx
1  Cl  Cp  Fz  Gm  Ka  Na  Ne  Sp  St  Sx  Te  Tm  LCp
2 
19993086  Poultry    S.Thompson    S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
19993115  Human  Sporadic  S.Enteritidis  4  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
19993156  Human  Turkey  S.Virchow    S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
19993222  Human  Sporadic  S.Enteritidis  1  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
19993411  Human  Sporadic  S.Enteritidis  1  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
19993539  Human  Sporadic  S.Enteritidis  Untypable  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
19993553  Poultry    S.Mbandaka    S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
19993731  Poultry    S.Senftenberg    S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
19993739  Human  Unknown  S.Enteritidis  1  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
19993787  Human  Sporadic  S.Enteritidis  4  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
19993795  Human  Spain  S.Enteritidis  RDNC  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
19993807  Environmental    S.Liverpool    S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
19994202  Poultry    S.Senftenberg    S  S  S  S  S  S  S  R  S  S  S  S  S  S  R  
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SSRL 
No.  Isolate Source  Epidemiology  Organism Name  PT  Ap  Cx
1  Cl  Cp  Fz  Gm  Ka  Na  Ne  Sp  St  Sx  Te  Tm  LCp
2 
19994385  Human  Sporadic  S.Enteritidis  1  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
19994455  Human  Gran Canaria  S.Typhimurium  104b  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
19994609  Human  Morocco  S.Enteritidis  14b  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
20000139  Bovine    S.Dublin    S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
20000466  Environmental    S.Thompson    S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
20000672  Poultry    S.Liverpool    S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
20000923  Human  Sporadic  S.Enteritidis  21  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
20001314  Human  Family outbreak  S.Enteritidis  4  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
20001505  Human  Lanzarote  S.Enteritidis  1  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
20001526  Human  Thailand  S.Virchow    S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
20002001  Human  Family outbreak  S.Virchow    S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
20002138  Human  Sporadic  S.Virchow    S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
20002195  Human  Morocco  S.Enteritidis  1  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R  
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SSRL 
No.  Isolate Source  Epidemiology  Organism Name  PT  Ap  Cx
1  Cl  Cp  Fz  Gm  Ka  Na  Ne  Sp  St  Sx  Te  Tm  LCp
2 
20002216  Human  Spain  S.Enteritidis  1  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
20002238  Human  Sporadic  S.Enteritidis  1  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
20002261  Human  South Africa  S.Enteritidis  1  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
20002298  Environmental    S.Mbandaka    S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
20002308  Environmental    S.Mbandaka    S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
20002439  Human  Sporadic  S.Enteritidis  1  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
20002542  Environmental    S.Mbandaka    S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
20002590  Human  Sporadic  S.Enteritidis  RDNC  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
20002618  Human  Family outbreak  S.Enteritidis  21  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
20002621  Human  Sporadic  S.Enteritidis  6  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
20002660  Human  Ibiza  S.Enteritidis  1c  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
20002675  Human  Sporadic  S.Enteritidis  Untypable  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
20002873  Human  Sporadic  S.Enteritidis  1  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R  
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SSRL 
No.  Isolate Source  Epidemiology  Organism Name  PT  Ap  Cx
1  Cl  Cp  Fz  Gm  Ka  Na  Ne  Sp  St  Sx  Te  Tm  LCp
2 
20003149  Human  Turkey  S.Enteritidis  1  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
20003165  Human  Family outbreak  S.Enteritidis  1  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
20003184  Human  Sporadic  S.Enteritidis  21  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
20003270  Human  Lanzarote  S.Enteritidis  1  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
20003558  Human  Sporadic  S.Enteritidis  4  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
20003586  Human  Lanzarote  S.Enteritidis  21  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
20003659  Human  Sporadic  S.Enteritidis  21  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
20003924  Human  Gran Canaria  S.Enteritidis  4  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
20003957  Human  Sporadic  S.Kottbus    S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
20004057  Human  Sporadic  S.Enteritidis  1  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
20004078  Human  Ibiza  S.Enteritidis  3  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
20004230  Human  Morocco  S.Enteritidis  1  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
20004338  Human  Spain  S.Enteritidis  1c  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R  
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SSRL 
No.  Isolate Source  Epidemiology  Organism Name  PT  Ap  Cx
1  Cl  Cp  Fz  Gm  Ka  Na  Ne  Sp  St  Sx  Te  Tm  LCp
2 
20004342  Human  Sporadic  S.Enteritidis  6a  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
20004592  Human  Sporadic  S.Enteritidis  RDNC  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
20004730  Human  Lanzarote  S.Enteritidis  21  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
20004763  Human  Family outbreak  S.Enteritidis  1  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
20004915  Environmental    S.Mbandaka    S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
20004927  Human  Tenerife  S.Enteritidis  Untypable  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
20004928  Human  Tenerife  S.Antarctica    S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
20004947  Poultry    S.Senftenberg    S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
20004972  Human  Spain  S.Enteritidis  RDNC  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
20005031  Human  Tenerife  S.Enteritidis  7  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
20005084  Human  Java  S.Enteritidis  4  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
20005141  Human    S.Enteritidis  Untypable  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
20005226  Human  Lanzarote  S.Enteritidis  1  S  S  S  S  S  S  S  R  S  S  S  S  S  S  R  
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SSRL 
No.  Isolate Source  Epidemiology  Organism Name  PT  Ap  Cx
1  Cl  Cp  Fz  Gm  Ka  Na  Ne  Sp  St  Sx  Te  Tm  LCp
2 
20005319  Poultry    S.Thompson    S  S  S  S  S  S  S  R  S  S  S  S  S  S  R 
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Strains termed “FS” 
 
SSRL 
No.  Isolate Source  Epidemiology  Organism Name  PT  Ap  Cx
1  Cl  Cp  Fz  Gm  Ka  Na  Ne  Sp  St  Sx  Te  Tm  LCp
2 
19982543  Poultry    S.Enteritidis  4  S  S  S  S  S  S  S  S  S  S  S  S  S  S  S 
19983155  Human  Sporadic  S.Dublin    S  S  S  S  S  S  S  S  S  S  S  S  S  S  S 
19983351  Canary    S.Typhimurium  RDNC  S  S  S  S  S  S  S  S  S  S  S  S  S  S  S 
19993458  Human  Sporadic  S.Typhimurium  2  S  S  S  S  S  S  S  S  S  S  S  S  S  S  S 
19983717  Human  Sporadic  S.Virchow    S  S  S  S  S  S  S  S  S  S  S  S  S  S  S 
19990341  Human  Family 
outbreak  S.Typhimurium  104  S  S  S  S  S  S  S  S  S  S  S  S  S  S  S 
19990706  Poultry     S.Mbandaka     S  S  S  S  S  S  S  S  S  S  S  S  S  S  S 
19991035  Porpoise    S.Typhimurium  104  S  S  S  S  S  S  S  S  S  S  S  S  S  S  S 
19991073  Human  Family 
outbreak  S.Brandenburg    S  S  S  S  S  S  S  S  S  S  S  S  S  S  S 
19991452  Pheasant    S.Binza    S  S  S  S  S  S  S  S  S  S  S  S  S  S  S 
19991870  Human  Sporadic  S.Enteritidis  5c  S  S  S  S  S  S  S  S  S  S  S  S  S  S  S  
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SSRL 
No.  Isolate Source  Epidemiology  Organism Name  PT  Ap  Cx
1  Cl  Cp  Fz  Gm  Ka  Na  Ne  Sp  St  Sx  Te  Tm  LCp
2 
19991929  Human  Sporadic  S.Enteritidis  1  S  S  S  S  S  S  S  S  S  S  S  S  S  S  S 
19992150  Human  Sporadic  S.Enteritidis  6a  S  S  S  S  S  S  S  S  S  S  S  S  S  S  S 
19993805  Bovine    S.Dublin    S  S  S  S  S  S  S  S  S  S  S  S  S  S  S 
19993849  Human  Sporadic  S.Typhimurium  104  S  S  S  S  S  S  S  S  S  S  S  S  S  S  S 
19994076  Human  Family 
outbreak  S.Typhimurium  104  S  S  S  S  S  S  S  S  S  S  S  S  S  S  S 
20000136  Bovine    S.Dublin    S  S  S  S  S  S  S  S  S  S  S  S  S  S  S 
20001178  Poultry    S.Typhimurium  104  S  S  S  S  S  S  S  S  S  S  S  S  S  S  S 
20001735  Ovine    S.Dublin    S  S  S  S  S  S  S  S  S  S  S  S  S  S  S 
20001797  Bovine    S.Montevideo    S  S  S  S  S  S  S  S  S  S  S  S  S  S  S 
20003052  Bovine    S.Dublin    S  S  S  S  S  S  S  S  S  S  S  S  S  S  S 
20003940  Human  Sporadic  S.Typhimurium  40  S  S  S  S  S  S  S  S  S  S  S  S  S  S  S 
20003962  Human  Sporadic  S.Typhimurium  10  S  S  S  S  S  S  S  S  S  S  S  S  S  S  S 
20004447  Human  Ibiza  S.Enteritidis  21  S  S  S  S  S  S  S  S  S  S  S  S  S  S  S  
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SSRL 
No.  Isolate Source  Epidemiology  Organism Name  PT  Ap  Cx
1  Cl  Cp  Fz  Gm  Ka  Na  Ne  Sp  St  Sx  Te  Tm  LCp
2 
20005189  Porcine    S.Typhimurium  170  S  S  S  S  S  S  S  S  S  S  S  S  S  S  S 
Antimicrobial abbreviations: Ap, ampicillin; Cx, cefotaxime; Cl, chloramphenicol; Cp, ciprofloxacin (0.5mg/L); Fz, furazolidone; Gm, gentamycin; Ka, 
kanamycin; Na, nalidixic acid; Ne, netilmicin; Sp, spectinomycin; St, streptomycin; Sx, sulphamethoxazole; Te, tetracycline; Tm, trimethoprim; LCp, 
ciprofloxacin (0.125mg/L). 
1 Sensitivity testing for cefotaxime began in 1998 
2 Sensitivity testing for reduced susceptibility to ciprofloxacin began in 1997 
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Appendix II:  Preparation of working solutions for Plasmid profile 
analysis 
TE 50:1 
0.61g of Trizma base and 0.04g of EDTA was dissolved in 70ml of deionised water. The 
pH was adjusted to 8 and the volume was made up to 100mls. Stored at room temperature. 
 
TBE buffer 
500ml of 10X TBE buffer was added to 4500ml of deionised water. 
 
Kado and Liu lysis buffer 
3g of SDS and 0.6g of Trizma base were added to a beaker on a magnetic stirrer, 
containing approximately 70ml of deionised water. A probe from the Hydrus 300 pH 
machine from Fisherbrand was inserted into the beaker and monitored the pH. Sodium 
hydroxide solution was added slowly until a pH of 12.6 was achieved. The final volume 
was adjusted to 100ml. The buffer was stored at 4°C until needed, but as the SDS 
precipitates while being stored, it is necessary to place the buffer in a 56°C waterbath until 
the SDS has re-dissolved. 
Ethidium Bromide (50mM stock solution) 
10ml of Ethidium Bromide solution was added to 40 ml of deionised water, to make 50ml 
working solution and stored at 4°C. For staining, 0.5ml of this was added to 500ml of 
deionised water, which was sufficient to stain up to 20 gels.  
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Appendix III:  Plasmid profiles 
SSRL 
Reference  Serotype  Phage 
type  Plasmid profiles (kb) 
20004928  Antarctica     57 
19983922  Binza     2.1 
19991452  Binza     Plasmid-free 
19990838  Blockley     5.2;4.6 
19991711  Blockley     8.2;5.2 
19903865  Bovismorbificans     Plasmid-free 
19963399  Brandenburg     160;3.7 
19991073  Brandenburg     Plasmid-free 
19983155  Dublin     80 
19993056  Dublin     Plasmid-free 
19993805  Dublin     80 
20000136  Dublin     80 
20000139  Dublin     Plasmid-free 
20001735  Dublin     80 
20003052  Dublin     80 
19900377  Enteritidis  4  57 
19900497  Enteritidis  RDNC  57;2.1 
19900633  Enteritidis  RDNC  57 
19900813  Enteritidis  4  57 
19900828  Enteritidis  4  57 
19901024  Enteritidis  4  57 
19901059  Enteritidis  4  57 
19901127  Enteritidis  Untypable  57;2.1 
19901135  Enteritidis  Untypable  57;2.1  
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SSRL 
Reference  Serotype  Phage 
type  Plasmid profiles (kb) 
19901221  Enteritidis  Untypable  57;2.1 
19901257  Enteritidis  Untypable  57;2.1 
19901259  Enteritidis  4  57 
19901289  Enteritidis  Untypable  57;2.1 
19901301  Enteritidis  Untypable  57;2.1 
19901442  Enteritidis  RDNC  57;2.1 
19901527  Enteritidis  RDNC  57;2.1 
19901602  Enteritidis  4  57;2.1 
19901733  Enteritidis  Untypable  57 
19901754  Enteritidis  Untypable  57;2.1 
19901928  Enteritidis  4  57 
19903116  Enteritidis  RDNC  2.1 
19903993  Enteritidis  Untypable  2.1 
19910665  Enteritidis  4  57;2.1 
19911165  Enteritidis  4  57 
19911537  Enteritidis  4  Plasmid-free 
19933184  Enteritidis  4  57 
19933339  Enteritidis  4  57 
19935599  Enteritidis  4  57 
19940784  Enteritidis  4  57 
19940871  Enteritidis  4  57 
19940880  Enteritidis  4  57 
19941864  Enteritidis  4  57 
19943026  Enteritidis  4  57 
19964025  Enteritidis  5c  57 
19965081  Enteritidis  1  57  
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SSRL 
Reference  Serotype  Phage 
type  Plasmid profiles (kb) 
19970269  Enteritidis  7  57 
19982543  Enteritidis  4  57 
19984026  Enteritidis  1  Plasmid-free 
19990380  Enteritidis  4  57;4.4 
19990807  Enteritidis  8  57 
19991308  Enteritidis  4  57 
19991655  Enteritidis  21  57 
19991657  Enteritidis  1  57 
19991700  Enteritidis  4  57 
19991722  Enteritidis  4  100;57 
19991815  Enteritidis  1  57 
19991817  Enteritidis  7  57 
19991825  Enteritidis  4  57 
19991870  Enteritidis  5c  57;2.8 
19991929  Enteritidis  1  57 
19992150  Enteritidis  6a  57;55 
19992252  Enteritidis  1  120 
19993033  Enteritidis  4  Plasmid-free 
19993115  Enteritidis  4  57 
19993539  Enteritidis  untypable  57 
19994609  Enteritidis  14b  5.2 
19995017  Enteritidis  RDNC  70;57;3.0;2.1 
20001314  Enteritidis  4  57 
20002195  Enteritidis  1  57 
20002590  Enteritidis  RDNC  57 
20002618  Enteritidis  21  57;4.9;4.6  
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SSRL 
Reference  Serotype  Phage 
type  Plasmid profiles (kb) 
20002621  Enteritidis  6  57 
20002660  Enteritidis  1c  57 
20004057  Enteritidis  1  57 
20004078  Enteritidis  3  57 
20004300  Enteritidis  4  45;6.0;4.5 
20004338  Enteritidis  1c  57 
20004342  Enteritidis  6a  110;57 
20004447  Enteritidis  21  57;3.5 
20004592  Enteritidis  RDNC  57 
20004594  Enteritidis  1  Plasmid-free 
20004730  Enteritidis  21  110;57 
20004768  Enteritidis  1  57 
20005031  Enteritidis  7  57 
20005084  Enteritidis  4  57;4.8 
20005141  Enteritidis  untypable  57;6.0;5.0;3.8 
20005212  Enteritidis  1  57 
20005300  Enteritidis  1  Plasmid-free 
19932300  Hadar     6.1;3.3;2.1 
19935442  Hadar     6.1;3.3;2.1 
19940240  Hadar     6.1;3.2;2.1 
19990095  Hadar     7.2;2.1 
19990515  Hadar     15;7.4;3.2;2.1 
19991026  Hadar     2.1 
19992070  Hadar     2.1 
19992689  Hadar     15;6.2;5.3;4.8;3.2;2.1 
19992820  Hadar     15;4.8;2.1  
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SSRL 
Reference  Serotype  Phage 
type  Plasmid profiles (kb) 
20000721  Hadar     8.2;6.0;5.2;4.0;3.2;2.1 
20002113  Hadar     8.2;3.2;2.1 
20002399  Hadar     45;2.1 
20003106  Hadar     10;4.2;3.8;3.2;2.1 
20004010  Hadar     10;4.8;4.5;2.1 
20004028  Hadar     10;3.2;2.1 
19993048  Indiana     160;40;6.0;5.2;2.6 
20002427  Java     20;4.5;2.0 
19992003  Kottbus     2.1 
20003957  Kottbus     8.0;3.2;2.1;2.0 
19982854  Liverpool     5.1;4.3 
19993807  Liverpool     5.1;4.3 
20000672  Liverpool     5.1;4.3 
19910646  Mbandaka     6.8;4.4;2.8 
19912067  Mbandaka     4.8;3.4 
19921643  Mbandaka     6.8;4.6;2.8 
19933488  Mbandaka     4.6 
19934878  Mbandaka     6.8;4.2 
19941804  Mbandaka     6.8;4.2 
19982886  Mbandaka     4.6;4.4 
19990706  Mbandaka     90;3.6;2.8 
19990898  Mbandaka     70;6.8;4.4 
19990970  Mbandaka     90;6.8;4.4 
19990976  Mbandaka     6.8;4.2 
19993983  Mbandaka     6.8;4.8;3.6;3.4;2.1 
20000283  Mbandaka     70;60;3.0;2.1  
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SSRL 
Reference  Serotype  Phage 
type  Plasmid profiles (kb) 
20000635  Mbandaka     70 
20000821  Mbandaka     45;30;6.8;4.4 
20001054  Mbandaka     70 
20001058  Mbandaka     45;20;6.8;4.2 
20002298  Mbandaka     4.6;4.4;3.0 
20002524  Mbandaka     60;50;6.8;4.4;3.4 
20002550  Mbandaka     50;6.8;4.4 
20002563  Mbandaka     90;50;6.8;4.6;4.3;3.0 
20004661  Mbandaka     90;50;6.8;4.6;4.3;3.0 
19982602  Monophasic group C1     100;2.7 
2000 1797  Montevideo     120 
19932001  Oranienburg     160;147;120 
19983032  Senftenberg     50;20;5.3;4.4;3.2;2.5 
19992491  Senftenberg     50;2.1 
20000673  Senftenberg     20;4.3;3.2 
20004947  Senftenberg     50;5.3;4.4;3.2;2.5 
19990203  Thompson     6.5;5.5;2.8 
19991746  Thompson     7.2 
19993085  Thompson     Plasmid-free 
20005319  Thompson     Plasmid-free 
19902644  Typhimurium  66  90 
19933344  Typhimurium  204c  90;60 
19941463  Typhimurium  204  160;90 
19950004  Typhimurium  2  90 
19966072  Typhimurium  104b  90;7.1 
19970646  Typhimurium  104  90  
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SSRL 
Reference  Serotype  Phage 
type  Plasmid profiles (kb) 
19970917  Typhimurium  104  90 
19972895  Typhimurium  104  90 
19983351  Typhimurium  RDNC  Plasmid-free 
19983458  Typhimurium  2  90 
19990031  Typhimurium  104  90 
19990341  Typhimurium  104  90;50 
19991035  Typhimurium  104  90 
19992835  Typhimurium  3  90;2.8 
19993849  Typhimurium  104  90 
19994076  Typhimurium  104  90 
20000918  Typhimurium  104b  110;90 
20001178  Typhimurium  104  90 
20002014  Typhimurium  104b  90 
20002058  Typhimurium  104b  90;30;6.7;6.0 
20002257  Typhimurium  RDNC  145;4.9;3.1;2.5;2.0 
20003940  Typhimurium  40  Plasmid-free 
20003962  Typhimurium  10  90 
20005189  Typhimurium  170  Plasmid-free 
19910748  Virchow     150 
19953743  Virchow     100 
19983717  Virchow     Plasmid-free 
19990983  Virchow     6.8;4.4;2.1 
19991601  Virchow     4.5;2.5;2.1;1.7 
19992678  Virchow     Plasmid-free 
20001526  Virchow     Plasmid-free 
20002001  Virchow     Plasmid-free 
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Appendix IV: Preparation of working solutions for PFGE 
0.85% Saline 
4.25g of sodium chloride were dissolved in 500mlof distilled water and sterilized by 
autoclaving. 
ES Buffer 
18.6g of EDTA was added to a Pyrex beaker containing approximately 70ml of sterile 
deionised water, stirring on a magnetic stirrer. A probe from the Hydrus 300 pH machine 
from Fisherbrand was inserted into the beaker and monitored the pH. Sodium hydroxide 
solution was added to keep the pH above 8 to allow the EDTA to dissolve. Once all the 
EDTA was dissolved, the sodium hydroxide solution was added drop by drop until a final 
pH of 9.5 was achieved. The volume was adjusted to 100ml and stored at room 
temperature. 
Proteinase K 
0.5g of Proteinase K was dissolved in 20ml of sterile deionised water. Aliquots of 200µl 
were dispensed into sterile Treff tubes and frozen in the –20°C freezer. When needed, the 
required number of tubes would be removed from the freezer and allowed to thaw at room 
temperature. 
TE (PFGE) Wash buffer 
1.21g of Trizma base and 3.72g of EDTA were dissolved in approximately 900ml of 
deionised water. The pH was adjusted to 7.5. The volume was made up to one litre and 
sterilized by autoclaving. Store at room temperature. 
0.5X TBE buffer  
250ml of 10X TBE buffer was added to 4750ml of deionised water. Store at room 
temperature. 
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Appendix V: Pulsed Field Profiles  
SSRL 
Reference  Serotype  Phage 
type 
Pulsed field 
profile 
20004928  Antarctica     AMANT1 
19983922  Binza     AMBIN1 
19991452  Binza     AMBIN2 
19990838  Blockley     AMBLO1 
19991711  Blockley     AMBLO2 
19903865  Bovismorbificans     AMBOV1 
19963399  Brandenburg     AMBRN1 
19991073  Brandenburg     AMBRN2 
19983155  Dublin     AMDUB1 
19993056  Dublin     AMDUB1 
19993805  Dublin     AMDUB1 
20000136  Dublin     AMDUB1 
20000139  Dublin     AMDUB1 
20001735  Dublin     AMDUB2 
20003052  Dublin     AMDUB1 
19900377  Enteritidis  4  AMENT1 
19900497  Enteritidis  RDNC  SENTXB.0001 
19900633  Enteritidis  RDNC  SENTXB.0001 
19900813  Enteritidis  4  AMENT3 
19900828  Enteritidis  4  AMENT1 
19901024  Enteritidis  4  SENTXB.0001 
19901059  Enteritidis  4  AMENT2 
19901127  Enteritidis  Untypable  SENTXB.0001 
19901135  Enteritidis  Untypable  SENTXB.0001  
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SSRL 
Reference  Serotype  Phage 
type 
Pulsed field 
profile 
19901221  Enteritidis  Untypable  SENTXB.0001 
19901257  Enteritidis  Untypable  SENTXB.0001 
19901259  Enteritidis  4  SENTXB.0001 
19901289  Enteritidis  Untypable  SENTXB.0001 
19901301  Enteritidis  Untypable  SENTXB.0001 
19901442  Enteritidis  RDNC  SENTXB.0001 
19901527  Enteritidis  RDNC  SENTXB.0001 
19901602  Enteritidis  4  SENTXB.0001 
19901733  Enteritidis  Untypable  SENTXB.0001 
19901754  Enteritidis  Untypable  SENTXB.0001 
19901928  Enteritidis  4  SENTXB.0001 
19903116  Enteritidis  RDNC  SENTXB.0014 
19903993  Enteritidis  Untypable  AMENT7 
19910665  Enteritidis  4  SENTXB.0001 
19911165  Enteritidis  4  SENTXB.0001 
19911537  Enteritidis  4  SENTXB.0014 
19933184  Enteritidis  4  SENTXB.0001 
19933339  Enteritidis  4  SENTXB.0001 
19935599  Enteritidis  4  SENTXB.0001 
19940784  Enteritidis  4  SENTXB.0001 
19940871  Enteritidis  4  SENTXB.0001 
19940880  Enteritidis  4  SENTXB.0001 
19941864  Enteritidis  4  SENTXB.0001 
19943026  Enteritidis  4  SENTXB.0001 
19964025  Enteritidis  5c  AMENT4 
19965081  Enteritidis  1  SENTXB.0040  
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SSRL 
Reference  Serotype  Phage 
type 
Pulsed field 
profile 
19970269  Enteritidis  7  SENTXB.0040 
19982543  Enteritidis  4  SENTXB.0001 
19984026  Enteritidis  1  SENTXB.0014 
19990380  Enteritidis  4  SENTXB.0001 
19990807  Enteritidis  8  SENTXB.0009 
19991308  Enteritidis  4  SENTXB.0001 
19991655  Enteritidis  21  SENTXB.0001 
19991657  Enteritidis  1  SENTXB.0001 
19991700  Enteritidis  4  SENTXB.0001 
19991722  Enteritidis  4  SENTXB.0001 
19991815  Enteritidis  1  SENTXB.0001 
19991817  Enteritidis  7  SENTXB.0001 
19991825  Enteritidis  4  SENTXB.0001 
19991870  Enteritidis  5c  SENTXB.0001 
19991929  Enteritidis  1  SENTXB.0001 
19992150  Enteritidis  6a  SENTXB.0001 
19992252  Enteritidis  1  SENTXB.0014 
19993033  Enteritidis  4  SENTXB.0014 
19993115  Enteritidis  4  SENTXB.0001 
19993539  Enteritidis  untypable  AMENT5 
19994609  Enteritidis  14b  AMENT6 
19995017  Enteritidis  RDNC  SENTXB.0119 
20001314  Enteritidis  4  SENTXB.0001 
20002195  Enteritidis  1  SENTXB.0001 
20002590  Enteritidis  RDNC  SENTXB.0001 
20002618  Enteritidis  21  SENTXB.0001  
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SSRL 
Reference  Serotype  Phage 
type 
Pulsed field 
profile 
20002621  Enteritidis  6  SENTXB.0001 
20002660  Enteritidis  1c  SENTXB.0001 
20004057  Enteritidis  1  SENTXB.0001 
20004078  Enteritidis  3  SENTXB.0001 
20004300  Enteritidis  4  SENTXB.0001 
20004338  Enteritidis  1c  SENTXB.0001 
20004342  Enteritidis  6a  SENTXB.0001 
20004447  Enteritidis  21  SENTXB.0005 
20004592  Enteritidis  RDNC  SENTXB.0001 
20004594  Enteritidis  1  SENTXB.0014 
20004730  Enteritidis  21  SENTXB.0001 
20004768  Enteritidis  1  SENTXB.0005 
20005031  Enteritidis  7  SENTXB.0001 
20005084  Enteritidis  4  SENTXB.0001 
20005141  Enteritidis  untypable  SENTXB.0001 
20005212  Enteritidis  1  SENTXB.0001 
20005300  Enteritidis  1  SENTXB.0014 
19932300  Hadar     AMHAD1 
19935442  Hadar     SHADXB.0001 
19940240  Hadar     SHADXB.0001 
19990095  Hadar     SHADXB.0001 
19990515  Hadar     SHADXB.0001 
19991026  Hadar     SHADXB.0001 
19992070  Hadar     SHADXB.0001 
19992689  Hadar     SHADXB.0001 
19992820  Hadar     SHADXB.0001  
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SSRL 
Reference  Serotype  Phage 
type 
Pulsed field 
profile 
20000721  Hadar     SHADXB.0001 
20002113  Hadar     SHADXB.0001 
20002399  Hadar     AMHAD2 
20003106  Hadar     SHADXB.0001 
20004010  Hadar     SHADXB.0001 
20004028  Hadar     SHADXB.0001 
19993048  Indiana     AMIND1 
20002427  Java     SPTJXB.0003 
19992003  Kottbus     AMKOT1 
20003957  Kottbus     AMKOT2 
19982854  Liverpool     AMLPL1 
19993807  Liverpool     AMLPL1 
20000672  Liverpool     AMLPL1 
19910646  Mbandaka     AMMBA1 
19912067  Mbandaka     AMMBA2 
19921643  Mbandaka     SMBAXB.0012 
19933488  Mbandaka     AMMBA3 
19934878  Mbandaka     AMMBA3 
19941804  Mbandaka     AMMBA3 
19982886  Mbandaka     AMMBA3 
19990706  Mbandaka     AMMBA4 
19990898  Mbandaka     AMMBA11 
19990970  Mbandaka     AMMBA3 
19990976  Mbandaka     AMMBA5 
19993983  Mbandaka     AMMBA3 
20000283  Mbandaka     AMMBA3  
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SSRL 
Reference  Serotype  Phage 
type 
Pulsed field 
profile 
20000635  Mbandaka     AMMBA6 
20000821  Mbandaka     AMMBA7 
20001054  Mbandaka     AMMBA8 
20001058  Mbandaka     AMMBA10 
20002298  Mbandaka     AMMBA9 
20002524  Mbandaka     AMMBA5 
20002550  Mbandaka     AMMBA3 
20002563  Mbandaka     AMMBA12 
20004661  Mbandaka     AMMBA12 
19982602  Monophasic group C1     AMMPC1/1 
20001797  Montevideo     AMMVD1 
19932001  Oranienburg     AMORA1 
19983032  Senftenberg     AMSEN1 
19992491  Senftenberg     AMSEN2 
20000673  Senftenberg     AMSEN3 
20004947  Senftenberg     AMSEN4 
19990203  Thompson     AMTHO2 
19991746  Thompson     AMTHO1 
19993085  Thompson     AMTHO1 
20005319  Thompson     AMTHO1 
19902644  Typhimurium  66  AMTYM66/1 
19933344  Typhimurium  204c  AMTYM204c/1 
19941463  Typhimurium  204  AMTYM204/1 
19950004  Typhimurium  2  AMTYM2/1 
19966072  Typhimurium  104b  STYMXB.0001 
19970646  Typhimurium  104  STYMXB.0001  
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SSRL 
Reference  Serotype  Phage 
type 
Pulsed field 
profile 
19970917  Typhimurium  104  STYMXB.0001 
19972895  Typhimurium  104  STYMXB.0001 
19983351  Typhimurium  RDNC  AMTYMRDN1 
19983458  Typhimurium  2  AMTYM2/1 
19990031  Typhimurium  104  STYMXB.0001 
19990341  Typhimurium  104  AMSTYM104/1 
19991035  Typhimurium  104  STYMXB.0001 
19992835  Typhimurium  3  AMTYM3/1 
19993849  Typhimurium  104  STYMXB.0001 
19994076  Typhimurium  104  STYMXB.0001 
20000918  Typhimurium  104b  AMTYM104b/2 
20001178  Typhimurium  104  STYMXB.0001 
20002014  Typhimurium  104b  AMTYM104b/1 
20002058  Typhimurium  104b  STYMXB.0001 
20002257  Typhimurium  RDNC  AMTYMRDN2 
20003940  Typhimurium  40  AMTYM40/1 
20003962  Typhimurium  10  AMTYM10/1 
20005189  Typhimurium  170  AMTYM170/1 
19910748  Virchow     AMVIR2 
19953743  Virchow     SVIRXB.0001 
19983717  Virchow     AMVIR1 
19990983  Virchow     AMVIR3 
19991601  Virchow     AMVIR3 
19992678  Virchow     AMVIR2 
20001526  Virchow     AMVIR4 
20002001  Virchow     SVIRXB.0001 
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